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Chapter 1
Cancer is one of the leading causes of death in the world. In The Netherlands, the 
incidence in 2016 was approximately 650 patients/100.000 inhabitants/year.1 Most of 
these incident cases are carcinomas, i.e. cancers originating from the epithelial layers of 
the body. In contrast, sarcomas, i.e. cancers originating from the mesenchyme, are very 
rare. The mesenchyme is the embryonal layer giving rise to amongst others connective 
tissue, fat, muscles, synovium and bones. These tumours account for approximately 
1-2% of all cancers (6 patients/100.000 inhabitants/year).1 These sarcomas are split up in 
more than 50 histological entities.2 Besides the malignant tumours of the mesenchyme, 
the sarcomas, there are also several so-called intermediate, locally aggressive 
or rarely metastasizing, mesenchymal tumours.2 Prospective studies are difficult 
because the number of sarcoma patients is too low to study the different subtypes. 
Moreover, randomized phase III trials in all soft tissue sarcoma patients together need 
to be multicentre, and multinational, taking several years to complete. Therefore, it is 
important that the available data of historical patients is used to generate hypotheses 
that can be tested in these prospective studies. In this thesis, results from retrospective 
studies on various aspects of these tumours are reported with the objective of improving 
daily sarcoma patient care and generating hypotheses and background data for future 
studies.
Mesenchymal tumours
Before elaborating on the outline of this thesis, a short summary of the different 
mesenchymal tumours is important. The earlier cited WHO classification of Bone and 
Soft Tissue Tumours defines the different mesenchymal tumours and divides them in 
benign, intermediate and malignant.2 The intermediate group is further subdivided in 
locally aggressive tumours and rarely metastasizing tumours, i.e. metastasizing in less 
than 2 percent of patients.
Benign tumours
The most common category are the benign tumours. Tumours in this category are 
for example lipomas, fibromas, elastofibromas, localized type tenosynovial giant cell 
tumours and leiomyomas. In general, these tumours only need treatment in case of 
complaints or diagnostic uncertainty (differential diagnosis of a malignant tumour). 
The combination of radiology and pathology can often make the distinction between 
benign and malignant tumours and so, resection is not always necessary.
Intermediate category; locally aggressive and rarely metastasizing 
tumours
Locally aggressive tumours are for example desmoid-type fibromatosis and atypical 
lipomatous tumour/well-differentiated liposarcoma. These tumours do not metastasize, 
but have a clinical behaviour resulting in compression of surrounding organs or local 
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invasion of other structures and they thereby disturb normal anatomy. Treatment is often 
necessary to prevent or diminish symptoms caused by these tumours.
Rarely metastasizing tumours have the potential to metastasize, but do this rarely (<2%). 
However, the risk of metastases might be one of the reasons to opt for resection of these 
tumours. An example of such a tumour is Kaposi sarcoma.
Tumours can also have characteristics of both categories, e.g. giant cell tumour of 
bone (GCT-B).
Below, this introduction will elaborate on both desmoid-type fibromatosis and giant cell 
tumour of bone belonging to this category.
Malignant tumours
The last category of mesenchymal tumours are the overt malignant tumours, which 
are called sarcomas. These tumours do metastasize and need surgical resection, often 
combined with radiotherapy to get local control. Radiotherapy can be used either neo-
adjuvant or adjuvant and both have their risks and benefits. In case of locally advanced 
disease or distant metastatic disease, the goal of treatment is prolongation of survival 
and palliation, in which case chemotherapy is a possibility as treatment. However, 
in case of oligometastatic disease, the goal of treatment can still be curative. In this 
situation, the treatment often consists of more than one modality and more than once 
surgery.
Specific tumours
After this short introduction of the different groups of mesenchymal tumours regarding 
biologic behaviour, the current diagnostics and treatment of the main tumours studied 
in this thesis will be discussed, i.e. desmoid-type fibromatosis, gastro-intestinal stromal 




Desmoid-type fibromatosis are rare, locally aggressive, tumours. In the Netherlands, 
the incidence was 5.36 patients per million inhabitants per year in 2013.3 The peak 
age of patients is between 30-40 years of age.3,4 Clinical behaviour varies between 
spontaneous regression, long time stable disease and rapid progression.5 Although 
death due to progression of desmoid-type fibromatosis is rare, it can be a very 
debilitating disease. As it can be localised intraabdominal, in the chest and abdominal 
wall and in the extremities, complaints vary according to localisation. If localised 
1
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intraabdominal, the disease can result in obstructive symptoms of intraabdominal 
organs such as the intestine, resulting in an ileus, and of the bile ducts resulting in 
cholestasis. When localised in the abdominal or chest wall and in the extremities, it can 
result in pain, cosmetic complaints and impairment of mobility. So, although not full 
blown malignant, it can have a big impact on quality of life.
Histologically, tumours consist of spindle cells with nuclear expression of β-catenin. 
Genetically these tumours harbour either a somatic CTNNB1 mutation (either T41A, S45F 
or S45P) or a germline APC mutation.6,7 These mutations are mutually exclusive. In case of 
an APC (adenomatous polyposis coli) mutation, patients often have a full blown familial 
adenomatous polyposis (FAP) syndrome with a colon full of adenomatous polyps and 
a high risk of developing colorectal cancer. The combination of FAP and desmoid-type 
fibromatosis is also called Gardner syndrome. The CTNNB1 mutation is predictive of the 
clinical behaviour to some extent, with the S45F mutation having a more aggressive 
behaviour.6,7
Treatment of desmoid-type fibromatosis was long dominated by surgery, with 
complete removal of the tumour as goal of therapy. Due to the unpredictable behaviour 
sometimes resulting in spontaneous complete regression, currently patients are 
followed up to see the natural behaviour of the tumour.8,9 Although surgery can cure 
patients, there is always a risk of disease recurrence. Although there is a suggestion that 
microscopically positive resection margins are associated with local recurrence, this 
finding is not consistent.10-13 The CTNNB1 S45F mutation is associated with an increased 
risk of recurrence after surgery.6,7,14-16 Other treatment options are radiotherapy and 
systemic treatment with selective oestrogen receptor modulators, non-steroidal 
anti-inflammatory drugs (NSAID), tyrosine kinase inhibitors (TKI), chemotherapy or a 
combination of these.8 Radiotherapy was studied in a study by Keus et al., showing 
that radiotherapy has a local control rate of 81.5%, but has also adverse events, such 
as skin fibrosis and impaired wound healing.17 The evidence for systemic treatment 
is based on case reports, case series and single arm phase II studies, which is in this 
disease a problematic design because of the unpredictable natural behaviour of these 
tumours. Recently, for the first time a randomised phase III trial was published, reporting 
an increased 2-year progression-free rate for patients treated with sorafenib 400mg 
once daily versus placebo (81% vs. 36%).18
Gastro-intestinal stromal cell tumour
Gastro-intestinal stromal cell tumours (GISTs) are the most common mesenchymal 
tumours of the gastro-intestinal tract.19 The incidence of GIST has been estimated to be 
between 7.8 and 21.1/million inhabitants per year.20-26 These tumours occur throughout 
the whole gastrointestinal tract, but most of them are located in the stomach.
Binnenwerk_Productie.indd   12 2/10/2021   8:04:35 PM
13
Introduction
When GISTs are small, they often are asymptomatic and it is also a frequent finding during 
surgery for other indications. Symptoms of GISTs can be bleeding and obstruction.
Microscopically, GISTs are tumours consisting of spindle or epithelioid cells. 
Immunohistochemistry is often positive for CD117 and/or DOG-1 (discovered-on-
GIST-1).27-31 As most of the GISTs harbour a KIT or PDGFRa (platelet-derived growth factor 
receptor alpha) mutation, mutational analysis can also help to confirm the diagnosis 
of GIST in immunohistochemical CD117 negative cases.27 It is possible to predict clinical 
behaviour based on primary localisation, tumour size, mitotic index and tumour rupture.27 
Different risk classification systems exist, but they all use these same parameters. In 
2002 the first risk classifications were developed by Fletcher et al. and another was 
developed at the same time by Miettinen et al.32,33 Thereafter, risk classifications were 
published by Miettinen, Joensuu and Gold.34-36 These classifications predict the chance 
of development of metastases and are mainly used for the indication of adjuvant 
imatinib, the most effective tyrosine kinase inhibitor (TKI) used in GIST treatment. The 
response to imatinib and progression-free survival depend on mutational status.37,38 
Mutations in KIT are most frequent (80%), followed by PDGFRa (7.5%).31,39 Other GISTs are 
associated with succinate dehydrogenase complex deficiency or neurofibromatosis 
type 1. 28,40-43
Primary treatment consists of surgery with in case of a high risk of recurrence adjuvant 
treatment with imatinib.27 Both the 5-year recurrence free survival (65.6% vs. 47.9%) and 
5-year overall survival (92.0% vs 81.7%) are higher in patients treated with 3 years of 
adjuvant imatinib compared with 1 year of adjuvant imatinib.44 In patients with locally 
advanced disease, imatinib can be used as induction treatment.45 If unresectable, 
treatment with imatinib improves the overall survival of these patients with a 2-year 
progression-free survival of 44% for imatinib 1dd 400 mg.27,46-48 Second-line palliative 
treatment consists of sunitinib with a time to progression of 27.3 weeks with sunitinib 
(50 mg/day 4 weeks and 2 weeks off) versus 6.4 weeks with placebo.49 In another study 
a continuous schedule of 37.5 mg/day was shown to be active.50 Third, and currently 
last, line treatment for GIST is regorafenib with a progression-free survival of 4.8 months 
when treated with regorafenib 160mg daily 3 out of every 4 weeks versus 0.9 months 
with placebo.51
Soft tissue sarcomas
Multiple studies in this thesis consider the systemic treatment of soft tissue sarcoma. As 
already mentioned, soft tissue sarcomas comprise approximately 1-2% of all patients 
with cancer. It is a broad spectrum of tumours comprising amongst others liposarcoma, 
synovial sarcoma, leiomyosarcoma and malignant peripheral nerve sheath tumours. 
All these tumours have a different clinical behaviour and differ in their tendency to give 
distant metastases, risk of local recurrence, response to radiotherapy and to systemic 
1
Binnenwerk_Productie.indd   13 2/10/2021   8:04:35 PM
14
Chapter 1
treatment. However, because of the rarity of these tumours, the different histologic 
subtypes are often studied within one trial without stratification by histology.
Primary treatment, if possible, is complete surgical resection. Based on risk factors for 
local recurrence, such as high grade, origin deep to the fascia, probability of incomplete 
resection and/or other high risk features, neo-adjuvant or adjuvant radiotherapy is 
considered.52 The benefit of neo-adjuvant radiotherapy is the lower dose of radiotherapy 
and the smaller volume of healthy tissue irradiated, but with adjuvant treatment the 
indication is more clear.53,54 Neo-adjuvant or adjuvant treatment with chemotherapy 
is still under debate because some studies suggest benefit of systemic treatment to 
prolong overall survival while others do not.55-59
If distant metastases occur, first line treatment consists of doxorubicin monotherapy 
or doxorubicin/ifosfamide.52 In Europe, doxorubicin monotherapy is standard of care 
and combination therapy is used if rapid response is essential in case of induction 
chemotherapy or when complaints exist.52 In the EORTC (European Organisation for 
Research and Treatment of Cancer) 62012 trial, overall survival in patients treated 
with doxorubicin monotherapy was 12.8 months and with doxorubicin/ifosfamide was 
14.3 (difference not significant).60 More recently studies comparing doxorubicin with 
gemcitabine/docetaxel showed improved overall survival data with 17.6 months for 
doxorubicin and 15.5 months with gemcitabine/docetaxel.61 Moreover, in SARC021 the 
median overall survival was 18.4 months with doxorubicin/evofosfamide versus 19.0 
months with doxorubicin monotherapy.62 Second line treatment can be ifosfamide 
monotherapy, gemcitabine/docetaxel, trabectedin for leiomyosarcomas and 
liposarcomas, eribulin for liposarcomas and pazopanib for all soft tissue sarcomas 
except liposarcomas.63-69
As already mentioned, most of these studies in soft tissue sarcoma do not differentiate 
between the different histologic subtypes or different disease stages. This hampers the 
development of histotype tailored treatment. Some progress was made over the last 
decades, e.g. GIST and dermatofibrosarcoma protuberans (DFSP), previously included 
in these general studies, were found to be responsive to imatinib.46,47,70,71 Due to the low 
number of patients, no distinction is made in these studies between different disease 
stages (such as locally advanced tumours and distant metastatic disease). Also, other 
prognostic factors cannot be accounted for.
To improve overall survival of patients with metastatic soft tissue sarcoma several 
strategies are evaluated. First, new drugs are tested, for example olaratumab, a PDGFRa 
antibody. The results of this study were recently shown to be negative.72 Second, new 
combinations are considered. Last, maintenance treatment would be an option to 
improve both overall and progression-free survival. To design such trials of maintenance 
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therapy, data on overall and progression-free survival after the completion of 
doxorubicin therapy would support the development of adequate trials.
Pazopanib is one of the drugs used in later line treatment of metastatic soft tissue 
sarcoma. It has no significant improvement in overall survival (pazopanib 12.5 months 
versus placebo 10.7 months), but showed a significant improvement in progression-
free survival (4.6 months versus 1.6 months) in the phase III PALETTE study.65 The benefit 
of pazopanib is that it is an oral drug, which can be used at home. The side effects of 
pazopanib are, amongst others, diarrhoea, liver function abnormalities, fatigue, nausea 
and hypertension.65 Liver function abnormalities are a common reason for decreasing 
the dose of pazopanib and discontinuation of pazopanib treatment. The incidence of a 
grade ≥2 elevated alanine aminotransferase (ALAT) was 10% (placebo 3%) and aspartate 
aminotransferase (ASAT) was 8% (placebo 2%) in the PALETTE study.65 The addition of 
prednisolone to pazopanib treatment could be a way to continue pazopanib in the 
presence of pazopanib induced liver injury.73
Bone tumours
In the second part of this thesis we focus on tumours that arise primarily in bone. Also, 
in this type of tumours benign, intermediate and malignant tumours exist. The, in this 
thesis studied, giant cell tumour of bone is an example of a locally aggressive, rarely 
metastasizing tumour. On the other hand, osteosarcoma is an example of a high-grade 
malignant bone tumour. Other examples of malignant bone tumours are Ewing sarcoma 
and chondrosarcoma. These last two tumours were not studied in this thesis.
Giant cell tumour of bone
Giant Cell Tumours of Bone (GCT-B) are locally aggressive, rarely metastasizing tumours. 
GCT-B are composed of large osteoclast-like giant cells and sheets of mononuclear cells. 
These tumours primarily affect the metaphysis of long bones.74 The expression of the 
receptor of nuclear factor kappa-B ligand (RANKL) is one of the import pathophysiologic 
mechanisms of this disease.75,76 The incidence of GCT-B is currently not exactly known, 
but these tumours are extremely rare. Approximately 5% of all bone tumours are GCT-B 
and the incidence is estimated between 1.03-1.33 per million per year based on doctor-
driven registries.74,77,78 It affects patients in all age groups but the median age ranges 
between 20 and 40 years of age, with an equal distribution between the sexes or a slight 
female predominance.74,77,78
Typical symptoms are pain, swelling, often decreased joint movement and sometimes 
a pathological fracture.74,79 It is known to be locally aggressive and rarely metastasizes.74 
Treatment of GCT-B can consist of curettage, curettage with an adjuvant treatment 
or resection with joint replacement.80 As surgical treatment can be mutilating, it often 
results in loss of quality of life. In GCT-B local recurrence rate is 6-42%.79,81 Recently 
1
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denosumab, a human IgG2 monoclonal antibody against RANKL, was registered for 
use in GCT-B and showed tumour response in two phase II studies.82,83
Osteosarcoma
The last tumour discussed in this thesis is osteosarcoma. It is the most common, 
but still rare, primary bone malignancy. The age of osteosarcoma patients has a 
bimodal distribution with adolescents and patients of advanced age being affected. 
Osteosarcoma can arise at any site, but most tumours develop in the long bones 
with the distal femur (30%), proximal tibia (15%) and proximal humerus (15%) as most 
common sites.84 Osteosarcoma has several subtypes, i.e. conventional, teleangiectatic, 
chondroblastic and small cell.2
The intent of treatment in case of local disease or local disease with pulmonary 
metastases consists of chemotherapy and surgery. The 3-year event free survival is 
approximately 60-70%.85-88 The first line chemotherapy in most of the Western world 
consists of methotrexate, doxorubicin and cisplatin. Although studies in this rare disease 
are difficult, the EURAMOS study tried to improve cure rate in high risk patients by the 
addition of ifosfamide and etoposide to the perioperative regimen of methotrexate, 
doxorubicin and cisplatin.89 However, this study failed to reach its primary endpoint, 
but resulted in a higher rate of adverse events.89 Currently, approximately 40% of all 
osteosarcoma patients develop local recurrence or distant metastatic disease after 
first line treatment. In this situation cure is still possible, when the recurrence and/or 
metastases are still limited and surgery is possible.90,91
When the intent of treatment is no longer cure, different chemotherapeutic regimens 
can be considered, but which to use is not well defined. Regimens consisting of e.g. 
ifosfamide, etoposide, ifosfamide/etoposide and gemcitabine/docetaxel were reported, 
but in small, single arm, studies.92-98 None of these studies were randomized. Ifosfamide/
etoposide was tested in first line and had a response rate of 48-59%.92,93 Response 
rates for gemcitabine/docetaxel and for etoposide ranged between 12.5% and 17%.94,95 
Progression-free survival (PFS) for gemcitabine/docetaxel was 3.5 months.95 Ifosfamide 
as second line treatment was studied in several small studies (between 6 and 19 patients 
per study) studying varying ifosfamide doses, ranging from 5 g/m2 in one day to a total of 
14 g/m2 continuously over 7 days.96-99 None of these studies reported the overall survival 
(OS) and/or PFS. Overall response rates varied between 24% and 44%.
During the years, several studies were done with in the end ineffective drugs. These 
studies can be used to determine a reference standard to compare new drugs with. 
A retrospective analysis of 7 Children’s Oncology Group studies, all with inactive drugs 
(according to the study criteria), by Lagmay et al. showed an event free survival (which 
is usually called PFS) of 12% at 4 months, which can be used as reference for new single 
arm studies.100 In a recently published small randomised phase II study, including 43 
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patients, regorafenib was shown to have an 8 weeks PFS of 65% versus 0% for the placebo 
group.101
Outline of the thesis
This thesis studies several aspects of various mesenchymal tumours and is split in two 
parts. The first part studies soft tissue tumours and the second part bone tumours.
Soft tissue tumours
In this first part of the thesis, desmoid-type fibromatosis, GIST and soft tissue sarcomas 
in general are discussed.
As described above, the treatment of desmoid-type fibromatosis has changed during 
the past years from surgical treatment to non-surgical management, i.e. watchful 
waiting, radiotherapy and systemic treatment. Although some studies are reported, 
data of real-world patients treated in first line is scarce. In chapter 2 the outcome of 
first line treatment of patients in The Netherlands is reported.
Radiotherapy has proven activity in desmoid-type fibromatosis with a local control rate 
of 81.5%, but has also adverse effects, such as skin fibrosis and impaired wound healing.17 
Although extremely rare, radiotherapy can also cause the development of a malignancy. 
In chapter 3 we studied whether radiotherapy induced sarcomas developing after 
radiotherapy for desmoid-type fibromatosis developed from the tumour or from the 
healthy tissue surrounding it.
In 2004 a nationwide survey was performed in the Netherlands to estimate the incidence 
of GIST in 1995 and 1998 to 2003.20 In chapter 4 this study was repeated for the period 
between 2003 and 2012. Because the diagnosis is well established now, well-known to 
pathologists and effective treatments exist, the aim of this study was to estimate the 
current incidence of GIST, incidence of risk categories, frequency of various mutations, 
immunohistochemical markers and histological subtypes. Also, daily practice of 
pathology reporting was compared with the current ESMO (European Society for Medical 
Oncology) guidelines.
Imatinib is first-line treatment in GIST and is in general well tolerated. It is a TKI, which 
amongst others binds KIT and PDGFRA. The drug is also used in chronic myeloid 
leukaemia and a frequently described side effect is neutropenia in CML (chronic myeloid 
leukaemia). The frequency of this side effect is much lower in GIST, but we retrieved 4 
patients from 3 reference centres which had a neutropenia due to imatinib treatment for 
GIST. In chapter 5 the management of this side effect in GIST patients is described.
1
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The last chapters (chapters 6-9) of this first part discuss several studies in soft tissue 
sarcomas. In chapter 6 the results of an EORTC database study are reported studying the 
difference between patients with locally advanced disease, distant metastatic disease 
or both locally advanced and distant metastatic disease. Differences in overall and 
progression-free survival, overall response rate and prognostic factors were studied. 
These results are important for daily practice when considering palliative treatment 
and for designing studies.
In chapter 7 the results of a second EORTC database study are reported, in which all 
patients are studied who completed 6 or more cycles of doxorubicin-based therapy 
and the overall survival and progression-free survival is calculated. These data are 
important when designing studies with maintenance therapy after doxorubicin palliative 
treatment.
Chapter 8 and 9 study two complications of pazopanib treatment. Pazopanib is an oral 
tyrosine kinase inhibitor used in later line palliative treatment of soft tissue sarcomas. 
Chapter 8 is a case report discussing a way to manage liver function abnormalities. 
Besides, the patient was diagnosed with an endometrial stromal cell sarcoma and 
showed a remarkable response. In chapter 9 patients suffering from pneumothorax due 
to pazopanib treatment are discussed and a possible mechanism for the development 
of this complication is postulated.
Bone tumours
The incidence of tumours is important for health care planning and the design of studies. 
As the incidence of giant cell tumours of bone is only based on doctor-driven cancer 
registries, this incidence was studied in a national pathology database in chapter 10.
In the last chapter of this thesis, chapter 11, the results of the palliative systemic treatment 
of osteosarcoma patients with ifosfamide treatment is reported. It is important to know 
the overall survival, progression-free survival and overall response rate of this treatment 
when discussing the start of palliative treatment with patients. It also can be used as a 
reference treatment during development of new drugs.
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Non-surgical management of patients with desmoid-type fibromatosis (DF) is 
increasing. This study tries to provide insight on type, usage and outcome of first-line 
non-surgical management strategies.
Patients and Methods
From the Dutch Pathology Registry (PALGA) patients with extra-abdominal or trunk/
abdominal wall DF, diagnosed between 1993 and 2013, were identified. First-line 
treatment was analysed. Best response (BR) using RECIST-criteria from start of 
treatment/surveillance until change of treatment or last follow-up was analysed.
Results
Ninety-one of the 1141 identified patients had first-line non-surgical management. The 
percentage of patients treated non-surgically increased from 0.6% in 1993-1998 to 12.8% 
in 2009-2013. Thirty-seven patients had surveillance (41%), 35 radiotherapy (38%) and 19 
systemic treatment (21%). BR for surveillance was complete response (CR) in 2/37, partial 
response (PR) 4/37, stable disease (SD) 21/37, progressive disease (PD) 5/37 and unknown 
5/37 patients. BR for radiotherapy was CR in 4/35, PR 11/35, SD 16/35 and unknown 4/35. BR 
for systemic treatment was CR in 1/19, PR 1/19, SD 10/19, PD 2/19 and unknown 5/19. Totally, 
91% of patients did not progress.
Discussion
Given the low percentage (9%) of PD of non-surgical management, these data can be 
used in shared decision making with the patient regarding optimal treatment.
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Introduction
Desmoid-type fibromatosis (DF or aggressive fibromatosis) is an intermediate grade soft 
tissue tumour that does not metastasize, but can be locally aggressive.1 For long, surgery 
has been the primary treatment for resectable tumours, with or without additional 
radiotherapy. Currently, a more conservative approach is applied based on reports of 
disease stabilization and spontaneous regression, and on documented progression 
after surgery as radical resection may be difficult to achieve.2,3 An epidemiological study 
conducted in extra-abdominal and trunk/abdominal wall DF patients in the Netherlands 
reported an increase in the use of non-surgical modalities over the past decade.4
A European consensus on the management of DF has recently been published, 
advocating active surveillance as the initial treatment modality, with systemic 
treatment, surgery or radiotherapy in case of tumour progression.5 Despite a trend 
towards conservative treatment, knowledge on the outcome of different management 
modalities as first-line treatment is limited.
Studies on radiotherapy have described disease stabilization and tumour regression.6-8 
Literature on systemic treatment is limited, with a variety of treatment regimes, often 
applied at different stages of disease presentation.9-18 Active surveillance is currently 
being investigated in a prospective setting by three different groups; a French group 
(NCT01801176), an Italian group (NCT02547831) and a Dutch group (NTR4714).19 Non-
surgical management of patients with DF is increasing. Population-based studies are 
needed to gain insight into the actual implementation of non-surgical treatment in daily 
practice. This retrospective study provides insight in the application and outcome of 
all first-line treatment modalities in a nationwide cohort of DF patients during routine 
clinical care.
Patients and Methods
From the PALGA database, the nationwide network and registry of histo- and 
cytopathology in the Netherlands, patients diagnosed between 1-1-1993 and 31-12-
2013 having extra-abdominal or trunk/abdominal wall DF were identified. The PALGA 
database contains encoded excerpts of all nationwide pathology examinations 
obtained by diagnostic procedure, including tissue biopsy or resection since 1971 in 
selected laboratories and expanded to nationwide inclusion in 1991.20 Due to incomplete 
data registration, patients with disease presentation before 1993 were excluded. 
Excerpts contained standardized information: an encrypted patient identification, 
date of pathology report, age and gender of the patient, and the conclusion of the 
pathology reports. Reports were scored as biopsy, resection or re-resection. Patients 
with diagnostic biopsy of DF, without excision specimens within 6 months of biopsy were 
selected. Patients with excision specimens within 6 months of biopsy were considered 
2
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to have initial surgical treatment. Exclusion criteria were intra-abdominal DF, recurrent 
disease at presentation, uncertain diagnosis and initial surgical treatment.
Hospitals with more than 10 patients were contacted for information. Data collection 
was performed in seven tertiary referral centres, as most patients were referred to these 
centres after diagnosis. In addition to the PALGA database, centre-based registrations 
were searched for patients. For all selected patients in these seven centres medical 
records were reviewed. From the excerpts and the medical records, data was collected 
on age, gender, year of diagnosis, localization, size, nuclear Beta-catenin, CTNNB1 
mutations, APC mutations, treatment modalities, date of start of treatment, response 
to treatment and toxicities. Only the first-line of treatment was documented.
Tumour localization was categorized as: head/neck, trunk (including thoracic wall, 
breast and back), abdominal wall, extremity or groin. Type of systemic treatment was 
categorized as: non-steroidal anti-inflammatory drug (NSAID), anti-hormonal (HT), 
chemotherapy (ChT) or tyrosine kinase inhibitors (TKI).
Reports from all available imaging studies were reviewed. Best response to treatment 
was classified using RECIST 1.1 as complete response (CR), partial response (PR) in case 
of >30% decrease of the largest diameter, stable disease (SD) or progressive disease 
(PD) in case of >20% increase of largest diameter based on reported measurements.21 
Date of the start of treatment was defined as the date of visit with the physician in which 
the treatment modality was initiated or date of start radiotherapy. In most patients, 
active surveillance was initiated within 3 weeks after diagnosis. Results are shown as 
best response and time to progression (TTP). TTP was defined as the period from start 
of treatment to radiological PD as classified by RECIST 1.1. Follow-up period for each 
treatment was documented as time of start treatment or active surveillance until 
change of treatment or last documented follow-up visit, whichever came first.
Late toxicity after radiotherapy was retrospectively scored using RTOG-EORTC 
criteria.22
Statistical analysis was performed using IBM SPSS Statistics 21. Continuous variables are 
shown as median with interquartile range (IQR), and categorical variables as numbers 
with percentages.
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PALGA database of patients with new 
diagnosis of extra-abdominal DF
(n=1134)
Requested identification by PALGA
(n=277)
Exclusion on patients with excision <6 
months of diagnosis or patients with 
primary excision (n=857)
All laboratories were contacted for 
further identification based on local 
pathology numbers.
277 excerpts were linked to 328 
pathology numbers in 50 laboratories
(51 double identifications)
(n=328)
Centres with >10 pathology numbers 
were contacted for patient identification 
and file retrieval (n=186)
- 11 centres, 8 willing to cooperate. 
(n=152)
- Centre based databases were 
available for additional inclusion 
of patients (29 additional patients 
identified)
Response from 24 laboratories, 
responsible for 219 excerpts (including
unknown number of doubles).
(n=219)
Requested identification by PALGA to 
link excerpt number to pathology 
number and laboratory
181 patients identified and available for 
file review
Exclusion based on:
 16x not traceable
 4x no desmoid
 3x recurrent disease, no data on 
primary
 27x intra-abdominal disease 
(mostly pelvis)
 40x primary surgery
91 patients for analysis
Figure 1. CONSORT diagram of patient selection
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N % N % N % N %
Gender
Male 30 33 9 24.3 12 34.3 9 47.4
Female 61 67 28 75.7 23 65.7 10 52.6
Age (years)
Median (IQR) 39 (33.1-52.2) 36 (31.2-51.6) 43.6 (39.4-52.4) 34.8 (23.3-46.3)
Localization
 Head/Neck 9 9.9 3 8.1 6 17.1 - -
 Thorax/back 35 38.5 13 35.1 13 37.1 9 47.4
 Abdominal 
wall
25 27.5 17 45.9 1 2.9 7 36.8
 Extremity 21 23.1 4 10.8 15 42.9 2 10.5
 Other* 1 1.1 - - - - 1 5.3
Size
 <5 cm 25 27.5 16 43.2 7 20.0 2 10.5
 5-10 cm 48 52.7 18 48.6 19 54.3 11 57.9
 >10 cm 15 16.5 2 5.4 8 22.9 5 26.3
 Missing data 3 3.3 1 2.7 1 2.9 1 5.3
Beta-catenin 
(nuclear)
 Positive 56 61.5 28 75.7 16 45.7 12 63.2
 Negative 10 11 3 8.1 6 17.1 1 5.3
 Unknown 25 27.5 6 16.2 13 37.1 6 31.6
N=number of patients. Cm=centimetres. IQR = interquartile range. *groin.
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Results
The PALGA search covering the period between 1-1-1993 and 31-12-2013, identified 1134 
patients with extra-abdominal and trunk/abdominal wall DF. Patients were selected 
using in- and exclusion criteria (see Figure 1). Of these 1134 patients, 277 fulfilled the 
inclusion criteria for our study and 181 of these patients were treated in one of the 
seven hospitals selected for our study. Their files were reviewed for details on tumour 
characteristics and treatment modalities. After chart review 90 additional patients were 
excluded, because the chart review revealed additional information not available in 
the pathology report. Centre-based registrations provided data on additional patients 
(diagnosed in 2014). In total, 91 patients were included for further analysis based on 
in- and exclusion criteria. Baseline characteristics are listed in Table 1. Details on beta 
catenin (CTNNB1) and APC gene mutation status were reported sporadically. To our 
knowledge, 6 patients with APC gene mutation were included. Due to the scarce data, 
these factors were not included in further analyses.
Based on initial management patients were divided in 3 groups: active surveillance, 
radiotherapy and systemic treatment. Outcomes for each group are listed in Table 2. 
Median follow-up for active surveillance, radiotherapy and systemic treatment was 
16 months (IQR 7-31), 44 months (IQR 24-62) and 5 months (IQR 2-12) respectively.
Table 2. Outcome of non-surgical treatment, using best response according to RECIST
CR PR SD PD Unknown Total
N % N % N % N % N % N
Active 
surveillance 2 5.4% 4 10.8% 21 56.8% 5 13.5% 5 13.5% 37
Radiotherapy 4 11.4% 11 31.4% 16 45.7% 0 0% 4 11.4% 35
Systemic 
treatment 1 5.3% 1 5.3% 10 52.6% 2 10.5% 5 26.3% 19
N=number of patients. CR=complete response. PR=partial response. SD=stable disease. 
PD=progressive disease.
There is a clear increase in the use of non-surgical management over the years, from 
0.6% in 1993 -1998 up to 12.8% in 2009-2013 (Table 3). Table 3 also presents data of 7 
additional patients diagnosed in 2014, which were found during chart review.
2
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Table 3. First-line non-surgical treatment per 5 year time period.
1993-1998 1999 - 2003 2004 - 2008 2009 - 2013 2014 Total
N N N N N N
PALGA registration4 180 185 331 438 1134




0 0 5 26 6 37
Radiotherapy 0 1 13 20 1 35
Systemic 
treatment
1 4 4 10 0 19
Percentage* 0.6 % 2.7% 6.6% 12.8% 8.0%
N=number of patients. * Percentage of non-surgical treatment compared to overall diagnoses as 
documented in the PALGA registration
Active surveillance
Thirty-seven patients had active surveillance after diagnosis. Tumour localization was as 
follows: 3 patients with head/neck tumours, 13 patients with truncal tumours, 17 patients 
with abdominal wall tumours and 4 patients with extremity tumours.
Best response during that period was spontaneous CR for 2 patients (5%), PR for 4 
patients (11%), SD for 21 patients (57%) and PD for 5 patients (14%). For 5 patients, images 
required for RECIST were not available. CR was documented after 12 and 17 months, PR 
after 5, 10, 12 and 36 months. During the follow-up period, 13 patients had progressive 
disease with a median TTP of 7.3 months (IQR 4.1 – 11.9). In total, 22 patients (63%) were 
still under active surveillance at the date of last follow-up after a median of 16 months, 
including all patients with CR or PR (median duration of active surveillance for patients 
with CR and PR was 22 months, IQR 13-46). Of the 21 patients with SD as best outcome, 
3 ended active surveillance due to complaints related to the tumour without actual 
progression and 5 patients ended due to progression (<20%). Thirteen patients with SD 
continued active surveillance till end of follow-up. Of the 5 patients with PD, 1 patient 
continued active surveillance. Two patients with unknown outcome continued active 
surveillance till end of follow-up.
Radiotherapy
Initial treatment was radiotherapy for 35 patients. Tumour localization was categorized 
as follows: 6 patients with head/neck tumours, 13 patients with truncal tumours, 1 patient 
with abdominal wall tumour and 15 patients with extremity tumours.
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Most patients (n=34) received 56 Gy in 28 fractions of 2 Gy or 25 fractions of 2 Gy and 
2 fractions with 3 Gy. One patient with a tumour on the head/neck received 54 Gy over 
30 sessions of 1.8 Gy.
Ten patients had no toxicity, 11 patients had grade 1 (mild joint stiffness, slight atrophy, 
pigmentation change), 10 patients had grade 2 (patch atrophy, moderate fibrosis, 
moderate joint stiffness) and one patient had grade 3 toxicity (severe joint stiffness). Of 
three patients insufficient data were available.
Best response to radiotherapy was CR in 4 patients (11%), PR in 11 patients (31%) and SD 
in 16 patients (46%). For 4 patients, no images were available to determine outcome 
according to RECIST. CR was documented after 12, 17, 26 and 29 months, PR after median 
15.5 months (range 4-56 months). During follow-up, 2 patients developed PD with TTP 
of 31 and 47 months.
Systemic treatment
Nineteen patients received initial systemic treatment. This consisted of non-steroid 
anti-inflammatory drugs (NSAID) in 10 patients, anti-hormonal therapy (HT) in 5 patients, 
chemotherapy (ChT) in 1 patient, a tyrosine kinase inhibitor (TKI) in 1 patient and a 
combination of HT and TKI in 1 patient. Details were missing for 1 patient.
Tumour localization was categorized as follows: thoracic/back in 9 patients, abdominal 
wall in 7 patients, extremity in 2 patients and groin in 1 patient.
Best response during initial systemic treatment was CR for 1 patient (5%), PR for 1 patient 
(5%), SD for 10 patients (53%), PD for 2 patients (11%) and unknown for 5 patients (26%). 
CR was documented after 12 months, PR after 24 months. The female patient with CR 
received HT. The patient with PR received an NSAID. The 10 patients with SD were on 
NSAIDs (n=7), HT (n=2) and TKI (n=1). PD was seen after an NSAID (n=1) and ChT (n=1). 
During follow-up, 3 patients developed PD with TTP of 6.3, 7.1 and 7.2 months.
After initial systemic treatment, multiple systemic treatments were given to 10 patients 
in different regimens. Seven patients received 2 treatment regimens and three patients 
received a total of 4 treatment regimens.
Discussion
The change in treatment strategies from initial surgery with or without radiotherapy to 
initial non-surgical management has been fuelled by several studies and increasing 
expertise about this disease with its unpredictable behaviour. The level of evidence is 
limited by the rarity of this disease. The Dutch cohort represents a unique and large 
group of patients with data on real life practice. Within this group, analyses show that a 
2
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25% response rate and 52% stable disease rate was achieved using initial non-surgical 
management.
Over the past 20 years, first-line non-surgical management has increased up to 12.8%. 
Although the ratio between the time periods might be biased by several factors (such 
as limited numbers and registration), the trend towards non-surgical management is 
evident and is expected to increase, as more specialists adhere to the current guidelines. 
Although there is an increase in non-surgical management, still most patients are 
managed by surgery. Complaints such as pain or cosmetic reasons are reasons to do 
a resection. A resection could also have been performed for diagnostic purposes. Finally, 
limited experience with non-surgical treatment in non-referral centres could explain 
this high incidence of surgical excisions. As only chart review was done for patients with 
first line non-surgical treatment we can only hypothesize about the reason for surgical 
management.
Literature on first-line non-surgical management is limited and most studies are reports 
from specialized centres. Retrospective studies with combined data from the French 
and Italian research groups reported promising results for all tumour localizations.23-25 
The present study was designed to provide more insight in common practice for this 
rare disease on a population based level. In a national database of 1134 patients, the 
number of non-surgically treated patients is small, but definitely increasing. Obviously, 
surgery has remained the first-line treatment over the last 20 years, but a paradigm shift 
towards active surveillance can be observed. The surveillance cohort is the largest group 
among patients managed non-surgically. Radiotherapy was the second used treatment 
modality. In general, radiotherapy is indicated only in serious cases where progression 
of the tumour can lead to serious morbidity.6 The risk of acute and late toxicity, including 
secondary malignancy, restricts its application, particularly in the young age group and 
in those patients with abdominal locations. Compared to the study by Colombo, et al., 
the current study showed a high frequency (38%) of patients treated with radiotherapy 
compared to 3% in the French/Italian study.23 No other studies are available and the 
reason for this high number of primary irradiated tumours is unknown. Compared to 
the surveillance cohort, there is a relative high number of patients with an extremity 
localization in the radiotherapy group. Although we do not exactly know, it could be 
that patients with an extremity tumour are less likely to be referred and when they are 
referred they are symptomatic and therefore prone to have surgery or radiotherapy. The 
small numbers of patients who received systemic treatment reflect the limited evidence 
for any of the treatment options and lack of clinical studies in the Netherlands. This study 
was not designed to compare the outcome of the different treatment modalities, merely 
to report common practice over the years.
Overall, outcome of first-line non-surgical treatment was good with a 25% response rate 
and 52% stable disease rate. Of all evaluable patients 90% did not have early progression 
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of disease. Among patients under active surveillance, 16% showed spontaneous 
regression and 57% disease stabilization. These results might be biased because in 
many cases choice for first-line treatment was made after referring the patient to a 
tertiary referral centre which enabled the physicians to observe the natural behaviour of 
the tumour, thereby selecting patients for either active surveillance or more aggressive 
treatments. As referring these patients to a tertiary referral centre is common practice in 
the Netherlands, this reflects the common practice in the Netherlands. For radiotherapy, 
the patients in the present study received radiotherapy at the recommended dose 
of 50-56 Gy.6-8,26 Results of radiotherapy showed a response in 43% and SD in 46% of 
the patients. During the follow-up period (median of 44 months (IQR 24-62) only 2 
patients had disease progression with long TTPs of 31 and 47 months. These results are 
promising and might seem to advocate radiotherapy. However, radiotherapy might 
be considered an aggressive treatment for this intermediate grade tumour, usually 
reserved for patients with advanced disease. Especially in younger patients, given the 
low, but present long term risk on irradiation induced sarcomas radiotherapy is not 
deemed as first line treatment. When systemic treatment is chosen, a large variety of 
possible agents and regimens are applied (despite the lack of a specific registration 
for DF), such as hormonal agents, NSAIDS, chemotherapy and angiogenesis inhibitors, 
making comparison impossible. Although the group in the present study was small 
and diverse, results show stabilization and response in 63% of patients. Again, due to 
the large variety, no conclusions can be made for on preference of specific agents or 
regimens.
Given the lack of randomized studies, treatment decisions should be made during 
multidisciplinary expert meetings. Decision making should take into account location 
and growth of the tumour, but in particularly the symptoms of the patient. A recent study 
by the French Patients advocacy group SOS desmoid, showed that 63% of patients that 
participated in a survey reported pain.27
The optimal first-line non-surgical management of DF has been discussed by many 
groups, predominantly based on expert opinions and specific treatment modalities. The 
European consensus, reported by Kasper et al.5 advises to start with active surveillance 
and switch to active treatment in case of 3 subsequent reports of progression, and 
that treatment should be guided by tumour localization. There is no staging system 
available to predict outcome at the time of diagnosis. Predictive factors have been 
described, such as age, tumour localization and CTNNB1 mutations.28-33 Recent data 
on CTNNB1 mutations show different behaviour for tumours with different mutations. 
In the future, these mutations could play an important role when deciding to initiate 
specific treatment modalities. Moreover, it is increasingly important to recognize the 
lack of association between radiological volume and symptoms.34-36 Given the chronic 
condition and the spontaneous fluctuations of the disease this should be taken into 
account in any decision that will be taken.
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By the use of PALGA, the Dutch pathology registry, and the long study period, we have 
tried to be as inclusive as possible. Because referral for a desmoid-type fibromatosis to 
one of the sarcoma referral centres is standard practice in the Netherlands, we consider 
this overview as unbiased. However, a part of the patients identified from PALGA, were 
not included because they were treated outside the referral centres. The referral of 
these patients is essential to develop expertise in the treatment of this rare disease.
A limitation of the study is it retrospective nature. As a result, details on symptoms during 
or after treatment are lacking, which could have provided insight in the way decisions to 
either management had been taken. Therefore, no comparisons can be made between 
the different strategies. The natural behaviour of these tumours is variable, varying from 
spontaneous regression to long-term disease stabilization and rapid progression. In the 
absence of randomization, no clear recommendations can be given.
Conclusion
Desmoid-type fibromatosis remains a rare disease, for which several treatment 
modalities are available. Active surveillance seems to be a good and safe initial 
treatment, with options for active treatment in case of progression. Importantly, 
expected benefits from therapy should be well balanced against potential treatment-
induced chronic and late effects.
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Radiation induced sarcomas 
occurring in desmoid-type 
fibromatosis are not always derived 
from the primary tumour
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Desmoid-type fibromatosis is a rare, highly infiltrative, locally destructive neoplasm 
which does not metastasize, but recurs often after primary surgery. Activation of the Wnt/
β-catenin pathway is the pathogenic mechanism, caused by an activating mutation in 
exon 3 of CTNNB1 (85% of the sporadic patients). Radiotherapy is a frequent treatment 
modality with a local control rate of approximately 80%. In very rare cases this may result 
in the development of radiation induced sarcoma. It is unclear whether these sarcomas 
develop from the primary tumour or arise de novo in normal tissue. In four tertiary 
referral centres for sarcoma, six cases of desmoid-type fibromatosis that subsequently 
developed sarcoma after radiotherapy were collected. The DNA sequence of CTNNB1 
exon 3 in the desmoid-type fibromatosis and the subsequent post-radiation sarcoma 
was determined. Sarcomas developed 5-21 years after the diagnosis of desmoid-
type fibromatosis and included two osteosarcomas, two high grade undifferentiated 
pleomorphic sarcomas, one fibrosarcoma and one undifferentiated spindle cell 
sarcoma. Three patients showed a CTNNB1 hotspot mutation (T41A, S45F or S45N) in 
both the desmoid-type fibromatosis and the radiation induced sarcoma. The other 3 
patients showed a CTNNB1 mutation in the original desmoid type fibromatosis (two with 
a T41A and one with a S45F mutation), which was absent in the sarcoma. In conclusion, 
post-radiation sarcomas that occur in the treatment area of desmoid-type fibromatosis 
are extremely rare and can arise through malignant transformation of CTNNB1 mutated 
desmoid fibromatosis cells, but may also originate from CTNNB1 wild-type normal cells 
lying in the radiation field.
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Introduction
Desmoid-type fibromatosis (ICD-O 8821/1) is a rare, locally aggressive (myo-) fibroblastic 
neoplasm that arises in deep soft tissues.1 It does not metastasize, but is characterized 
by infiltrative growth and it may recur in a high proportion of cases after primary 
surgery.2-4
Desmoid-type fibromatosis may occur in the context of familial adenomatous polyposis 
(FAP) (OMIM #175100), which is caused by an inactivating mutation of the adenomatous 
polyposis gene (APC). The product of the APC gene is part of the destruction complex of 
β-catenin and consequently APC inactivating mutations result in activation of the Wnt/β-
catenin pathway. An alternative mechanism for activation of this pathway is a mutation 
in exon 3 of CTNNB1, the gene encoding β-catenin, which results in stabilization of the 
protein. CTNNB1 mutations occur in 85% of the sporadic desmoid-type fibromatoses.5 
Activating mutations are located at the GSK3β phosphorylation sites located in the 
N-terminus of β-catenin and alter the functionality of these sites, thereby preventing 
degradation of the protein.6 Stabilization of β-catenin facilitates its translocation to the 
nucleus where it associates with a member of the TCF family of DNA binding proteins 
and subsequently causes transcription activation of target genes such as MYC, CCND1 
and AXIN2. Activation of this so-called canonical Wnt signal transduction pathway can 
be assessed by nuclear immunohistochemical staining for β-catenin. When β-catenin 
is not activated by canonical Wnt signalling, it is degraded in the cytoplasm or can 
be found at the membrane as part of the cadherin mediated adherens junctions.7
The treatment of desmoid-type fibromatosis is under debate, because the natural 
course of the disease varies between spontaneous regression, stable disease for a 
long time and rapid progression.8,9 A policy of wait and see is now the first line option in 
many patients and in cases where local therapy is considered to lead to high morbidity, 
medical treatment is considered a first line option.
Until recently, desmoid-type fibromatosis was preferably treated by surgery with a wide 
margin. However, these lesions often are poorly circumscribed and may infiltrate in 
the surrounding tissue, which hampers adequate surgical excision. If surgery is not 
possible or insufficient to eradicate the entire tumour, radiation therapy is effective 
with a local control rate of approximately 80%.10 For general cancer treatment, the 
incidence of radiotherapy-induced sarcoma was estimated to be 0.06%.11 Three case 
reports were found in literature describing the occurrence of a radiotherapy-induced 
sarcoma in patients with desmoid-type fibromatosis.12-14 It is unclear whether these 
sarcomas developed from the primary tumour or arose de novo in normal tissue. To 
assess this issue, we determined whether post-radiation sarcomas arising in desmoid-
type fibromatosis contain mutations in CTNNB1. We examined six cases from four tertiary 
3
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sarcoma reference centres and determined the DNA sequence of exon 3 in the desmoid-
type fibromatosis and the subsequent post-radiation sarcoma.
Methods
Cases
Cases were obtained from the institutional cancer databases of four tertiary referral 
centres for sarcoma. Slides of the desmoid-type fibromatosis and sarcoma were 
reviewed to confirm the diagnosis. Radiation induced sarcoma was defined as a 
sarcoma occurring in the previously irradiated fields.
CTNNB1 mutation analysis
DNA was isolated from formalin-fixed paraffin-embedded tissue using a previously 
described protocol.15 Exon 3 of CTNNB1 gene was sequenced as described.16 
Immunohistochemical staining for b-catenin was done routinely. Staining for p53 was 
performed using an antibody from Dako (Carpinteria, CA, USA, clone DO-7, dilution 1:500, 
antigen retrieval pH 9, positive control normal skin).
Results
Brief case descriptions
Patient 1 was a 12-year-old boy, when he was diagnosed with a desmoid-type 
fibromatosis of the right shoulder, which was resected and recurred approximately 40 
months after the resection. (This case was previously described in a study of post-
radiotherapy histologic changes in desmoid-type fibromatosis.17) The recurrence was 
treated with radiotherapy, total dose 60 Gy. Almost sixteen years after radiotherapy, 
a radiotherapy induced fibrosarcoma was found, and treated with a forequarter 
amputation.
Patient 2 was a 16-year-old woman, when she developed a large desmoid-type 
fibromatosis of the right leg and thigh, which was treated with surgery multiple times 
and external radiotherapy. At age 32, 16 years after the first diagnosis of the desmoid-
type fibromatosis, she received iridium 192 as brachytherapy 25 Gy over approximately 
50 hours minimum tumour dose. This was preceded by one hour of hyperthermia at 
42 to 43 degrees Celsius. Two years later, at age 34 years, she was diagnosed with 
an osteosarcoma of the midshaft of the right femur for which she was treated with a 
hemipelvectomy. She was lost to follow up in 2011 at the age of 49 with no evidence of 
disease, at which point it had been 17 years since her osteosarcoma was treated.
Patient 3 was a 60-year-old woman, when she developed a desmoid-type fibromatosis 
tumour of the left side of the neck treated by surgery and radiation therapy. Six years 
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later she developed an osteosarcoma of the left scapula. Because this case was 
diagnosed in 1977, we could not retrieve any additional information.
Patient 4 was a 21-year-old male, when he was diagnosed with a desmoid-type 
fibromatosis of the left shoulder. He was treated medically with a non-steroidal anti-
inflammatory drug (NSAID) (stopped because of progression) and later on a combination 
of an anti-oestrogen treatment and a selective COX-2 inhibitor, and had radiotherapy 
twice, first of the left shoulder 4 years before the development of the sarcoma (56 Gy) 
and then the second time for a recurrence at the distal field border 1.5 years before the 
development of the sarcoma (56 Gy). Six years after the primary diagnosis, biopsy of a 
progressive lesion in the left axilla showed a high grade undifferentiated pleomorphic 
sarcoma, for which a forequarter amputation was performed. He died 3 months later 
of pleural and pulmonary metastases.
Patient 5 was a 32-year-old male, who was diagnosed with a desmoid-type fibromatosis 
of the right shoulder/neck. He was treated with repeated surgery, medical treatment, 
i.e. NSAID/anti-oestrogen treatment, MTX/vinblastine and an oral VEGFR tyrosine kinase 
inhibitor, and twice radiotherapy (11 years before development of the sarcoma 46 Gy + 14 
Gy boost and 1.5 year before 56 Gy). He was diagnosed 11 years after the initial diagnosis 
with an undifferentiated pleomorphic sarcoma in the radiotherapy fields with pulmonary 
metastases, for which he was treated with doxorubicin/ifosfamide without effect and 
died 6 months later of progressive disease.
Patient 6 was a 24-year-old female diagnosed with desmoid-type fibromatosis of the 
left upper arm. This tumour was excised with clear margins, but recurred and 18 months 
later was again treated with resection of what was now a 10 cm mass. As margins 
were microscopically positive, she received radiotherapy and subsequently received 
methotrexate, vinblastine, and capecitabine. When her desmoid again recurred, she 
was given sorafenib. Five years after her initial desmoid surgery (and three years after 
her radiation therapy at the site of recurrence), she developed an undifferentiated 
spindle cell sarcoma within the prior radiation site. This was resected with limb sparing 
surgery followed by treatments with doxorubicin and ifosfamide. Chemotherapy 
was complicated by cardiotoxicity and development of a pulmonary embolism. 
Approximately 3 months ago, she presented with adjacent local recurrences of both 
her desmoid and the undifferentiated spindle cell sarcoma for which she is currently 
under treatment.
3
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Histology and immunohistochemistry
Representative photographs of the histology of the desmoid-type fibromatosis and 
the corresponding radiation induced sarcoma per patient are shown in figure 1. The 
diagnosis of desmoid-type fibromatosis was confirmed by nuclear beta catenin staining 
in five of six cases. Two out of six radiation induced sarcomas revealed nuclear staining 
for beta-catenin, while nuclear staining was absent in the remaining four sarcomas. 
(Figure 2, table 1)
Immunohistochemistry for p53 revealed overexpression in the sarcoma of patient 5, 
while staining in the sarcomas of patients 1, 4 and 6 revealed a wild-type pattern. (Figure 
3) The sarcomas developed 3-21 years after radiation therapy.
CTNNB1 mutation testing
In all six cases a CTNNB1 mutation was detected in the desmoid-type fibromatosis. 
Three patients had a T41A mutation, two a S45F mutation and one a S45N mutation. In 
three patients the mutation was not present in the radiation-induced sarcoma. In the 
other three cases the T41A, S45F and S45N mutation were also present in the radiation-
induced sarcoma. (Table 1)
3

























Figure 1: Hematoxylin and eosin stained slides of both desmoid-type fibromatosis 
and radiation induced sarcoma of all patients. 
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Figure 2: Immunohistochemical staining for B-catenin, which shows nuclear expres-
sion of B-catenin in desmoid-type fibromatosis of all patients, except for patient 3. 
B-catenin showed also nuclear positivity in the sarcoma of patient 5. All other 
sarcomas had a membranous localisation of B-catenin.
3
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Figure 3: Immunohistochemical staining for p53, which shows nuclear expression of 
p53 in the radiation induced sarcoma of patient 5. All other tumours were negative for 
p53. Patient 6 also had a wild-type pattern, but photographs were not available.
Discussion
The high recurrence rate of desmoid-type fibromatoses (14-64%)2-4 when only surgery is 
used, together with the difficulty to achieve complete resection without positive margins, 
has led to the use of adjuvant or alternative treatments of this locally aggressive but 
non-metastatic tumour. Radiation therapy has been used both as an adjuvant to surgery 
or as first-line single modality treatment and has shown local control rates of 80% with 
an average dose of 56 Gy.10 There were no morphological and immunophenotypical 
differences when comparing desmoid-type fibromatoses before and after radiation 
therapy, which suggests that histomorphologic alterations attributable to the effects of 
ionizing radiation in desmoid-type fibromatosis are usually minimal.17
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In the current study we show that the development of a sarcoma in desmoid-type 
fibromatosis after radiotherapy is extremely rare, as we have collected six such cases 
from four different referral centres. For instance, in the Leiden University Medical Centre, 
57 patients were treated with radiotherapy for desmoid-type fibromatosis of which 
two developed a radiation induced sarcoma (patients 4 and 5). A CTNNB1 hotspot 
mutation in exon 3 is the hallmark of sporadic desmoid-type fibromatosis and was 
indeed found in all desmoid-type fibromatosis tumours analysed in this study. The 
sarcomas presented 3-21 years after radiotherapy, and histological subtypes included 
osteosarcoma, fibrosarcoma and undifferentiated sarcoma. We show that radiation 
induced sarcomas can develop as a new primary, lacking CTNNB1 mutations, as well 
as result from malignant transformation of the desmoid-type fibromatosis, retaining 
the CTNNB1 mutation.
It has been suggested that desmoid-type fibromatosis patients with a S45F mutation 
are at higher risk for recurrence than those with T41A or no mutation in CTNNB15,18; 
however other studies did not find this difference.19,20 Although our series is small, 
different mutation types, including a rare variant (S45N) were found in the desmoid-
type fibromatosis that preceded the radiation induced sarcomas, so it seems unlikely 
that mutation type is associated with malignant transformation. The S45N mutation 
of case 6 is caused by two nucleotide substitutions, i.e. TCT to AAT. It is not reported 
as mutation in the COSMIC database (http://cancer.sanger.ac.uk/cosmic), however it 
was reported as a mutation in CTNNB1 recently, and personal communication with the 
authors confirms that it was detected in a case of fibromatosis.21
Only one out of four sarcomas, for which we could perform immunohistochemistry for 
p53, revealed overexpression of the protein, suggestive of a TP53 mutation. Therefore, 
it seems unlikely that TP53 plays a major role in the development of radiation induced 
sarcoma in desmoid-type fibromatosis.
In conclusion, postradiation sarcomas are rare though may arise in the treatment area 
of desmoid-type fibromatosis either de novo, lacking the CTNNB1 mutation characteristic 
of the original desmoid-type fibromatosis, or may arise from malignant transformation 
of pre-existing desmoid-type fibromatosis cells, retaining the CTNNB1 mutation.
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Symptomatic Gastrointestinal Stromal Tumours (GIST) are infrequent with an incidence of 
12.7 per million inhabitants in the western population. We studied whether the incidence 
of GIST has further increased between 2003 and 2012 and assessed the frequency of 
mutations, risk groups, histological subtypes and immunohistochemistry results.
Methods
From PALGA, the nationwide Dutch Pathology Registry, pathology excerpts from all 
patients with a GIST or GIST-like tumour between 2003 and 2012 were retrieved to 
calculate incidence rates. Full pathology reports were retrieved of resections in 2011 
and 2012 to study the frequency of mutations, risk groups, histological subtypes and 
immunohistochemistry results.
Results
The incidence of GIST increased to 17.7 per million inhabitants in 2012 with a median 
age of 67 years. Mutational analysis was performed in 33.9% of patients with a 
resection between 2011 and 2012 (KIT mutation 67.5%, PDGFRA 16.3%, wild-type 11.4%). The 
percentage of high-risk patients in the different risk classifications varied from 19.9% 
to 38.0% depending on the used classification. Only 35.9% of patients had diagnosis or 
revision of pathology diagnosis within three months in a designated GIST referral centre. 
No increase in proportion of central pathology reviews was found. Proportion of patients 
with mutational analysis increased over the years.
Conclusion
The registered incidence of GIST, 17.7 per million inhabitants in 2012 in the Netherlands, is 
still rising. Despite incorporation in the ESMO GIST guidelines since 2008 for mutational 
testing and since 2010 for central review of pathology, both are performed in a minority 
of patients.
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Introduction
The most common mesenchymal tumours of the gastrointestinal tract are 
Gastrointestinal Stromal Tumours (GISTs).1 Clinical behaviour is predicted by primary 
localisation, tumour size, mitotic index and tumour rupture.2 The differential diagnosis 
contains gastrointestinal leiomyoma and leiomyosarcomas, desmoid-type fibromatosis 
and schwannoma.3 The estimated incidence of GIST in the Netherlands was 12.7 per 
million inhabitants in 2003.4 Studies in other countries report incidences between 7.8 
and 21.1/million.5-10 Most studies were non-nationwide, doctor-driven cancer registry 
studies.11
Primary treatment remains surgery and when non-resectable, imatinib has considerably 
improved prognosis of these patients.2,12-15 Response to imatinib and progression free 
survival depend on mutational status.16,17 KIT is the most commonly mutated gene (76.2-
83.6%), followed by PDGFRA (3.2-11.2%).18,19 A significant subset of the 10-15% of GISTs that 
lack mutations in KIT or PDGFRA, are associated with loss of function of the succinate 
dehydrogenase complex, the so called SDH deficient GIST, which has specific histological 
features.20-24
The diagnosis of GIST is based on morphology and CD117 and/or DOG1 
immunohistochemistry.2,18,22,25,26 Mutational analysis is considered standard of care in the 
diagnostic work-up for GIST for the first time in the 2008 ESMO guidelines and after 2010 
confirmation by an expert pathologist is recommended.2,27,28 These recommendations 
are incorporated in the Dutch guidelines.29
In 2004 a nationwide survey was performed in the Netherlands to estimate the incidence 
of GIST in 1995 and 1998 to 2003.4 We repeated this study for the following ten years (2003-
2012) during which the diagnosis GIST was well established. Our primary objective was 
to estimate the incidence of GIST and the classification into the different risk categories, 
the frequency of the various mutations, immunohistochemical markers and histological 
subtypes. The secondary aim was to compare the current daily practice of pathology 
reporting with the actual ESMO guidelines.
Methods
Patients
From PALGA, the nationwide network and registry of histo- and cytopathology in the 
Netherlands,30 all excerpts were retrieved matching the following search criteria: GIST 
or metastasis of GIST OR ((malignant) leiomyoma (i.e. leiomyoma, leiomyosarcoma, 
leiomyoblastoma etc.) AND gastrointestinal tract). A second search was performed 
with the following criteria (used earlier by Goettsch et al.4): (gastro-intestinal tract OR 
abdomen OR retroperitoneal OR abdominal wall) AND (liposarcoma OR desmoid-type 
4
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fibromatosis OR solitary fibrous tumour OR schwannoma OR malignant peripheral nerve 
sheath tumour). The standardized excerpts contain encrypted patient identification, age 
at diagnosis, sex, the date of arrival of the pathology specimen, whether the analysis 
was done in a clinical centre active in GIST (defined below) and the conclusion of the 
pathology report. Patients with a first, incident GIST were included. AJV extracted the 
data and uncertain pathology conclusions in the reports were discussed with HG and 
JVMGB. For uncertain cases, full pathology reports were retrieved. Because not all 
questions could be answered with the information in the excerpts, full pathology reports 
were retrieved for all patients with a primary resection for a GIST in 2011 or 2012.
A clinical centre active in GIST was defined as a centre with more than 15 new pathology 
diagnosis of GIST per year and a dedicated multidisciplinary sarcoma team. Five 
Dutch centres met these criteria: the Erasmus Medical Centre, Rotterdam, the Antoni 
van Leeuwenhoek hospital, Amsterdam, the University Medical Centre Groningen, 
the Radboud University Medical Centre, Nijmegen, and the Leiden University Medical 
Center.
Data collection
Data was collected on age at diagnosis, sex, year of diagnosis, localisation, tumour size, 
mitotic rate, immunohistochemical staining results (CD117, DOG-1, SDHB, desmin, smooth 
muscle actin and CD34), mutation analysis and surgical resection margins. Tumour 
size and mitotic rate were categorized into to the categories used in the various risk 
classifications, i.e. <2, 2-5, 5-10, >10 cm and 0-5, 6-10, >10 mitoses per 50 HPF or 5 mm2, 
depending on what was reported.
Risk stratification scores
For the analysis of the different risk stratification scores patients were grouped according 
to the criteria of Fletcher31, Miettinen 200232, revised Miettinen/AFIP33, Joensuu34 and 
Gold nomogram35. Most risk classifications give a long-term indication of the risk 
of recurrence, but the Gold nomogram specifies the 2- and 5-year recurrence free 
survival (RFS) after surgery. For the comparison the 5-year RFS was used. RFS rates were 
categorized to a low risk group (Gold nomogram 5-year RFS 90-100%), moderate risk 
group (75-90%) and high-risk group (<75%), which are comparable to percentages given 
in the revised Miettinen/AFIP criteria. Because it is not possible in the RFS calculation to 
have a RFS >96%, no very low risk group was identified.
Statistical analysis
The incidence rate of GIST was calculated per million inhabitants, also standardised 
for 5 year age groups and sex for the Dutch population of 2012 and standardized to the 
WHO and European (ESR) standard population.36,37 Time trends for incidence were either 
tested for significance with regression analysis or a Mantel-Haenszel Χ2–test for trend. 
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Spearman’s rank correlation coefficient was used to test the correlation between the 
different risk classifications.
Results
Figure 1 shows the search strategy and numbers of patients identified. In total 2456 
patients were included for incidence analysis and 489 patients were included for full 
pathology report analysis.
4551 Patients retrieved from first 
search
4038 Other diagnosis than GIST 
2842 Patients with possibly GIST
2456 Total patients included for 
analysis
150  First diagnosis before 2003
59 Patients with uncertain 
diagnosis
600 Patients with information on size, 
localisation and mitotic rate 
(based on excerpts)
2329 Additional patients 
after second search
2 Diagnosis after death
175 Foreign 2nd opinions
495 Patients with resections in 2011 
and 2012 for whom full PA reports 
were requested
470 Patients with at least one full PA 
report retrieved
363 Patients with sufficient information 
for risk classification 
(based on full reports)
Figure 1 Diagram of inclusion and exclusion of patients
The mean age of patients was 65 years (SD 13), median 67 years (range 3-96) and 1307 
(53.2%) patients were male. (See also supplementary figure 1) The localisation of the 
GISTs (patients with excerpts between 2003 and 2012) was the stomach in 59.8%, small 
intestine in 21.1%, rectum in 2.2%, colon in 1.6%, oesophagus in 0.6% and intra-abdominal 
not further specified in 11.0%. For the patients with full reports between 2011 and 2012 the 
localisation was stomach in 65.0%, small intestine in 26.8%, rectum in 3.1%, colon in 1.6%, 
oesophagus in 0.8% and intra-abdominal not further specified 1.8%. The group with a 
small intestine GIST was further subdivided in duodenum 6.1%, jejunum 5.1%, ileum 1.0%, 
and not specified in 14.5%. (supplementary table 1)
4
Binnenwerk_Productie.indd   63 2/10/2021   8:04:44 PM
64
Chapter 4
Of the 6 patients <21 years of age, 4 were female (3, 15, 18 and 20 years) and 2 were male 
(14 and 17 years). Localisations were the stomach (n=4), colon (n=1) and intra-abdominal 
not further specified (n=1).
Incidence rates (table 1 and figure 2A)
The standardized incidence rate increased from 12.2 per million in 2003 to 17.7 in 2012 
(p<0.05). Age of peak incidence was 70-74 years with an incidence of 73.9 per million in 
2012 for this age group. The incidence of GIST before the age of 21 was 0.13 per million 
per year.
Figure 2A. Incidence of GIST standardized for the Dutch population of 2012
Figure 2B. Relative incidence of the four tumour diameter groups
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2003 174 10.7 7.2 12.2 13.5
2004 224 13.8 9.3 15.5 17.2
2005 233 14.3 9.5 15.7 17.2
2006 230 14.1 8.9 15.5 17.2
2007 240 14.7 9.6 15.8 17.3
2008 260 15.8 10.1 16.8 18.5
2009 247 15.0 9.2 15.7 17.1
2010 252 15.2 9.6 15.7 17.1
2011 300 18.0 10.9 18.3 20.1
2012 296 17.7 10.8 17.7 19.4
During the 10-year study period, the proportion of tumours with a size < 2 cm significantly 
increased (p<0.0001) from 4.0 to 13.5% with at the same time a decrease in the proportion 
of patients for which tumour size is not reported from 47.1 to 34.8% (ns) with a stable 
absolute number. (Figure 2B)
Histology
Detailed histological findings were only evaluated for patients with a full pathology 
report. Of the 429 patients (87.7% of patients with a full report) with known morphology, 
81.6% had spindle cell morphology, 9.3% epithelioid subtype and 9.1% mixed epithelioid/
spindle cell subtype. No differences in morphology were found for the specified 
localisations. For GIST patients <21 years histologic subtype was mixed morphology in 
two, epithelioid subtype in two and unknown in two patients.
Immunohistochemistry results were analysed for patients with full pathology reports. 
CD117 was reported in 89.4% of patients and of these 93.6% tested positive. For DOG1 
42.9% of patients were tested with a positive result in 98.6%. For additional results of 
immunohistochemistry see supplementary table 2. For 49 patients (10.0%) no positive 
immunohistochemistry was reported for CD117 and/or DOG-1 in the full pathology reports 
or excerpts of the patients with a full pathology report. Only one was actually reported as 
being negative for both CD117 and DOG-1, all others had at least one of both not reported. 
4
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Resection margins were reported in 404 of 489 patients (82.6%) with a R0 resection in 
84.9%, R1 in 11.6% and R2 in 3.5%.
Risk classification (table 2 and supplementary table 3)
Full pathology reports were requested of all resections performed in 2011 and 2012. Of 
the 489 patients with at least one full pathology report, 414-444 patients had sufficient 
data for risk classification depending on the applied risk classification (because of 
different criteria not all classifications were able to classify the same patients). Although 
comparison of the incidence of risk categories is difficult because risk classifications 
differ in the number of patients eligible for risk stratification, both the Gold risk 
assessment and the Miettinen 2002 classification seem to allocate more patients to 
the highest risk group compared to the other risk classifications. All risk classifications 
had a significant and good to very good correlation (p<0.001) with each other, with an 
R ranging from 0.808 (Gold vs Joensuu) to 0.957 (Miettinen 2002 vs Miettinen/AFIP).
Table 2: Distribution of patients (with full reports) in the different risk classifications




Percentage of patients that could be 
stratified (not possible: percentage 
of all patients)
Fletcher 2002
Very low risk 74 16.7%
Low risk 137 30.9%
Intermediate risk 109 24.5%
High risk 124 27.9%
Not possible 45 9.2%
Miettinen 2002
Probably benign 159 38.5%
Uncertain or low malignant 
potential
97 23.5%
Probably malignant 157 38.0%
Not possible 76 15.5%
Joensuu 2006
Very low, if any malignant 
potential
66 16.2%
Low malignant potential 191 46.8%
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Table 2: Continued.




Percentage of patients that could be 





Probably malignant 81 19.9%
Not possible 81 16.6%
Miettinen 2006
None 68 16.4%
Very low risk 93 22.5%
Low risk 101 24.4%
Moderate risk 67 16.2%
High risk 85 20.5%
Not possible 75 15.3%
Gold 2009 (chance of 5-year recurrence free survival)
90-100% (low risk) 185 42.7%
75-90% (moderate risk) 102 23.6%
0-75% (high risk) 146 33.7%
Not possible 56 11.5%
Not all patients are present in every classification because they do not have all data essential for 
that classification.
Mutational status (table 3)
Mutational status was reported in 461 of the 2456 patients (18.8%) based on excerpts and 
in 166 of 489 patients (33.9%) based on patients with full pathology reports. The presence 
of PDGFRA mutations is relatively high with a frequency of 16.3%. Supplementary figure 
2 shows the distribution of mutated genes compared to age. The number of patients 
with mutational analysis performed increased during the years of study from 5.2% in 
2003 to 29.4% in 2012. (p=0.000)
The frequency of reported mutational analysis increased from low risk tumours (24.7%) 
to the high-risk group (67.1%) (p=0.000). (Supplementary table 4)
4
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Table 3: Mutation frequencies
Gene mutated
All patients after analysis of 
the excerpts 2003-2012
All patients with full pathology 










Percentage of total 
known mutations 
(n=166)1
KIT 322 69.8% 112 67.5%
Exon 9 30 9.3% 11 9.8%
Exon 11 261 81.1% 97 86.6%
Exon 13 8 2.5% 2 1.8%
Exon 17 1 0.3% 1 0.9%
Not reported 22 6.8% 1 0.9%
PDGFRA 64 13.9% 27 16.3%
Exon 12 5 7.8% 1 3.7%
Exon 14 3 4.7% 3 11.1%
Exon 18 46 71.9% 22 81.4%
Not reported 10 15.6% 1 3.7%
BRAF 1 0.2% 1 0.6%
SDHB deficiency 5 1.1% 3 1.8%
Neurofibromatosis 3 0.7% 4 2.4%
Wild-type, i.e. 
KIT and PDGFRA 
negative, in most 
patients no other 
mutation tested2
66 14.3% 19 11.4%
1 For the exons: percentage of patients with a mutation in the specific gene.
2 Patients with a wild-type GIST were at least tested for mutations in KIT exon 9 and 11 and PDGFRA exon 
12 and 18. Most of these patients were not tested for SDH deficiency or BRAF mutations.
Centres of diagnosis, resection and revision
Fifty-two laboratories diagnosed GIST and 49 laboratories had at least one surgical 
resection specimen during the two years for which we requested full pathology reports. 
The pathology department of five GIST centres in the Netherlands diagnosed and 
revised more than 30 pathology resection specimens (>15/year) of GIST in 2011 and 
2012 (15 laboratories <5 specimens, 25 laboratories 6-20 specimens, 4 laboratories 
20-30 specimens in these 2 years and 3 no specimen). If this cut-off of >15 pathology 
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specimens of GIST/year is used as definition of a GIST reference centre and with inclusion 
of all the regional soft tissue pathology panels, then for 13.2% of patients the primary 
diagnosis was established in a GIST centre, surgery was done in 16.2% of the patients 
in a GIST centre and 35.9% of the patients were diagnosed or had a revision of their 
diagnosis within 3 months in a GIST reference centre. No significant increase was found 
in the number of pathology revisions over the years of study (2003 28.7%, 2012 41.2% of 
patients), although there seems to be an increasing trend in the number of reviews after 
the guidelines of 2010. (Supplementary table 5)
It was also assessed whether the pathology specimens revised by a reference centre 
or specialised soft tissue pathology panel were high risk classified patients according 
to the Miettinen/AFIP criteria. Only 30.9% of the patients with a full pathology report with 
no risk for recurrence had a revision of the pathology diagnosis compared to 67.1% of the 
patients with a high risk. (Supplementary table 4) Of all patients with a resection and a 
revision in a reference centre, 61.2% had mutational analysis performed compared to 
10.4% of all the other patients.
Last we analysed whether high risk patients diagnosed in 2011 and 2012 had a mutation 
analysis. Of the patients diagnosed in a GIST reference centre, 92.3% had a mutation 
analysis, but only 16.7% of the patients diagnosed in one of the other centres.
Discussion
The current study shows an increase in incidence of pathology proven GIST from 12.2 
to 17.7 per million inhabitants between 2003 and 2012. This increase in incidence is also 
found in several other studies, like the SEER study (SEER database study, standardized to 
the 2000 US standard population, 2001: 5.5/million, 2011 7.8/million)5, a Taiwanese study 
(Taiwanese Cancer Registry, standardized to the 2000 US standard population, 1998: 11.3/
million, 2008: 19.7/million)6 and last a study from Shanghai (Shanghai Cancer Registry, 
WHO standardized, 2004: 10.1/million, 2008: 14.5/million).7 None of these studies report a 
cause for this increase. Studies reporting incidences before 2000 report also an increase 
in incidence, however this is caused by the introduction of CD117 immunohistochemistry 
to identify GIST.10
We can only hypothesize about the cause of the increase in The Netherlands. First, it 
could be an increased use of diagnostic procedures such as CT scans, gastroscopy and 
endoscopic ultrasound, which is supported by the increase in number of patients with a 
small tumour size. Another possible reason is an increased awareness of the diagnosis 
after the introduction of imatinib as effective treatment. The last possibility could be a 
real increase in the incidence; although this is a possibility, until now no causal factors 
or risk factors for the development of GIST are known.
4
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The difference in crude incidence for 2003 in the Goettsch paper4 and our paper(our data 
174 patients vs. Goettsch 206 patients) could be explained by the revision of historical 
pathology specimens after 2003 or by improvements in patient identification by PALGA, 
resulting in less double counted patients for incidence analysis.
The incidence of 17.7 per million inhabitants is to the upper limit of reported incidences, 
although comparison is hampered by a lack of standardized incidence rates.5-10 This high 
incidence rate is probably caused by one of the strengths of our study: the way PALGA 
registers diagnoses. PALGA is a fully automated archive of pathology reports, with 100% 
coverage of all Dutch pathology reports and registers also small and incidental GISTs not 
appearing in cancer registries. With the addition of the extensive search, the long study 
period and the inclusion of small and incidentally found GISTs, this study gives the best 
possible estimate of GIST incidence. Most of the earlier studies used cancer registries 
that use a health care provider notification system, which is probably biased as small 
and incidentally found GISTs are clinically less relevant as was shown in a recent study.11 
A Dutch Cancer Registry (DCR) study on rare cancers reported an incidence of 9 per 
million inhabitants for 2004-2008 compared to an incidence of 13.8 to 15.8 per million in 
our study.38 The DCR is probably not registering small GISTs, explaining the difference.
The ESMO guideline of 2010 recommends to perform mutation analysis in all GISTs, 
because mutational status is related both to prognosis and efficacy of treatment. 
However, only a minority of patients in 2011 and 2012 (33.9%) had mutational status 
reported.16,17,28 When considering high risk patients, mutational analysis was performed 
in 67.1% of patients.16,17 Because this study is based on pathology reports, exact reasons 
for not performing mutational analysis are not known. Almost all patients with a high 
risk GIST and a primary diagnosis or revision in a GIST centre had a mutational analysis 
(2011 and 2012 92.3%) compared to a much lower rate in the non-GIST centres (2011 
and 2012 16.7%), explaining the rather low rate of mutational analysis performed in high 
risk patients and stressing the importance of referring patients to a GIST centre. The 
frequency of mutations was in line with that reported in a French study.9 PDGFRa mutant 
GIST was slightly overrepresented, which may be explained by the imatinib resistance 
of PDGFRa mutated GIST and therefore due to progression leading to an indication for 
mutation analysis.39 The relative high percentage of patients which were characterized 
as wild-type could have technical reasons because most patients were only sequenced 
for KIT and PDGFRa mutations in the most common hotspots.
In the past, risk classification was not incorporated in the guidelines, and so, mitotic 
rate and size often not reported in the conclusion. To get a better overview of the risk 
classifications, we requested full pathology reports for all patients with a resection in 
2011 and 2012. Comparing the different risk classifications it seems that the Gold and 
Miettinen 2002 criteria allocate more patients to the highest risk category compared 
to the other known risk stratifications, but comparison is difficult because these 
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classifications do not include exactly the same patients in our analysis. E.g., both the 
Joensuu and the Miettinen 2002 criteria do only provide stratification rules for gastric 
and intestinal tumours. Also, the number of risk groups differs between classifications. 
These factors hamper comparison of the different stratifications.
Since 2008 the ESMO guideline recommends mutation analysis for all GISTs and the 2010 
guidelines recommends revision of pathology by an expert pathologist, we here show 
that in 2012 only 41.2% of patients had a revision of pathology within 3 months and only 
29.4% of patients had mutational analysis performed. This was much better for high 
risk patients (based on the Miettinen/AFIP classification) with 67.1% for both mutational 
analysis and pathology review.
In conclusion, this is the second nationwide GIST incidence study ever performed in 
the Netherlands and follows the previous study in the Netherlands in 2003.4 It shows 
that the registered incidence of GIST has risen from 12.2 to 17.7 per million, which can 
be partly explained by an increase in the incidence of small GISTs. Both the Gold risk 
assessment and the Miettinen 2002 criteria seem to allocate more patients than the 
other commonly used risk classification systems to a high-risk category. We found that 
the majority of pathology reports currently do not contain the recommended data of 
the ESMO guideline. So, the incidence of GISTs apparently increases, mainly due to the 
increase of small GIST and for these small GISTs the guidelines are probably less well 
adhered to.
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Supplementary figure 1: Age distribution
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Supplementary figure 2: Distribution of mutations for age
Wild-type GIST patients were tested for mutations at least in KIT exon 9, 11 and PDGFRA exon 12 and 
18. Most of these patients were not tested for SDH deficiency or BRAF mutations.
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(also containing the patients 





Number Percentage Number Percentage
Stomach 1469 59.8 % 318 65.0%
Small intestine 521 21.1 % 131 26.8%
Duodenum 89 3.6 % 30 6.1%
Jejunum 94 3.8 % 25 5.1%
Ileum 33 1.3 % 5 1.0%
Not specified 305 12.4 % 71 14.5%
Rectum 53 2.2 % 15 3.1%
Colon 39 1.6 % 8 1.6%




46 1.9 % 2 0.4%




270 11.0 % 9 1.8%
Other 25 1.0 % 1 0.2%
Unknown 8 0.3 % 0 0.0%
Total 2456 100.0 % 489 100.0%
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Supplementary table 2: Results of immunohistochemistry
Marker
Full pathology reports
Percentage of patients in 
which it is reported
Patients with a positive result
CD117 89.4% 93.6%
DOG1 42.9% 98.6%






1 Recently introduced and only of interest in KIT/PDGFRA wild-type GIST







Percentage of patients that could 
be stratified
(not possible: percentage of all 
patients)
Fletcher 2002
Very low risk 89 9.9%
Low risk 241 26.8%
Intermediate risk 208 23.1%
High risk 362 40.2%
Not possible 1556 63.4%
Miettinen 2002
Probably benign 252 30.4%
Uncertain or low malignant 
potential
182 21.9%
Probably malignant 396 47.7%
Not possible 1626 66.2%
4
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Percentage of patients that could 
be stratified
(not possible: percentage of all 
patients)
Joensuu 2006
Very low, if any malignant 
potential
79 10.1%




Probably malignant 205 26.3%
Not possible 1677 68.3%
Miettinen 2006
None 82 10.8%
Very low risk 173 22.9%
Low risk 185 24.4%
Moderate risk 133 17.6%
High risk 184 24.3%
Not possible 1699 69.2%
Gold 2009 (chance of 5-year recurrence free survival)
90-100% (low risk) 285 35.6%
75-90% (moderate risk) 190 23.8%
0-75% (high risk) 325 40.6%
Not possible 1656 67.4%
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Percentage reference centre 
review
None (68) 8.8 % 30.9 %
Very low (93) 24.7 % 32.3 %
Low (101) 29.7 % 33.7 %
Moderate (67) 43.3 % 38.8 %
High (85) 67.1 % 67.1 %
Unknown (75) 36.0 % 48.0 %
Supplementary table 5: reference centre review during years of study
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Agranulocytosis is a rare but serious side-effect of imatinib in gastrointestinal stromal 
tumour (GIST) patients. Imatinib is an inhibitor of the proto-oncogene, tyrosine kinase 
c-kit and the first-line agent in patients with locally advanced and metastatic GIST. 
Little evidence is available on the management of this adverse event, and consensus-
based guidelines are lacking. In this article, we describe 4 patients with agranulocytosis 
after starting imatinib. In addition, an overview of the available literature concerning 
the underlying mechanisms is given, and therapeutic strategies for overcoming this 
adverse event are discussed. In our experience it appears safe to restart imatinib after 
normalization of neutrophil count. In case of relapse of agranulocytosis, reintroduction 
combined with prednisolone, with treatment with granulocyte colony-stimulating factor 
(G-CSF) or dose reduction can be considered.
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Introduction
Gastrointestinal stromal tumours (GISTs) are rare mesenchymal tumours originating 
from the gastrointestinal tract. Constitutive activation of KIT receptor tyrosine kinase 
plays a pivotal role in the pathogenesis of GIST. Imatinib (Glivec; Gleevec) is a selective 
tyrosine kinase inhibitor active against the proto-oncogene c-kit (CD117), BCR-ABL (or 
Philadelphia chromosome in chronic myeloid leukaemia) and platelet-derived growth 
factor receptor (PDGFR) tyrosine kinases. Currently, imatinib is the standard treatment 
in locally advanced and metastatic GIST patients. Furthermore, imatinib has been 
approved for patients with chronic myeloid leukaemia (CML).
Overall, imatinib therapy is well tolerated. Common side effects are periorbital oedema, 
nausea, diarrhoea, muscle cramps, fatigue and skin rash. Dose-dependent hematologic 
toxicity affecting all hematopoietic lineages to a variable degree is observed clinically, 
especially in imatinib-treated CML-patients.1 In GIST patients treated with imatinib 
grade 3-4 neutropenia is reported in 4.8% of all cases.2 Nevertheless, imatinib-induced 
complete agranulocytosis (a neutrophil count less than 0.1 x103 /µL) is thought to be a 
rare adverse event.3 After a first episode of imatinib-induced agranulocytosis treating 
clinicians are often reluctant restarting this effective drug.
In this article we report 4 GIST patients with imatinib-induced agranulocytosis (Table 1). 
Additionally, we give an overview of available literature regarding the possible underlying 
mechanisms and the different therapeutic strategies for overcoming this adverse event. 
Finally, we give our recommendations for treating imatinib-induced agranulocytosis.
Case report
Patient A, an 87-year old man, presented with a large intra-abdominal tumour (7.0 x 
6.5 cm) and pulmonary lesions. Biopsy of the abdominal mass showed a GIST (mitotic 
index 4/10 HPF, KIT exon 11 mutated). His medical history included restless legs syndrome, 
gastroesophageal reflux disease and locally advanced prostate cancer (T3bN0M0) 
1 year earlier, for which he was treated with radiotherapy and hormonal therapy. His 
medications included gosereline implant, tolterodine, tamsulosin, hydroquinine, 
pantoprazole and acetaminophen. Baseline laboratory testing showed a decreased 
haemoglobin level (Hb 10.3 g/dL, range 14.0-17.5 g/dL), all other bone marrow and 
organ functions were normal. Treatment with imatinib at a dose of 400 mg daily was 
commenced. Five weeks later he was admitted to our hospital because of fever and 
hypotension (90/50 mmHg). Further physical examination was unremarkable. Laboratory 
testing showed an Hb of 9.2g/dL, white blood cell count (WBC) of 8.3 x103 /µL (range 4.0 – 
10.5 x103 /µL) with a complete agranulocytosis (absolute neutrophil count; ANC <0.1 x103 /
µL, range 1.8-7.2 x103 /µL) and a thrombocytopenia (119 x103/µL, range 150-400 x103/µL). 
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G-CSF, Granulocyte colony-stimulating factor; IM, imatinib mesylate; N/A, not applicable. 
aReintroduction was done after complete recovery of the agranulocytosis. bRecurrence of 
agranulocytosis.
Imatinib was discontinued and broad-spectrum antibiotics were initiated. As possible 
contributing factor to neutropenia hydroquinine was stopped. Further investigation 
including urine analysis and culture, chest X-ray and blood cultures did not reveal a 
source of infection. He was afebrile on the second day, and he was discharged from 
hospital on the sixth day. Full neutrophil recovery was reached 10 days after imatinib 
discontinuation. Three weeks after discharge, imatinib was restarted (400 mg/day) with 
weekly monitoring of blood levels. Six weeks afterward, the ANC dropped to 0.5 x 103 /
µL. Imatinib was discontinued again and now ANC normalized within 2 weeks (2.2 x103 /
µL). Within 1 month, 400mg imatinib once daily was restarted in combination with 10mg 
prednisolone. After 3 months of prednisolone, the dose was decreased to 10mg every 
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other day and stopped a week later. Eight months later, agranulocytosis did not recur, 
and the patient remained progression free.
Patient B, a 41-year old female, underwent incomplete surgical resection of a multinodular 
gastric GIST (7 cm, spindle cell type, c-kit positive, mitotic index 0/50 HPF). At the time of 
diagnosis, metastases in liver and intra-abdominal lymph nodes were present. Palliative 
imatinib treatment at a dose of 400 mg daily was commenced. Baseline laboratory 
testing revealed mild normocytic anaemia (Hb 11 g/dL; MCV 81 µm3), WBC 8.9x103 /µL 
and ANC 7.1 x103 /µL. One month after initiation of systemic treatment, she was admitted 
because of fever. Laboratory testing showed a microcytic anaemia (Hb 10.3 g/dL; MCV 78 
µm3), WBC 1.9 x103/µL and ANC 0.17 x103/µL. Two days later ANC dropped below detection 
threshold (<0.05 x103/µL). Imatinib was discontinued, and broad-spectrum antibiotics 
were started. Because of ongoing neutropenia on the fifth inpatient day, bone marrow 
examination was performed revealing an impaired granulopoiesis. A maturation arrest 
of neutrophils in the myelocyte stadium was seen without any other abnormalities. In 
addition, “normal” bowel tissue and neutrophil granulocytes in blood were screened 
for KIT exon 11 mutations. No mutations could be demonstrated in these samples.
Granulocyte colony-stimulating factors (G-CSF; 300 µg daily) was given for 5 days, 
resulting in rapid normalization of ANC (18.5x103 /µL). Further investigation did not reveal 
a source of infection, and she was discharged with a good clinical condition. Repeated 
bone marrow examination 2 weeks after discharge was unremarkable. Imatinib was 
restarted at a dose of 300 mg daily. Two weeks later neutropenia recurred (ANC 1.2 x103 
/µL), and imatinib was discontinued. Full neutrophil recovery was reached 1 week later, 
and imatinib was restarted (300 mg). Routine laboratory tests in the following 3 months 
were normal. Then imatinib was stopped because of imatinib-induced hepatitis. No 
alternative treatment was started. Follow-up CT scans showed no progression of the 
residual lesions in the last 11 years.
Patient C, a 45-year old woman, was diagnosed with an abdominal tumour (8.1 x 7.9 cm) 
originating from the small bowel. Ultrasound-guided biopsy showed a wild type GIST. 
Neo-adjuvant treatment with imatinib (400 mg daily) was started. The patient was taking 
no other medication. Baseline laboratory testing was unremarkable. One month after 
starting imatinib, she complained of fever, chills, and a sore throat. Laboratory testing 
showed a WBC of 3.1 x 103/µL and ANC of <0.1 x 103/µL. Imatinib was promptly discontinued, 
and she was admitted for the administration of broad-spectrum antibiotics and G-CSF 
(filgrastim 1x300 µg). Within 2 days she clinically improved, the fever resolved, and the 
ANC rose to 0.6 x 103/µL. Response evaluation after 1 month showed progressive disease, 
and an R0 resection of the tumour was performed. Adjuvant imatinib treatment was 
not given.
5
Binnenwerk_Productie.indd   87 2/10/2021   8:04:45 PM
88
Chapter 5
Patient D, a 53-year old man, was found to have a rectal mass during evaluation for 
rectal bleeding. Biopsy revealed a c-kit-positive spindle cell wild-type GIST. Laboratory 
testing showed an Hb of 7.1 g/dL. Neo-adjuvant treatment with imatinib (400 mg daily) 
was started because of the close relationship of the tumour with the anal sphincter. 
During routine laboratory testing 1 month after the start of imatinib, an ANC of 0.1 x 103/
µL was detected, and imatinib was discontinued. Ten days later the ANC recovered to 
3.7 x 103/µL, and imatinib was restarted at a dose of once daily 300 mg. Neo-adjuvant 
treatment with imatinib could be continued during 6 months in total without recurrence 
of agranulocytosis, CT scans after 3 and 6 months showed partial response and stable 
disease, respectively, after which the patient was planned for resection.
Discussion
Non-chemotherapy drug-induced agranulocytosis is a rare but potentially serious 
adverse event that is characterized by a decrease in peripheral neutrophil count to 
less than 0.5 x 103/ µL due to cytotoxic or immunogenic mechanisms. The most feared 
complication of severe neutropenia is the development of potentially life-threatening 
infection. In 1 GIST patient, pulmonary tuberculosis secondary to grade 3 imatinib-
induced neutropenia was described in 2005 by Takashima et al.4
Imatinib is a selective tyrosine kinase inhibitor active against c-kit (CD117), BCR-ABL 
and PDGFR tyrosine kinases. Imatinib is approved for treatment of CML and GIST. 
Myelosuppression can occur at any time during imatinib therapy, but it usually begins 
within the first 2 to 4 weeks of treatment.5 In our cases, neutropenia occurred within 
approximately 1 month after initiation of imatinib. The incidence of hematotoxicity in 
CML patients treated in the first months is previously described to be most predominant 
at the start of treatment and decreases after 18 months.6 Hematologic side effects 
are mainly dose-dependent, include all 3 lineages, and are reversible on cessation of 
treatment. However, 1 study comparing imatinib 400 mg daily with 800 mg daily found 
no difference in the incidence of neutropenia.7 Whether the development of imatinib-
induced agranulocytosis is related to drug exposure (imatinib drug levels) is unknown. 
In none of our 4 cases imatinib drug levels were measured. In the future, measuring 
the imatinib drug level may provide further insight into the underlying mechanisms of 
imatinib-induced agranulocytosis.
For now, it remains unclear which patients are at risk for developing hematologic 
toxicity. A low ANC and low haemoglobin concentration at the initiation of imatinib are 
potential risk factors.8 The development of myelosuppression is particularly common in 
CML patients treated with imatinib. In this specific group, grade 3-4 neutropenia (ANC 
0.5-1.0 and <0.5 x 103/µL, respectively) was reported to occur in 35-45% of patients who 
were treated with 400 mg daily.9 In CML patients, myelosuppression is expected due to 
suppression of the malignant clone by inhibiting the BCR-ABL.
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Interestingly, myelosuppression is also seen in imatinib-treated GIST patients who are 
assumed to have an uncompromised bone marrow function. The fact that imatinib can 
affect the function of normal, non-malignant cells suggests that additional pathways 
are involved leading to myelosuppression.6
The c-kit proto-oncogene (CD117), which is targeted by imatinib, has been shown to be 
present in several cell types including normal hematopoietic stem cells.10 However, in 
vitro studies showed that the inhibitory effect of imatinib on normal CD34+ progenitor 
cells is largely independent of c-kit signalling. This suggests that other mechanisms 
might be involved in the inhibitory effect.11 The exact mechanism by which imatinib 
induces its anti-proliferative effect on normal CD34+ cells has yet to be clarified.
In addition to BCR-ABL and c-kit, imatinib also inhibits platelet-derived growth factor 
(PDGF) activity. PDGF has been demonstrated to be an effective cytokine for the ex vivo 
expansion of normal early stem and progenitor cells.12 Inhibition of PDGF activity by 
imatinib can therefore also contribute to myelosuppression.
Significant myelosuppression results in treatment interruptions or dose reduction, 
which may compromise responses to imatinib. In the case of clear agranulocytosis, 
cessation of imatinib treatment remains crucial to avoid further hazardous exposure. In 
patient B, repeated bone marrow examination demonstrated impaired granulopoiesis 
with a maturation arrest of neutrophils in the myelocyte stadium, which was reversible 
on cessation of imatinib treatment. All our patients experienced full recovery of 
the neutrophil count only a few days after discontinuation of imatinib. This is in line 
with 1 case study on imatinib induced agranulocytosis in a GIST patient describing 
agranulocytosis and severe skin rash, which both spontaneously recovered after 
cessation of therapy.13
Limited data are available about the risk of recurrent neutropenia when imatinib is 
readministered when ANC >1.5 x 103/µL. Re-challenge with imatinib in a slightly reduced 
dose after agranulocytosis in patient D was uneventful with normal ANC. Patients A and 
B experienced recurrence of the neutropenia after imatinib rechallenge. Patient A was 
able to continue imatinib treatment in combination with prednisolone therapy. Patient B 
could restart imatinib after the second episode without further hematologic toxicity.
Administration of G-CSF in patients B and C might have accelerated neutrophil 
regeneration.14 In patients with CML, G-CSF has been shown to be effective in overcoming 
imatinib-induced neutropenia.4,15-17 In this way, recovery of neutrophil counts can 
even be achieved during uninterrupted imatinib therapy. Treatment with G-CSF in 
nonchemotherapy drug-induced agranulocytosis is associated with a lower median 
duration of neutropenia (8 days in treated patients vs. 9 days in untreated patients, 
P = .015). In this report no significant association between decreased case-fatality 
5
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rates and use of hematopoietic cell growth factors could be observed.3 However, 
imatinib therapy was not included in this analysis, and to our best knowledge, G-CSF 
administration in imatinib-induced neutropenia in GIST patients has never been studied. 
It therefore remains questionable whether the use of expensive G-CSF results in a 
clinically significant benefit and is justified in the absence of severe infection.
Patient A was able to continue imatinib treatment in combination with prednisolone 
therapy. This strategy was not previously described in imatinib induced agranulocytosis. 
Considering the short period this treatment is given to the patient and its low cost, 
this option can be considered. However, one can argue that re-introduction without 
prednisolone might have been uneventful as well. Furthermore, no immunological 
response was seen in the patient’s bone marrow. Therefore, any possible effect of 
corticosteroids is unclear. Patient B could restart imatinib after the second episode 
without further hematologic toxicity. In this case, imatinib was reintroduced in a 
decreased dose of 300 mg. This strategy was also used in a study describing 13 CML 
patients receiving G-CSF without discontinuation of imatinib. 5 Hwang et al described 
a dose reduction to 100 mg in one GIST patient, without relapse of agranulocytosis 
or skin toxicity observed.13 Despite dose reductions all patients in both reports show 
response.
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In Table 2 a summary of available studies on different treatment strategies for imatinib-
induced agranulocytosis is given.
Based on the sparse literature and our, albeit limited, experience in these 4 cases, we 
propose recommendations for patients with GIST presented with imatinib-induced 
agranulocytosis (Figure 1). At the first episode of agranulocytosis, we recommend 
cessation of imatinib treatment until full neutrophil recovery. When neutrophils are 
recovered, imatinib can be restarted at the same dose. If there is a relapse of imatinib-
induced agranulocytosis, we recommend a rechallenge with dose reduction, or the 
use of either G-CSF or low dose corticosteroids in combination with full-dose imatinib. 
In case of a second relapse or in case of life-threatening relapse, one can consider 
alternative therapy. This can consist of second-line tyrosine kinase, like sunitinib, or early 
planned surgery in case of neo-adjuvant therapy.
Figure 1. Recommendations for management of imatinib-induced agranulocytosis
When a patient presents with imatinib-induced agranulocytosis, we recommend stopping 
imatinib and waiting for full recovery. If the patient has a fever, broad-spectrum antibiotics should 
be administered. After full recovery, imatinib can be reintroduced at the same dose. In case of 
relapse of agranulocytosis, one should consider a rechallenge with imatinib in combination with 
dose reduction, granulocyte colony-stimulating factor (G-CSF), or low-dose corticosteroids, that is, 
prednisone 10 mg once daily. Prednisone dose can be slowly tapered with strict monitoring of the 
hemogram. One can also move to alternative therapy, for example, second-line therapy or surgery 
in the case of neoadjuvant therapy.
5




Imatinib-induced agranulocytosis is a rare but potentially serious adverse event with 
life-threatening infection as most feared complication. Imatinib is usually effective 
in locally advanced and metastatic GIST, and a rechallenge with imatinib should be 
considered after a first episode of agranulocytosis and full recovery of the neutrophil 
count. In our limited experience this appears a safe approach, with strict monitoring 
of the hemogram. The use of G-CSF or corticosteroids can be considered. Imatinib 
treatment should not routinely be withheld to GIST patients encountering a first episode 
of imatinib-induced agranulocytosis.
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In patients with advanced soft tissue sarcoma treated with chemotherapy, WHO 
performance status, histologic subtype and histologic grade are known prognostic 
factors. Although the difference between the subgroups: locally advanced disease 
only, metastatic disease only and both local and metastatic disease is easily made, its 
prognostic relevance is thus far unknown. The aim of this EORTC database study was to 
study the difference in prognosis between these subgroups in patients receiving first 
line chemotherapy for advanced soft tissue sarcoma.
Methods
A retrospective database analysis was performed on 2473 patients receiving first line 
chemotherapy for advanced soft tissue sarcoma from 12 EORTC sarcoma trials in order 
to establish the difference in prognosis for the three subgroups. Endpoints were overall 
survival, progression-free survival and overall response rate. Factors studied were age, 
sex, histologic subtype, histologic grade, WHO performance status, treatment and time 
since initial diagnosis.
Results
Overall survival differed significantly between patients with locally advanced disease 
only, with metastatic disease only and with both locally advanced and metastatic 
disease with a median overall survival of 15.4, 12.9 and 10.6 months respectively. 
Similar differences were seen for progression-free survival (5.8, 4.3 and 3.2 months 
respectively).
Conclusion
This large retrospective database study shows that patients with advanced soft tissue 
sarcomas treated with first line chemotherapy with locally advanced disease, metastatic 
disease and both local and metastatic disease have different outcomes. This should 
be accounted for in future study design, interpretation and comparison of study results 
and daily practice.
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Introduction
Soft tissue sarcomas (STS) are a rare group of tumours consisting of more than 70 
histological different subtypes.1 For the treatment of most subtypes, doxorubicin alone 
or in combination remains first line treatment with e.g. pazopanib and trabectedin as 
second line options.2-5 For anthracycline and ifosfamide based treatments, prognostic 
and predictive factors were established.6-9 These studies identified response to 
chemotherapy, WHO performance score, histological subtype and time since initial 
diagnosis to be prognostic for overall survival (OS) in STS.6-9 One of these studies also 
identified a difference in OS between patients with locally advanced disease (LAD) and 
patients with distant metastases (DM), favouring the first subgroup when treated with 
first-line ifosfamide therapy.6
Although the difference between LAD and DM is easily made, no study investigated 
whether differences in outcome and response exist between these two subgroups, 
which could make them factors of prognostic relevance. The identification of prognostic 
factors is necessary for patient care and design of clinical trials. The aim of this study 
is to investigate whether important differences exist in OS, progression free survival 
(PFS) and response rate (ORR) between the different disease subgroups and is an 
exploratory analysis of the prognostic factors for OS, PFS and ORR in patients with STS 
and either LAD or DM at the moment of inclusion in a first line chemotherapy study of 
the European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue 
and Bone Sarcoma Group (STBSG).
Methods
Patients
The EORTC-STBSG database contains data of 3708 patients from 15 EORTC advanced 
STS trials considering first line treatment.4,5,10-22 Supplementary table 1 and 2 describe the 
different studies and the number of patients included in this study. From this database 
patients were excluded who had no documentation of lesions at trial entry, who had 
no survival data available, who were treated with a CYVADIC (cyclophosphamide/
vincristine/doxorubicin/dacarbazine) regimen (EORTC-study 62761)10 or docetaxel (1 arm 
of 62941)17, who had prior (adjuvant or palliative) chemotherapy, for whom not enough 
information was available to distinguish primary from metastatic disease (62883 and 
62901)14,15, or who were diagnosed with gastrointestinal stromal tumour (GIST) or an 
ineligible tumour, being not STS.
Patients were grouped in a group with local disease only (LAD), a group with metastatic 
disease only (DM) and both locally advanced and metastatic disease. LAD was defined 
either as locally advanced disease not amenable to surgery or locally recurrent disease. 
DM only was defined as distant metastatic disease without evidence for local disease. 
6
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Patients in the group with both had local disease and distant metastatic disease at 
study inclusion.
Endpoints
Study endpoints were OS, PFS and ORR to therapy. OS was computed from the date 
of randomization or the date of prospective registration (nonrandomized trials) to 
date of death. Patients alive at last follow up were censored. PFS was defined as time 
interval between date of randomization or prospective registration and date of first 
documented progression or death, whichever comes first. ORR to chemotherapy was 
evaluated according to WHO or RECIST criteria depending on the study.23-25 In this study 
it was analysed as binary variable, i.e. complete response and partial response are 




Demographic data included were age, sex and performance status before the start 
of chemotherapy. Performance status was measured on the WHO scale. Variables 
related to the history of the sarcoma were the site of the primary tumour, the use of prior 
radiotherapy and/or prior surgery, and time since first diagnosis of sarcoma. Because 
information on prior radiotherapy or prior surgery was not collected in the more recent 
trials it has not been included in the univariate and multivariate prognostic factor 
analysis to reduce the loss of data due to missing information. In most of the included 
studies patients had to have progression in the six months before study inclusion or  had 
to have a histological grade of at least 2 or intermediate. Treatment was aggregated in 4 
categories: anthracyclines alone (doxorubicin, epirubicin), ifosfamide alone, combination 
of anthracyclines and ifosfamide and other (brostallicin and trabectedin).
The way histological grade and histological subtype were used was earlier described in 
a study by our group.6 Histological subtype was aggregated into the 4 most common 
groups: synovial sarcoma, leiomyosarcoma, liposarcoma and others. If both a local and 
central histological subtype were available, the central diagnosis was used. Twenty-five 
percent of patients had a discrepancy between the central and local diagnosis. If only 
a local diagnosis was available this diagnosis was used.
Statistics
Categorical data were summarized by frequencies and percentages, continuous 
covariates were summarized by median, interquartile range and overall range and were 
presented according to the three different groups. The characteristics were compared 
with a χ2-test for categorical variables and a (non-parametric) Kruskal Wallis test for 
the continuous variables.
Binnenwerk_Productie.indd   102 2/10/2021   8:04:46 PM
103
Prognostic relevance of disease stage in soft tissue sarcoma
The potential prognostic value of all factors was investigated by univariate analysis, 
using univariate Cox or logistic regression models according to outcome. The prognostic 
value of the factors was subsequently assessed in a multivariate model, using stepwise 
selection. All models were stratified by treatment for heterogeneity that may be 
introduced by merging data from several clinical trials. Statistical significance was set 
at 0.05 for all analyses.
To reduce the loss of a considerable amount of information for the multivariate analysis 
due to a substantial amount of missing data for grade and site of primary tumour, 
the value “missing” was a separate category in all these models. Sensitivity analyses 
were performed to study the impact of this approach on the final interpretation of the 
models.
In addition, the analyses were repeated for only those patients included in studies after 
1999 to account for the diagnosis of GIST, improved radiology techniques and improved 
treatment regimens, which is included in the supplementary materials.
Results
Patients
In total, 2473 patients from 12 trials were included in this study, which were separated 
in 3 subgroups: LAD (329 patients), DM (1202 patients) and patients with both LAD and 
DM (942 patients). (Supplementary figure 1) Table 1 shows the characteristics of the 
three subgroups. Median follow-up in years, as determined by the reverse Kaplan-Meier 
estimates, was 3.6 years (interquartile range 2.2-6.4) for LAD, 3.2 years (2.1-4.9) for DM, 
and 3.6 years (2.1-6.4) for patients with both.
Differences in survival and ORR
Compared to LAD, patients with DM had a worse prognosis (hazard ratio (HR) 1.25 (95% CI 
1.08-1.45)) and patients with both LAD and DM had the worst (HR 1.59 (1.37-1.84)) (P<0.001). 
(Figure 1A) Median OS was 15.4 (95% CI 13.0-16.9), 12.9 (12.4-13.9) and 10.6 months (9.8-11.3) 
respectively. Of all patients 94.5% showed disease progression during follow-up. For 
PFS the same differences in survival were seen, with HR of 1.40 (1.23-1.59) for DM and 1.58 
(1.38-1.81) for both LAD and DM (P<0.001). (Figure 1B) Median PFS was 5.8 (95% CI 4.4-6.5), 
4.3 (3.9-4.7) and 3.2 months (2.9-3.5) respectively.
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N (%) N (%) N (%) N (%)
Gender  0.002
Male  143 (43.5)  565 (47.0)  500 (53.1)  1208 (48.8)
Female  186 (56.5)  637 (53.0)  442 (46.9)  1265 (51.2)
Performance status  <0.001
PS 0  132 (40.1)  635 (52.8)  390 (41.4)  1157 (46.8)
PS 1  155 (47.1)  515 (42.8)  476 (50.5)  1146 (46.3)
PS 2+  38 (11.6)  50 (4.2)  74 (7.9)  162 (6.6)
Unknown  4 (1.2)  2 (0.2)  2 (0.2)  8 (0.3)
Age (years) 0.387
< 40 yrs  78 (23.7)  257 (21.4)  216 (22.9)  551 (22.3)
40-50 yrs  66 (20.1)  278 (23.1)  210 (22.3)  554 (22.4)
50-60 yrs  85 (25.8)  360 (30.0)  274 (29.1)  719 (29.1)
>=60 yrs  95 (28.9)  285 (23.7)  230 (24.4)  610 (24.7)
Median 52 51 51 51 0.949a
Range 16 - 79 17 - 84 10 - 88 10 - 88
Q1-Q3 40 - 61 42 – 60 41 - 60 41 - 60
Unknown  5 (1.5)  22 (1.8)  12 (1.3)  39 (1.6)
Prior radiotherapy <0.001
No  274 (83.3)  590 (49.1)  690 (73.2)  1554 (62.8)
Yes  33 (10.0)  464 (38.6)  170 (18.0)  667 (27.0)
Unknown  22 (6.7)  148 (12.3)  82 (8.7)  252 (10.2)
Prior Surgery <0.001
No surgery  53 (16.1)  16 (1.3)  161 (17.1)  230 (9.3)
Non-optimal 
surgery
 91 (27.7)  106 (8.8)  184 (19.5)  381 (15.4)
Complete 
surgery
 68 (20.7)  487 (40.5)  178 (18.9)  733 (29.6)
Unknown  117 (35.6)  593 (49.3)  419 (44.5)  1129 (45.7)
Binnenwerk_Productie.indd   104 2/10/2021   8:04:46 PM
105















N (%) N (%) N (%) N (%)
Histology <0.001
Leiomyosarcoma  85 (25.8)  412 (34.3)  281 (29.8)  778 (31.5)
Synovial sarcoma  23 (7.0)  160 (13.3)  77 (8.2)  260 (10.5)
Liposarcoma  48 (14.6)  114 (9.5)  87 (9.2)  249 (10.1)




Grade I  36 (10.9)  97 (8.1)  68 (7.2)  201 (8.1)
Grade II  86 (26.1)  345 (28.7)  261 (27.7)  692 (28.0)
Grade III  104 (31.6)  436 (36.3)  315 (33.4)  855 (34.6)
Unknown  103 (31.3)  324 (27.0)  298 (31.6)  725 (29.3)
Site of primary 
tumour
<0.001
Other  222 (67.5)  501 (41.7)  540 (57.3)  1263 (51.1)
Extremity  37 (11.2)  457 (38.0)  233 (24.7)  727 (29.4)
Unknown  70 (21.3)  244 (20.3)  169 (17.9)  483 (19.5)
Time between the 
initial diagnosis 
of sarcoma and 
registration
<0.001
<6 months  233 (70.8)  416 (34.6)  650 (69.0)  1299 (52.5)
6-12 months  32 (9.7)  190 (15.8)  80 (8.5)  302 (12.2)
1-2 yrs  22 (6.7)  238 (19.8)  82 (8.7)  342 (13.8)
>=2 yrs  40 (12.2)  352 (29.3)  118 (12.5)  510 (20.6)
Median (months) 1.9 11.8 2.3 6.3 <0.001a
Range (months) 0.0 - 222.8 0.0 - 346.5 0.0 - 198.7 0.0 - 346.5
Q1-Q3 (months) 0.8 - 9.2 4.3 - 28.5 0.9 - 9.5 1.4 - 19.1
Unknown  2 (0.6)  6 (0.5)  12 (1.3)  20 (0.8)
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N (%) N (%) N (%) N (%)
Treatment
Anthracyclines  137 (41.6)  461 (38.4)  369 (39.2)  967 (39.1)
DOX+IFO  129 (39.2)  432 (35.9)  394 (41.8)  955 (38.6)
IFO ALONE  53 (16.1)  206 (17.1)  125 (13.3)  384 (15.5)
Other  10 (3.0)  103 (8.6)  54 (5.7)  167 (6.8)
Primary site involved
No  0 (0.0)  1202 (100.0)  0 (0.0)  1202 (48.6)
Yes  329 (100.0)  0 (0.0)  942 (100.0)  1271 (51.4)
Lung metastases
No  329 (100.0)  316 (26.3)  361 (38.3)  1006 (40.7)
Yes  0 (0.0)  886 (73.7)  581 (61.7)  1467 (59.3)
Bone metastases
No  329 (100.0)  1071 (89.1)  810 (86.0)  2210 (89.4)
Yes  0 (0.0)  131 (10.9)  132 (14.0)  263 (10.6)
Liver metastases
No  329 (100.0)  979 (81.4)  745 (79.1)  2053 (83.0)
Yes  0 (0.0)  223 (18.6)  197 (20.9)  420 (17.0)
Other metastases
No  329 (100.0)  709 (59.0)  532 (56.5)  1570 (63.5)
Yes  0 (0.0)  493 (41.0)  410 (43.5)  903 (36.5)
aKruskal-Wallis test
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(months)












O N Number of patients at risk : Disease stage
228 329 240 171 115 89 67 49 39
931 1202 939 580 354 242 150 93 57


















O N Number of patients at risk : Disease stage
288 329 154 86 60 45 35
1150 1202 464 167 85 49 34








Figure 1 Overall survival (A) and progression free survival (B) according to disease 
stage
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ORR differed among the three groups with the lowest ORR in patients with both LAD and 
DM (p=0.003). (Table 2)












N (%) N (%) N (%) N (%)
Best overall response
Complete Response (CR)  16 (4.9)  34 (2.8)  16 (1.7)  66 (2.7)
Partial Response (PR)  47 (14.3)  226 (18.8)  133 (14.1)  406 (16.4)
Stable Disease (SD)  145 (44.1)  482 (40.1)  362 (38.4)  989 (40.0)
Progressive Disease (PD)  77 (23.4)  385 (32.0)  347 (36.8)  809 (32.7)
Not Evaluable  44 (13.4)  75 (6.2)  84 (8.9)  203 (8.2)
Responders
Failure  266 (80.9)  942 (78.4)  793 (84.2)  2001 (80.9)
Responders (CR+PR)  63 (19.1)  260 (21.6)  149 (15.8)  472 (19.1)
Prognostic factors for OS
Table 3 shows the results of the univariate analysis. Multivariate analyses for LAD 
identified good performance status, histological subtype (synovial and liposarcoma), 
time since initial diagnosis (being not 6-12 months) and extremity site of tumour as 
favourable prognostic factors (table 4). For DM, the favourable prognostic factors were 
good performance status, histological subtype (synovial and liposarcoma) and long 
interval since initial diagnosis (table 4). Favourable prognostic factors for OS for patients 
with both LAD and DM were good performance status, female gender, younger age, 
lower grade, extremity site of primary tumour and long interval since initial diagnosis 
(table 4).
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PS 0 1.00 1.00 1.00
PS 1 1.71 (1.27, 2.31) 1.62 (1.41, 1.86) 1.44 (1.24, 1.69)
PS 2+ 2.40 (1.51, 3.81) 3.52 (2.56, 4.84) 1.77 (1.33, 2.34)
P<0.001 (df=2) P <0.001 (df=2) P <0.001 (df=2)
Histology Leiomyosarcoma 1.00 1.00
Liposarcoma 0.62 (0.37, 1.04) 0.64 (0.50, 0.83)
Other 1.17 (0.85, 1.62) 0.95 (0.81, 1.10)
Synovial sarcoma 0.76 (0.41, 1.42) 0.82 (0.66, 1.00)
P =0.047 (df=3) P =0.003 (df=3)
Site of primary 
tumour
Other 1.00 1.00
Extremity 0.40 (0.24, 0.66) 0.77 (0.65, 0.92)
Unknown 0.78 (0.54, 1.12) 0.90 (0.73, 1.10)
P =0.001 (df=2) P =0.016 (df=2)
Time since 
initial diagnosis
<6 months 1.00 1.00 1.00
6-12 months 2.03 (1.31, 3.14) 1.16 (0.95, 1.41) 1.09 (0.84, 1.42)
1-2 yrs 1.56 (0.89, 2.74) 0.91 (0.76, 1.10) 0.95 (0.74, 1.23)
>=2 yrs 0.90 (0.57, 1.42) 0.69 (0.58, 0.82) 0.67 (0.53, 0.85)
P =0.006 (df=3) P <0.001 (df=3) P =0.008 (df=3)
Gender Male 1.00
Female 0.84 (0.72, 0.97)
P =0.019 (df=1)
Age < 40 yrs 1.00
40-50 yrs 1.05 (0.85, 1.31)
50-60 yrs 1.44 (1.18, 1.77)





Grade II 1.32 (0.97, 1.80)
Grade III 1.76 (1.30, 2.39)
Unknown 1.45 (1.06, 1.98)
P <.001 (df=3)
6
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Prognostic factors for PFS
Table 5 shows the results of the univariate analysis. Multivariate analyses for LAD 
identified good performance status and time since initial diagnosis (being not 6-12 
months) as favourable prognostic factors (table 6). For DM, the favourable prognostic 
factors were good performance status, histological subtype (synovial and liposarcoma) 
and long time since initial diagnosis (table 6). Favourable prognostic factors for PFS for 
patients with both LAD and DM were good performance status, histological subtype 
(synovial and liposarcoma) and lower grade (table 6).
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PS 0 1.00 1.00 1.00
PS 1 1.43 (1.10, 1.87) 1.28 (1.13, 1.45) 1.20 (1.04, 1.39)
PS 2+ 2.11 (1.41, 3.17) 1.90 (1.40, 2.57) 1.24 (0.95, 1.62)
P <.001 (df=2) P <.001 (df=2) P =0.031 (df=2)
Histology Leiomyosarcoma 1.00 1.00
Liposarcoma 0.69 (0.55, 0.85) 0.77 (0.60, 1.00)
Other 0.86 (0.75, 0.99) 0.85 (0.73, 0.99)
Synovial 
sarcoma
0.77 (0.64, 0.93) 0.70 (0.54, 0.92)




<6 months 1.00 1.00
6-12 months 1.92 (1.28, 2.88) 1.11 (0.93, 1.33)
1-2 yrs 2.07 (1.26, 3.39) 1.01 (0.85, 1.19)
>=2 yrs 1.08 (0.74, 1.58) 0.74 (0.64, 0.87)




Grade II 1.31 (0.99, 1.73)
Grade III 1.50 (1.14, 1.98)
Unknown 1.41 (1.07, 1.87)
P =0.029 (df=3)
Prognostic factors for overall response
Results of the univariate analysis and multivariate analysis for prognostic factors for 
ORR are shown in table 7 and 8.
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Table 8a Multivariate analysis for overall response rate for metastatic disease only (a 
lower odds ratio indicates a higher change for good response)
Parameter Levels Odds Ratio (95% CI) P-value
Histology Leiomyosarcoma 1.00 0.002 (df=3)
Liposarcoma 0.40 (0.24, 0.66)
Other 0.80 (0.56, 1.16)
Synovial sarcoma 0.58 (0.36, 0.93)
Site of primary 
tumour
Other 1.00 0.001 (df=2)
Extremity 0.51 (0.36, 0.73)
Unknown 0.80 (0.53, 1.22)
Table 8b Multivariate analysis for overall response rate for patients with both locally 
advanced and metastatic disease (a lower odds ratio indicates a higher change for 
good response)
Parameter Levels Odds Ratio (95% CI) P-value
Grade Grade I 1.00 0.022 (df=3)
Grade II 1.93 (0.90, 4.12)
Grade III 0.87 (0.44, 1.75)
Unknown 1.10 (0.54, 2.23)
Discussion
This study is the first showing that for all frontline treatments in locally advanced and/or 
metastatic soft tissue sarcomas OS, PFS and ORR outcomes differ according to disease 
subgroup. This difference should be accounted for in daily practice and when designing 
and interpreting clinical trials. We also established prognostic factors for OS, PFS and ORR 
in these different disease subgroups and important differences in prognostic factors 
between these disease subgroups were identified, which underlines the importance of 
accounting for the different disease subgroups. Patients with LAD had a better prognosis 
compared to both other groups. This difference may be explained by additional 
treatment with either surgery or radiotherapy in the locally advanced setting. No data 
on post-chemotherapy treatment was available in the study database used for this 
project and so we cannot provide evidence for this statement. The difference in survival 
between the different disease subgroups stresses the importance of stratification for 
disease subgroup in future trials.
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In line with this observation, locally advanced tumours of the extremity had a better OS 
than other tumour sites, because these are more accessible to surgery and radiotherapy 
with relatively low morbidity. This was also found recently in an Indian study which 
showed that patients with extremity tumours and patients with multimodality treatment 
had a favourable prognosis, suggesting that the possibility of aggressive treatment of 
the primary tumour localization may result in a better survival.26 Tumour site is also a 
known prognostic factor in surgically treated non-metastatic sarcoma patients.27 Time 
since initial diagnosis behaves differently as prognostic factor between patients with 
LAD (both a very short time and a very long time from initial diagnosis were associated 
with a favourable prognosis) and both the other groups (only a long time interval from 
initial diagnosis having a favourable diagnosis). This could be because aggressive 
tumours tend to respond fast to chemotherapy and so become amenable to surgical 
therapy as a local treatment, which could prolong the OS. This was already shown in a 
previous database study of our group.7 In the metastatic setting surgery usually is not an 
option and aggressive tumours will progress early. The fact that high histological grade 
is a favourable prognostic factor for ORR in patients with both LAD and DM supports 
this hypothesis. On the other hand, very early relapse, i.e. recurrence within 6 months 
after resection, could be caused by incomplete surgery, which would result in a group 
with mixed biology, and early relapse, i.e. recurrence between 6 and 12 months after 
resection, is caused mainly by bad biology. Because bad biology will lead to more 
rapidly progression compared to the mixed biology of the very early relapse group. This 
could also explain the difference in prognosis.
As in earlier studies for STS and other tumours performance status, histologic subtype 
and time since initial diagnosis were prognostic factors for OS.8,9,28-30 Remarkably, in the 
multivariate analyses histologic subtype was no longer prognostic for patients with 
both LAD and DM. As was already mentioned in the methods section, histopathologic 
diagnosis was in approximately 25% of the patients different between local and central 
review. This difficulty with correctly classifying sarcomas could result in the differences in 
outcome between the various studies when studying histological subtype as prognostic 
factor. Histologic grade, also a known prognostic factor, was not identified as prognostic 
factor for OS in patients with LAD and dropped out in the multivariate model of metastatic 
disease, however this could be due to an underpowered comparison due to the lower 
number of patients in this group.8 In general, synovial and liposarcoma are known to 
be sarcomas with a relatively good prognosis.31 For both patients with LAD and patients 
with both LAD and DM, age and gender were both prognostic factors for patients with 
both local and metastatic disease compared to the two other groups. The difference in 
prognosis between sexes was found previously in other studies and it was hypothesized 
that it was caused by differences in pharmacokinetics of cytostatic drugs of amongst 
other cyclophosphamide and doxorubicin, with a decreased metabolism in women and 
so a higher drug exposure.32 On the other hand the difference could be explained by the 
high grade undifferentiated uterine sarcomas, which of course only occur in women 
6
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and have a very poor prognosis.33 However, whether these two explanations are the full 
explanation is questionable because it was not a prognostic factor for OS in patients 
with LAD or DM and it was not a prognostic factor for PFS and ORR. For PFS the known 
risk factors performance status, histological subtype, time since initial diagnosis and 
grade were identified as prognostic factors. No new prognostic factors were identified. 
The same difference for time since initial diagnosis was found as for OS. Grade was 
only prognostic for patients with both LAD and DM and such that a higher grade was 
associated with a worse PFS.8 For LAD no prognostic factors for ORR were identified in 
contrast to patients with DM and patients with both LAD and DM. For patients with DM 
histology and site of primary tumour were identified. The role of primary tumour site 
may relate to later diagnosis and bulkier disease at presentation for non-extremity 
disease. As earlier mentioned low grade and high grade had a favourable prognosis 
compared to intermediate grade tumours for ORR in patients with both LAD and DM. 
High histologic grade was previously found to be prognostic, but the finding that low 
histologic grade was associated with a better overall response rate is surprising.7 As 
grading of sarcomas is difficult and it was an inclusion criterion for the studies to be 
progressive within 6 months before study inclusion, it could be that the included grade 
I sarcomas had a more aggressive behaviour like grade III tumours.
The results of this retrospective study should be interpreted with care. First, the database 
contains studies over 32 years. In this time, treatment has changed and supportive 
measurements have improved. These could influence the prognostic factors. Also, 
the histologic subtypes of STS have changed over the years. High incident subtypes 
like malignant fibrous histiocytoma no longer exist in the current WHO classification.1 
Also new subtypes were identified during these years, like GIST often diagnosed as 
leiomyosarcoma before 2000.34-36 An additional subgroup analysis with only those 
patients included in studies after 1999 was done to account for these changes. Although 
this subgroup analysis was hampered by the reduced number of patients, it resulted in 
comparable outcomes. (Supplementary data: additional subgroup analysis)
In the future, treatment will be more and more histological subtype and molecular driver 
specific. Furthermore, some studies included regimens which are currently no longer 
in use, such as ifosfamide 5 g/m2 as a 24-hour infusion and doxorubicin/ifosfamide 
combinations with lower doses than currently used. Ideally the results of this study 
should be validated in a prospective observational study, comparing the overall survival 
in these three subgroups under the current treatments available.
The results of this study are important for daily practice, because current treatment 
regimens are based on phase III studies currently not accounting for these differences 
and thereby introducing bias, as these studies suggest that included LAD patients are 
comparable to patients with both locally advanced and distant metastatic disease. 
Second, the prognosis is essential information for patients when considering palliative 
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treatment and the differences in prognosis between patients with LAD, DM and both 
should be used in this decision.
In conclusion, this study shows a difference in prognosis between patients with LAD, DM 
and patients with both LAD and DM. This study does indicate that there are a number of 
differences in prognostic factors between patients with LAD, DM and with both LAD and 
DM. Thus, in future trials the randomization should be stratified for disease stage.
Funding
This work was financially supported by the European Organisation for Research and 
Treatment of Cancer unconditionally.
Acknowledgements
We would like to thank the EORTC Cancer Research Fund for their support.
Conflicts of interest
AJV, HG, SL, SM, AG and EW have no conflicts of interest to report. IJ received research 
funding from Novartis, GSK and Eisai, he received travel grants from Lilly and GSK, and 
has also other relations with Ariad, Amgen, Bayer, GSK, and Lilly. ALC received honoraria 
from Novartis, Pfizer, Lilly, Pharmamar and MSD. MT received honoraria from Novartis and 
travel grants from Pharmamar, Novartis and Pfizer. WTG had an advisory role for Bayer 
and received a speakers fee from Lilly.
6




1. Fletcher CDM, Bridge JA, Hogendoorn PC, Mertens F. WHO Classification of Tumours of Soft 
Tissue and Bone. Fourth Edition. 4th ed. Lyon: IARC press; 2013.
2. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma 
(PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 
2012;379:1879-86.
3. Samuels BL, Chawla S, Patel S, et al. Clinical outcomes and safety with trabectedin therapy 
in patients with advanced soft tissue sarcomas following failure of prior chemotherapy: 
results of a worldwide expanded access program study. Annals of oncology : official 
journal of the European Society for Medical Oncology / ESMO 2013;24:1703-9.
4. Judson I, Verweij J, Gelderblom H, et al. Doxorubicin alone versus intensified doxorubicin 
plus ifosfamide for first-line treatment of advanced or metastatic soft-tissue sarcoma: a 
randomised controlled phase 3 trial. The lancet oncology 2014.
5. van Oosterom AT, Mouridsen HT, Nielsen OS, et al. Results of randomised studies of 
the EORTC Soft Tissue and Bone Sarcoma Group (STBSG) with two different ifosfamide 
regimens in first- and second-line chemotherapy in advanced soft tissue sarcoma 
patients. European journal of cancer 2002;38:2397-406.
6. Sleijfer S, Ouali M, van Glabbeke M, et al. Prognostic and predictive factors for outcome 
to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft 
tissue sarcomas: an exploratory, retrospective analysis on large series from the European 
Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group 
(EORTC-STBSG). European journal of cancer 2010;46:72-83.
7. Van Glabbeke M, van Oosterom AT, Oosterhuis JW, et al. Prognostic Factors for the Outcome 
of Chemotherapy in Advanced Soft Tissue Sarcoma: An Analysis of 2,185 Patients Treated 
With Anthracycline-Containing First-Line Regimens—A European Organization for Research 
and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study. Journal of Clinical 
Oncology 1999;17:150.
8. Canter RJ, Beal S, Borys D, Martinez SR, Bold RJ, Robbins AS. Interaction of histologic 
subtype and histologic grade in predicting survival for soft-tissue sarcomas. Journal of 
the American College of Surgeons 2010;210:191-8.e2.
9. Karavasilis V, Seddon BM, Ashley S, Al-Muderis O, Fisher C, Judson I. Significant clinical 
benefit of first-line palliative chemotherapy in advanced soft-tissue sarcoma: 
retrospective analysis and identification of prognostic factors in 488 patients. Cancer 
2008;112:1585-91.
10. Pinedo HM, Bramwell VH, Mouridsen HT, et al. Cyvadic in advanced soft tissue sarcoma: a 
randomized study comparing two schedules. A study of the EORTC Soft Tissue and Bone 
Sarcoma Group. Cancer 1984;53:1825-32.
11. Mouridsen HT, Bastholt L, Somers R, et al. Adriamycin versus epirubicin in advanced soft 
tissue sarcomas. A randomized phase II/phase III study of the EORTC Soft Tissue and Bone 
Sarcoma Group. European journal of cancer & clinical oncology 1987;23:1477-83.
12. Schutte J, Mouridsen HT, Stewart W, et al. Ifosfamide plus doxorubicin in previously 
untreated patients with advanced soft tissue sarcoma. The EORTC Soft Tissue and Bone 
Sarcoma Group. European journal of cancer 1990;26:558-61.
Binnenwerk_Productie.indd   122 2/10/2021   8:04:47 PM
123
Prognostic relevance of disease stage in soft tissue sarcoma
13. Santoro A, Tursz T, Mouridsen H, et al. Doxorubicin versus CYVADIC versus doxorubicin plus 
ifosfamide in first-line treatment of advanced soft tissue sarcomas: a randomized study 
of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone 
Sarcoma Group. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 1995;13:1537-45.
14. Steward WP, Verweij J, Somers R, et al. Granulocyte-macrophage colony-stimulating factor 
allows safe escalation of dose-intensity of chemotherapy in metastatic adult soft tissue 
sarcomas: a study of the European Organization for Research and Treatment of Cancer 
Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : official journal of the 
American Society of Clinical Oncology 1993;11:15-21.
15. Nielsen OS, Dombernowsky P, Mouridsen H, et al. High-dose epirubicin is not an alternative 
to standard-dose doxorubicin in the treatment of advanced soft tissue sarcomas. A study 
of the EORTC soft tissue and bone sarcoma group. British journal of cancer 1998;78:1634-9.
16. Le Cesne A, Judson I, Crowther D, et al. Randomized phase III study comparing 
conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus 
ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor 
in advanced soft tissue sarcomas: A trial of the European Organization for Research and 
Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. Journal of clinical oncology : 
official journal of the American Society of Clinical Oncology 2000;18:2676-84.
17. Verweij J, Lee SM, Ruka W, et al. Randomized phase II study of docetaxel versus doxorubicin 
in first- and second-line chemotherapy for locally advanced or metastatic soft tissue 
sarcomas in adults: a study of the european organization for research and treatment of 
cancer soft tissue and bone sarcoma group. Journal of clinical oncology : official journal 
of the American Society of Clinical Oncology 2000;18:2081-6.
18. Nielsen OS, Judson I, van Hoesel Q, et al. Effect of high-dose ifosfamide in advanced soft 
tissue sarcomas. A multicentre phase II study of the EORTC Soft Tissue and Bone Sarcoma 
Group. European journal of cancer 2000;36:61-7.
19. Judson I, Radford JA, Harris M, et al. Randomised phase II trial of pegylated liposomal 
doxorubicin (DOXIL/CAELYX) versus doxorubicin in the treatment of advanced or metastatic 
soft tissue sarcoma: a study by the EORTC Soft Tissue and Bone Sarcoma Group. European 
journal of cancer 2001;37:870-7.
20. Lorigan P, Verweij J, Papai Z, et al. Phase III trial of two investigational schedules of 
ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft 
tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft 
Tissue and Bone Sarcoma Group Study. Journal of clinical oncology : official journal of 
the American Society of Clinical Oncology 2007;25:3144-50.
21. Gelderblom H, Blay JY, Seddon BM, et al. Brostallicin versus doxorubicin as first-line 
chemotherapy in patients with advanced or metastatic soft tissue sarcoma: An European 
Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma 
Group randomised phase II and pharmacogenetic study. European journal of cancer 
2014;50:388-96.
22. Bui-Nguyen B, Butrynski JE, Penel N, et al. A phase IIb multicentre study comparing the 
efficacy of trabectedin to doxorubicin in patients with advanced or metastatic untreated 
soft tissue sarcoma: the TRUSTS trial. European journal of cancer 2015;51:1312-20.
23. Miller AB, Hoogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. 
Cancer 1981;47:207-14.
6
Binnenwerk_Productie.indd   123 2/10/2021   8:04:47 PM
124
Chapter 6
24. Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to 
treatment in solid tumors. European Organization for Research and Treatment of Cancer, 
National Cancer Institute of the United States, National Cancer Institute of Canada. Journal 
of the National Cancer Institute 2000;92:205-16.
25. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (version 1.1). European journal of cancer 2009;45:228-47.
26. Iqbal N, Shukla NK, Deo SV, et al. Prognostic factors affecting survival in metastatic soft 
tissue sarcoma: an analysis of 110 patients. Clinical & translational oncology : official 
publication of the Federation of Spanish Oncology Societies and of the National Cancer 
Institute of Mexico 2016;18:310-6.
27. Italiano A, Le Cesne A, Mendiboure J, et al. Prognostic factors and impact of adjuvant 
treatments on local and metastatic relapse of soft-tissue sarcoma patients in the 
competing risks setting. Cancer 2014;120:3361-9.
28. Sargent DJ, Kohne CH, Sanoff HK, et al. Pooled safety and efficacy analysis examining the 
effect of performance status on outcomes in nine first-line treatment trials using individual 
data from patients with metastatic colorectal cancer. Journal of clinical oncology : official 
journal of the American Society of Clinical Oncology 2009;27:1948-55.
29. Kawaguchi T, Takada M, Kubo A, et al. Performance status and smoking status are 
independent favorable prognostic factors for survival in non-small cell lung cancer: a 
comprehensive analysis of 26,957 patients with NSCLC. Journal of thoracic oncology : 
official publication of the International Association for the Study of Lung Cancer 2010;5:620-
30.
30. Maurel J, López-Pousa A, de las Peñas R, et al. Efficacy of Sequential High-Dose Doxorubicin 
and Ifosfamide Compared With Standard-Dose Doxorubicin in Patients With Advanced 
Soft Tissue Sarcoma: An Open-Label Randomized Phase II Study of the Spanish Group for 
Research on Sarcomas. Journal of Clinical Oncology 2009;27:1893-8.
31. Vlenterie M, Litiere S, Rizzo E, et al. Outcome of chemotherapy in advanced synovial 
sarcoma patients: Review of 15 clinical trials from the European Organisation for Research 
and Treatment of Cancer Soft Tissue and Bone Sarcoma Group; setting a new landmark 
for studies in this entity. European journal of cancer 2016;58:62-72.
32. Klimm B, Engert A. Differences in hematotoxicity between male and female patients with 
Hodgkin lymphoma and other malignancies. Nature clinical practice Oncology 2008;5:316-
23.
33. Abeler VM, Royne O, Thoresen S, Danielsen HE, Nesland JM, Kristensen GB. Uterine sarcomas 
in Norway. A histopathological and prognostic survey of a total population from 1970 to 
2000 including 419 patients. Histopathology 2009;54:355-64.
34. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec®, Gleevec™) 
is an active agent for gastrointestinal stromal tumours, but does not yield responses in 
other soft-tissue sarcomas that are unselected for a molecular target: Results from an 
EORTC Soft Tissue and Bone Sarcoma Group phase II study. European journal of cancer 
2003;39:2006-11.
35. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate 
in advanced gastrointestinal stromal tumors. The New England journal of medicine 
2002;347:472-80.
36. Gronchi A, Bui BN, Bonvalot S, et al. Phase II clinical trial of neoadjuvant trabectedin in 
patients with advanced localized myxoid liposarcoma. Annals of Oncology 2012;23:771-6.
Binnenwerk_Productie.indd   124 2/10/2021   8:04:47 PM
125
Prognostic relevance of disease stage in soft tissue sarcoma
Supplementary data
Supplementary table 1 Included studies and study treatments
Study Phase & 
design













R. Ph II/III DOX 75 (106) EPI 75 (104) 184
3. EORTC 
62842

















R. Ph II/III DOX 75 (112) # EPI 3*50 (111) # EPI 1*150 (111) # -
7. EORTC 
62903
R. Ph III DOX 50 + IFO 
5000 (157)





R. ph II IFO 5000 (93) IFO 3*3000 (89) 100
9. EORTC 
62941





Ph II IFO 12 (124) 91
11. EORTC 
62962
R. Ph II DOX 75 (45) Caelyx (50) 88
12. EORTC 
62971




















R. randomized, Ph phase, CYVADIC cyclophosphamide, vincristine, doxorubicin, dacarbazin, DOX 
doxorubicin, EPI epirubicin, IFO ifosfamide, given dose is in mg/m2
# Treatment arms that were excluded
6
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cy 62012 62061 62091 62801 62842 62851 62903 62912 62941 62953 62962 62971 Total
1980 0 0 0 4 0 0 0 0 0 0 0 0 4
1981 0 0 0 84 0 0 0 0 0 0 0 0 84
1982 0 0 0 72 0 0 0 0 0 0 0 0 72
1983 0 0 0 24 0 0 0 0 0 0 0 0 24
1984 0 0 0 0 74 0 0 0 0 0 0 0 74
1985 0 0 0 0 114 11 0 0 0 0 0 0 125
1986 0 0 0 0 1 123 0 0 0 0 0 0 124
1987 0 0 0 0 0 122 0 0 0 0 0 0 122
1988 0 0 0 0 0 146 0 0 0 0 0 0 146
1989 0 0 0 0 0 95 0 0 0 0 0 0 95
1990 0 0 0 0 0 15 0 0 0 0 0 0 15
1992 0 0 0 0 0 0 48 0 0 0 0 0 48
1993 0 0 0 0 0 0 123 0 0 0 0 0 123
1994 0 0 0 0 0 0 105 13 0 0 0 0 118
1995 0 0 0 0 0 0 17 66 24 0 0 0 107
1996 0 0 0 0 0 0 0 21 16 28 0 0 65
1997 0 0 0 0 0 0 0 0 0 63 40 0 103
1998 0 0 0 0 0 0 0 0 0 0 48 49 97
1999 0 0 0 0 0 0 0 0 0 0 0 106 106
2000 0 0 0 0 0 0 0 0 0 0 0 86 86
2001 0 0 0 0 0 0 0 0 0 0 0 51 51
2003 10 0 0 0 0 0 0 0 0 0 0 0 10
2004 55 0 0 0 0 0 0 0 0 0 0 0 55
2005 68 0 0 0 0 0 0 0 0 0 0 0 68
2006 63 3 0 0 0 0 0 0 0 0 0 0 66
2007 59 71 0 0 0 0 0 0 0 0 0 0 130
2008 63 42 0 0 0 0 0 0 0 0 0 0 105
2009 86 0 0 0 0 0 0 0 0 0 0 0 86
2010 31 0 0 0 0 0 0 0 0 0 0 0 31
2011 0 0 27 0 0 0 0 0 0 0 0 0 27
2012 0 0 106 0 0 0 0 0 0 0 0 0 106
Total 435 116 133 184 189 512 293 100 40 91 88 292 2473
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N (%) N (%) N (%) N (%)
Histological cell type for other
Malignant fibrous histiocytoma  41 (23.7)  124 (24.0)  90 (18.1)  255 (21.5)
Fibrosarcoma  12 (6.9)  37 (7.2)  40 (8.0)  89 (7.5)
Rhabdomyosarcoma  10 (5.8)  17 (3.3)  29 (5.8)  56 (4.7)
Angiosarcoma  12 (6.9)  28 (5.4)  45 (9.1)  85 (7.2)
Neurogenic sarcomas  25 (14.5)  50 (9.7)  34 (6.8)  109 (9.2)
Miscellaneous  47 (27.2)  210 (40.7)  180 (36.2)  437 (36.8)
Unclassified  26 (15.0)  50 (9.7)  79 (15.9)  155 (13.1)
Supplementary figure 1 Consort diagram
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Subgroup analysis of patients treated after 1999
Post 1999 subgroup analysis: protocols 62012, 62061, 62091
Limited subgroup (N =684) of which the majority belongs to 62012 (435) – phase 3 and 
two smaller phase 2 studies













N (%) N (%) N (%) N (%)
Gender
Male  22 (44.0)  172 (46.2)  129 (49.2)  323 (47.2)
Female  28 (56.0)  200 (53.8)  133 (50.8)  361 (52.8)
Performance status
PS 0  28 (56.0)  225 (60.5)  119 (45.4)  372 (54.4)
PS 1  22 (44.0)  145 (39.0)  143 (54.6)  310 (45.3)
PS 2+  0 (0.0)  2 (0.5)  0 (0.0)  2 (0.3)
Age (years)
< 40 yrs  13 (26.0)  54 (14.5)  49 (18.7)  116 (17.0)
40-50 yrs  4 (8.0)  88 (23.7)  68 (26.0)  160 (23.4)
50-60 yrs  19 (38.0)  131 (35.2)  85 (32.4)  235 (34.4)
>=60 yrs  14 (28.0)  99 (26.6)  60 (22.9)  173 (25.3)
Median 54 54 51 53
Range 21 - 78 18 - 84 19 - 88 18 - 88
Q1-Q3 36 - 60 44 - 60 43 - 59 44 - 60
Prior radiotherapy
No  26 (52.0)  110 (29.6)  143 (54.6)  279 (40.8)
Yes  2 (4.0)  116 (31.2)  38 (14.5)  156 (22.8)
Missing  22 (44.0)  146 (39.2)  81 (30.9)  249 (36.4)
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N (%) N (%) N (%) N (%)
Prior Surgery
Unknown  50 (100.0)  372 (100.0)  262 (100.0)  684 (100.0)
histology
Leiomyosarcoma  10 (20.0)  107 (28.8)  69 (26.3)  186 (27.2)
Synovial sarcoma  3 (6.0)  53 (14.2)  23 (8.8)  79 (11.5)
Liposarcoma  16 (32.0)  44 (11.8)  37 (14.1)  97 (14.2)
Other  21 (42.0)  168 (45.2)  133 (50.8)  322 (47.1)
Histopathological grade
Grade I  4 (8.0)  15 (4.0)  12 (4.6)  31 (4.5)
Grade II  19 (38.0)  123 (33.1)  98 (37.4)  240 (35.1)
Grade III  16 (32.0)  170 (45.7)  113 (43.1)  299 (43.7)
Missing  11 (22.0)  64 (17.2)  39 (14.9)  114 (16.7)
Site of primary tumour
Other  40 (80.0)  183 (49.2)  183 (69.8)  406 (59.4)
Extremity  10 (20.0)  176 (47.3)  76 (29.0)  262 (38.3)
Missing  0 (0.0)  13 (3.5)  3 (1.1)  16 (2.3)
Time between the initial 
diagnosis of sarcoma and 
registration
<6 mon  31 (62.0)  121 (32.5)  175 (66.8)  327 (47.8)
6-12 mon  7 (14.0)  60 (16.1)  21 (8.0)  88 (12.9)
1-2 yrs  6 (12.0)  64 (17.2)  26 (9.9)  96 (14.0)
>=2 yrs  6 (12.0)  127 (34.1)  40 (15.3)  173 (25.3)
Median 2.3 12.3 2.6 8.1
Range 0.0 - 117.7 0.2 - 249.8 0.0 - 198.7 0.0 - 249.8
Q1-Q3 1.1 - 11.9 5.2 - 33.5 1.2 - 12.2 1.9 - 24.6
6
















N (%) N (%) N (%) N (%)
Treatment
Anthracyclines  25 (50.0)  159 (42.7)  115 (43.9)  299 (43.7)
DOX+IFO  15 (30.0)  110 (29.6)  93 (35.5)  218 (31.9)
Other  10 (20.0)  103 (27.7)  54 (20.6)  167 (24.4)
Primary site involved
No  0 (0.0)  372 (100.0)  0 (0.0)  372 (54.4)
Yes  50 (100.0)  0 (0.0)  262 (100.0)  312 (45.6)
Lung metastases
No  50 (100.0)  86 (23.1)  80 (30.5)  216 (31.6)
Yes  0 (0.0)  286 (76.9)  182 (69.5)  468 (68.4)
Bone metastases
No  50 (100.0)  323 (86.8)  213 (81.3)  586 (85.7)
Yes  0 (0.0)  49 (13.2)  49 (18.7)  98 (14.3)
Liver metastases
No  50 (100.0)  300 (80.6)  211 (80.5)  561 (82.0)
Yes  0 (0.0)  72 (19.4)  51 (19.5)  123 (18.0)
Other metastases
No  50 (100.0)  148 (39.8)  89 (34.0)  287 (42.0)
Yes  0 (0.0)  224 (60.2)  173 (66.0)  397 (58.0)
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(months)












O N Number of patients at risk : Stage
26 50 38 29 17 13 9 8 7 7
248 372 285 172 108 79 53 33 20 19



























50 26 17.84 (13.80, 
39.39)

































O N Number of patients at risk : Disease stage
44 50 29 17 10 7 5
362 372 157 55 28 17 10



































 372 362 4.78 (3.91, 
5.59)
14.8 (11.4, 18.6) 1.65 (1.20, 
2.28)
Both  262 250 4.27 (2.89, 
5.52)
12.4 (8.7, 16.8) 1.79 (1.29, 
2.48)
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N (%) N (%) N (%)
Best overall response
Complete Response (CR) 0 (0.0) 6 (1.6) 1 (0.4)
Partial Response (PR) 4 (8.0) 77 (20.7) 30 (11.5)
Stable Disease (SD) 31 (62.0) 159 (42.7) 125 (47.7)
Progressive Disease (PD) 11 (22.0) 116 (31.2) 84 (32.1)
Not Evaluable 4 (8.0) 14 (3.8) 22 (8.4)
Responders
Failure 46 (92.0) 289 (77.7) 231 (88.2)
Responders (CR+PR) 4 (8.0) 83 (22.3) 31 (11.8)
Multivariate analysis
Very low power in locally advanced subgroup with only N=50




Performance status PS 0 1.00 <.001 (df=2)
PS 1 1.84 (1.42, 2.39)
PS 2+ 9.52 (2.24, 40.47)
Time since initial diagnosis <6 months 1.00 <.001 (df=3)
6-12 months 0.58 (0.40, 0.86)
1-2 yrs 0.59 (0.40, 0.86)
>=2 yrs 0.44 (0.32, 0.61)
Gender Male 1.00 0.034 (df=1)
Female 0.76 (0.59, 0.98)
6
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Overall survival – both
Parameter Levels Hazard Ratio
(95% CI)
P-value
Performance status PS 0 1.00 0.002 (df=1)
PS 1 1.57 (1.18, 2.09)




Performance status PS 0 1.00 <.001 (df=2)
PS 1 1.51 (1.21, 1.87)
PS 2+ 3.22 (0.78, 13.19)
Time since initial diagnosis <6 months 1.00 <.001 (df=3)
6-12 months 0.73 (0.53, 1.00)
1-2 yrs 0.66 (0.48, 0.90)
>=2 yrs 0.51 (0.39, 0.66)




Grade Grade I 1.00 0.050 (df=3)
Grade II 1.21 (0.66, 2.22)
Grade III 1.72 (0.94, 3.15)
Unknown 1.68 (0.83, 3.39)
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Histology Leiomyosarcoma 1.00 0.001 (df=3)
Liposarcoma 0.26 (0.11, 0.62)
Other 1.36 (0.66, 2.81)
Synovial sarcoma 1.03 (0.40, 2.62)
Site of primary 
tumour
Other 1.00 0.001 (df=2)
Extremity 0.31 (0.16, 0.59)
Unknown 0.21 (0.05, 0.87)
Grade Grade I 1.00 0.013 (df=3)
Grade II 3.35 (0.90, 12.51)
Grade III 2.20 (0.60, 8.07)
Unknown 0.66 (0.15, 2.80)
SEX Male 1.00 0.045 (df=1)
Female 0.56 (0.32, 0.99)
Response rate – both:
None significant
6
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Survival of soft tissue sarcoma 
patients after completing six cycles 
of first-line anthracycline containing 
treatment: 
an EORTC-STBSG database study
Clin Sarcoma Res 2020; 10:18
A.J. Verschoor, S. Litière, S. Marréaud, I. Judson, M. Toulmonde, E. Wardelmann, 
A. Le Cesne, H. Gelderblom





Doxorubicin based chemotherapy is standard first line treatment for patients with soft 
tissue sarcoma. Currently several options to improve survival after doxorubicin-based 
chemotherapy are being studied. This study reports on survival after completing 6 
cycles of doxorubicin containing first line treatment, which is important when designing 
studies trying to improve outcomes of first line treatment.
Methods
A retrospective database analysis was performed on 2045 patients from 12 EORTC 
sarcoma trials receiving first line doxorubicin-based chemotherapy for advanced soft 
tissue sarcoma in order to establish progression free survival and overall survival after 
completing 6 cycles of first line doxorubicin-based chemotherapy. Endpoints were 
overall survival and progression free survival. Factors studied were histologic subtype 
and type of doxorubicin chemotherapy.
Results
748 of 2045 patients (36.6%) received at least 6 cycles and did not progress during or 
at the end of chemotherapy. 475 of 2045 (23.2%) patients received exactly 6 cycles and 
did not progress during or at the end of chemotherapy. Median progression free survival 
after 6 cycles of doxorubicin-based chemotherapy was 4.2 months (95% confidence 
interval 3.7-4.8) and median overall survival 15.7 months (14.0-17.8). Significant differences 
in progression free survival were found between chemotherapy regimens, but not for 
overall survival.
These data are also reported for patients receiving 7 or more cycles of chemotherapy 
and for patients with 3 or more cycles of chemotherapy.
Conclusion
This large retrospective study is the first to report progression free survival and overall 
survival after completion of 6 cycles of first line doxorubicin containing chemotherapy. 
These results are important when designing new studies exploring for example 
maintenance therapy after doxorubicin-based chemotherapy. Approximately one third 
of all patients may qualify for maintenance therapy.
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Introduction
Soft tissue sarcomas (STS) are a rare group of tumours comprising approximately 1% 
of all cancers and containing approximately 70 different histological entities.1 Clinical 
behaviour differs between the various histological entities.1 Surgery is the primary 
treatment for localized disease when resection is possible with the option of adding neo-
adjuvant or adjuvant radiotherapy.2 For patients with locally advanced and/or distant 
metastatic disease the goal of treatment is to prolong survival and treatment mainly 
consists of systemic treatment, e.g. cytotoxic drugs and tyrosine kinase inhibitors.2
The current first line chemotherapy consists of anthracycline based chemotherapy 
either as monotherapy or combination therapy.3 Survival remains poor for patients 
presenting with incurable disease. Overall survival (OS) with doxorubicin monotherapy 
is approximately 12.8 months and with doxorubicin/ifosfamide combination therapy 
approximately 14.3 months.3 More recent trials report slightly better median OS for 
doxorubicin monotherapy with 17.6 months (GeDDiS), 16.9 months (PICASSO III) and 19.0 
months (SARC021).4-6 In 2016, Tap et al. reported the results of a phase Ib/II trial adding 
olaratumab, a PDGFRα blocking monoclonal antibody, to doxorubicin.7 The results of this 
study were promising with an increase in progression free survival (PFS) of 2.5 months 
and an impressive increase in median OS from 14.7 months to 26.5 months with the 
addition of olaratumab.7 This improvement in OS resulted in an accelerated approval 
by the U.S. Food and Drug Administration and a conditional approval by the European 
Medical Agency. However, recently the results of the phase III study with olaratumab, 
ANNOUNCE (NCT02451943), were presented during the annual meeting of the ASCO 
2019 and did not show a difference between doxorubicin/placebo and doxorubicin/
olaratumab. Based on these results olaratumab was withdrawn from the market.8
Now, other treatment strategies have to be studied to increase the PFS and OS of STS 
patients including the addition of maintenance therapy after completing six cycles of 
doxorubicin. In order to assist in the design of maintenance studies it is important to have 
survival data of patients after completing six cycles of doxorubicin containing treatment 
and to understand the extent of the attrition in the number of patients available for 
study, indeed the percentage who could possibly benefit from maintenance therapy 
by not having progressed before completing 6 cycles of treatment. This study reports 
the OS data of study patients completing six cycles of anthracycline or anthracycline 
combination therapy in the European Organisation for Research and Treatment of 
Cancer Soft Tissue and Bone Sarcoma Group trial database.
7





The European Organisation for Research and Treatment of Cancer Soft Tissue and Bone 
Sarcoma Group study database contains data from 12 trials studying doxorubicin alone 
or in combination with ifosfamide.3,9-19 All but one study, included patients with locally 
advanced or metastatic STS. The study by Steward et al. only included patients with 
metastatic STS.12 Patients with at least 1 cycle of treatment were considered for this study. 
Reasons for exclusion were previous treatment with chemotherapy either as adjuvant 
or palliative treatment, patients without data on progression and death and patients 
diagnosed with Gastrointestinal Stromal Tumour (GIST). Among these patients, we 
focused on patients who did not progress before the end of treatment. End of treatment 
was considered to be 21 days after the date of administration of the last treatment. 
(Supplementary figure 1) Analysis was done in three different subgroups: patients who 
received exactly 6 cycles of doxorubicin containing chemotherapy, patients with 7 or 
more cycles and patients with less than 6 cycles who stopped treatment for reasons 
other than progression.
The EORTC studies 62012, 62061, 62091, 62962 and 62971 had treatment regimens 
including a maximum number of 6 cycles of doxorubicin, 62941 7 cycles and the other 
studies aimed for a cumulative dose of 550 mg/m2 of doxorubicin allowing for more if 
the ejection fraction remained within certain limits.
Endpoints
Endpoints were PFS and OS after completing treatment, because the aim of the study 
was to determine PFS and OS after completion of 6 cycles of doxorubicin containing 
treatment in patients who did not have progressive disease at that time point. PFS was 
defined as the time between end of treatment and progression or death. OS was defined 
as the time between end of treatment and death. Also calculated were PFS from date 
of randomisation to date of progression or death and OS from date of randomisation 
to date of death. Patients progressing between start of treatment and 21 days after 
the last administration date were not considered for the PFS and OS after treatment 
analysis, because only those patients who do not have progression before the start of 
maintenance treatment will qualify for maintenance treatment. Time on treatment was 
calculated from date of randomisation or registration and the end of treatment.
Covariates
Patients were grouped according to treatment i.e. doxorubicin 75mg/m2 monotherapy, 
doxorubicin 50mg/m2 combined with ifosfamide 5g/m2, doxorubicin 75mg/m2 combined 
with ifosfamide 5g/m2 and doxorubicin 75mg/m2 combined with ifosfamide 10g/m2. The 
other covariate considered in this study was histologic subtype. If central pathology 
review was available the central pathology diagnosis was used, if it was not present the 
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local pathology diagnosis was used. Only histologic subtypes comprising more than 
ten percent of patients were considered for separate analysis.
Statistics
PFS and OS were calculated using the Kaplan Meier method. PFS and OS were compared 
using a cox proportional hazard model. Significance was set at p=0.05.
Results
In total, 2045 patients were included in this study. Almost 50% of patients were treated 
with doxorubicin 75 mg/m2 as monotherapy; the other patients were treated with one 
of the combination regimens. (Supplementary Table 1 shows the distribution of patients 
according to study and treatment regimen. Supplementary Table 2 shows the number 
of treatment cycles by study.) Median time on treatment was 15 weeks, corresponding 
to a median number of 5 cycles. Of all patients, 43.7% of patients (894) were treated 
with 6 or more cycles of chemotherapy, 70.2% of patients were treated with 3 or more 
cycles. Five hundred fifty-five patients (27.1%) received exactly 6 cycles of chemotherapy. 
Median follow-up for all patients was 4.1 years (Inter quartile range (IQR) 2.5-6.5 years). 
Most of the patients receiving more than 6 cycles, were included in studies studying 
the doxorubicin 50 mg/m2/ifosfamide 5 gram/m2 regimen. (Supplementary table 1)
Of these patients with at least 6 cycles of treatment 748 patients (83.7% of all patients 
treated with 6 or more cycles) did not progress before or at the end of treatment. For 
exactly 6 cycles, 475 patients (85.6% of patients treated with exactly 6 cycles) did 
not progress before the end of treatment. Table 1 shows the percentage of patients 
considered for this study per treatment strategy.
Baseline characteristics
Table 2a/b and 3a/b and supplementary table 1a-d show the characteristics of the 
included patients. No important differences exist between the different groups. The 
most common histologic subtype was leiomyosarcoma (31%), followed by the no longer 
existing histologic entity malignant fibrous histiocytoma (MFH) (13%) and synovial 
sarcoma (10%). (Supplementary Table 3) As none of the other subtypes did comprise 
ten percent of the patients as an entity, these were considered together when histologic 
subtype was studied (also MFH was added to the miscellaneous group as this entity no 
longer exists; smaller subgroups would reduce the statistical power).
7
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Table 3b Tumour and treatment characteristics



















N (%) N (%) N (%) N (%) N (%)
Histopathological grading
Grade I and II  26 (11.7)  12 (15.0)  8 (12.7)  6 (5.5)  52 (10.9)
Grade III  158 (70.9)  38 (47.5)  33 (52.4)  102 (93.6)  331 (69.7)
Unknown  39 (17.5)  30 (37.5)  22 (34.9)  1 (0.9)  92 (19.4)
Site of primary tumour
Other  130 (58.3)  40 (50.0)  17 (27.0)  58 (53.2)  245 (51.6)
Extremities  76 (34.1)  15 (18.8)  12 (19.0)  49 (45.0)  152 (32.0)
Missing  17 (7.6)  25 (31.3)  34 (54.0)  2 (1.8)  78 (16.4)
Histology
Leiomyosarcoma  66 (29.6)  25 (31.3)  13 (20.6)  24 (22.0)  128 (26.9)
Synovial sarcoma  37 (16.6)  8 (10.0)  7 (11.1)  19 (17.4)  71 (14.9)
Other  119 (53.4)  42 (52.5)  40 (63.5)  65 (59.6)  266 (56.0)
Missing  1 (0.4)  5 (6.3)  3 (4.8)  1 (0.9)  10 (2.1)
Prior Surgery
No surgery  8 (3.6)  11 (13.8)  0 (0.0)  0 (0.0)  19 (4.0)
Non optimal surgery  11 (4.9)  12 (15.0)  0 (0.0)  0 (0.0)  23 (4.8)
Complete surgery  42 (18.8)  24 (30.0)  0 (0.0)  0 (0.0)  66 (13.9)
Unknown  162 (72.6)  33 (41.3)  63 (100.0)  109 (100.0)  367 (77.3)
Prior radiotherapy
No  115 (51.6)  57 (71.3)  41 (65.1)  66 (60.6)  279 (58.7)
Yes  66 (29.6)  22 (27.5)  22 (34.9)  43 (39.4)  153 (32.2)
Missing  42 (18.8)  1 (1.3)  0 (0.0)  0 (0.0)  43 (9.1)
Primary site involved
No  122 (54.7)  42 (52.5)  22 (34.9)  58 (53.2)  244 (51.4)
Yes  86 (38.6)  38 (47.5)  17 (27.0)  51 (46.8)  192 (40.4)
Missing  15 (6.7)  0 (0.0)  24 (38.1)  0 (0.0)  39 (8.2)
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Table 3b Continued.



















N (%) N (%) N (%) N (%) N (%)
Metastatic Site involved
No  22 (9.9)  14 (17.5)  5 (7.9)  8 (7.3)  49 (10.3)
Yes  186 (83.4)  66 (82.5)  34 (54.0)  101 (92.7)  387 (81.5)
Missing  15 (6.7)  0 (0.0)  24 (38.1)  0 (0.0)  39 (8.2)
Patients treated with at least 6 cycles of treatment
Considering the 748 patients with at least 6 cycles of treatment and without progression 
before or at the end of treatment, the median PFS from randomisation was 9.4 months 
(95% confidence interval: 8.9-9.9) and median PFS from end of treatment was 4.3 
months (95% confidence interval: 3.8-4.7). (Supplementary table S4 shows the PFS per 
treatment regimen) PFS for the different histologies was comparable and is provided 
in supplementary table 5.
Median OS from randomisation was 19.5 months (95% confidence interval: 18.2-21.3) and 
median OS from end of treatment was 14.5 months (95% confidence interval: 12.8-16.1). 
(Supplementary table 6) The median OS according to histology were approximately the 
same and are provided in supplementary table 7.
Patients treated with exactly 6 cycles of treatment
Because longer treatment duration could lead to bias, we also did the analysis for 
patients treated with exactly 6 cycles. For this analysis, 475 patients were included (85.6% 
of the total receiving 6 cycles). The median PFS from randomisation was 8.7 months 
(95% confidence interval: 8.2-9.1) and the median PFS from end of treatment was 4.2 
months (95% confidence interval: 3.7-4.8). (Supplementary table 8) A significant effect of 
treatment on PFS was found, patients receiving doxorubicin monotherapy had a worse 
PFS compared to patients receiving doxorubicin 75mg/m2 combined with ifosfamide 
10 g/m2 combination therapy (p=0.021 and p=0.036 respectively, as already reported 
by Judson et al. 3). In this analysis, no significant effect of histology on PFS was found. 
(Supplementary table 9)
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Median OS from randomisation for these patients was 20.1 months (95% confidence 
interval: 18.3-22.3 months) and median OS from end of treatment was 15.7 months (95% 
confidence interval: 14.0-17.8). There was no statistically significant effect of treatment 
regimen or histology on OS. (Supplementary table 10 and 11)
Patients treated with less than 6 cycles and no progressive disease
The progression-free survival for patients treated with less than 6 cycles of doxorubicin-
containing treatment regimens was 3.8 months (95% confidence interval 3.5-4.3 months) 
from randomisation. (Supplementary table 12) OS was 10.0 months (95% confidence 
interval 9.1-10.8 months). (Supplementary table 14) As there can be a bias due to the 
number of cycles given, no formal statistical comparisons were done. The median 
progression-free survival and OS for the different treatment regimens are shown in 
supplementary tables 13 and 15 respectively, but did not differ.
Discussion
In this study, we report the progression-free and OS of patients completing 6 cycles 
of doxorubicin-based chemotherapy who did not progress before completion of this 
treatment. Knowledge of the PFS and OS of patients completing 6 cycles of doxorubicin 
without progressive disease is essential for planning maintenance studies with cytotoxic 
chemotherapy or tyrosine kinase inhibitors. It is also important to know what percentage 
of the total number of patients receiving systemic therapy is likely to be available for 
such trials.
The prognosis of patients with metastatic STS remains poor, with a median OS of 12.8 
to 14.3 months respectively in a recently reported study of first-line doxorubicin versus 
doxorubicin/ifosfamide.3 More recent studies show a median OS around 18 months.4-6 
As already mentioned in the introduction, since 2016 olaratumab has been introduced 
in some countries in addition to doxorubicin following the demonstration of a major 
increase in OS in a phase II trial.7 However, the results of the phase III ANNOUNCE study 
did not show an improved OS of the addition of olaratumab to doxorubicin, as was 
recently presented during the annual meeting of ASCO 2019, leading to the withdrawal 
from the market.8 Now, one of the other strategies that could be explored to improve the 
OS of STS patients is the addition of maintenance therapy after first-line chemotherapy. 
This is a well-established concept in colorectal cancer, non-small cell lung cancer and 
ovarian cancer.20-22 Progression after first-line treatment can result in a deterioration in 
performance status making it difficult or impossible to administer second-line treatment. 
Maintenance treatment is intended to improve OS by prolonging the progression-free 
survival after first-line treatment by direct continuation of chemotherapy. In STS, this is 
even more a problem, because doxorubicin is first-line treatment and has a maximum 
safe cumulative dose of 450mg/m2 (6 cycles), although even at this dose there is 
evidence of cardiac damage in a significant percentage of patients. Administration of 
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higher cumulative doses, e.g. 600mg/m2 (8 cycles) as in the olaratumab study, is only 
possible with the co-administration of the cardioprotective agent cardioxane since 
the risk of cardiotoxicity at this dose without cardioprotection is in the region of 50%. 
An alternative to doxorubicin would be the use of liposomal doxorubicin, which does 
not have the cardiotoxic potential of doxorubicin.16 When considering maintenance 
treatment, one needs to take into account the risks of this therapy and the loss in quality 
of life caused by the maintenance treatment. Drugs that have some proven utility 
against sarcomas and could be used in maintenance treatment include pazopanib and 
trabectedin, which are both well-tolerated.23-25 Although the concept of maintenance 
treatment after doxorubicin is attractive, maintenance studies had trouble recruiting 
due to the temporary registration and availability of olaratumab in most of the western 
world. Probably, these trials will now recruit more easily, because olaratumab failed in 
the phase III trial. For designing future studies of maintenance therapy in STS, data on 
PFS and OS in this setting are essential.
It is important to realise that of all patients included in the database, only 43.7% received 
6 cycles or more and only 83.7% of these did not progress before the end of treatment 
(36.6% of all patients). Patients treated with more than 6 cycles have a similar OS as 
patients receiving exactly 6 cycles of doxorubicin, but patients receiving less than 6 
cycles without progressive disease at the end of treatment have a worse survival. Based 
on this database study we roughly estimate that only one third of all patients (all patients 
receiving 6 or more cycles and no progressive disease at end of treatment) will qualify 
for maintenance treatment.
The PFS of 8.7 months and the OS of 20.1 months from randomisation is much longer 
than the mean OS of patients included in first line studies. Of course, this is an expected 
difference because responding patients will have a better prognosis compared to 
patients not responding to chemotherapy. On the other hand, this improved survival 
should be accounted for when planning maintenance studies and single arm phase 
II studies.
One of the major limitations of this study is the long interval between the first included 
patient and the last included patient. Ifosfamide was already available in the early 
years of this study, but trabectedin, pazopanib and gemcitabine/docetaxel are new 
second or later line treatments prolonging PFS and/or OS.19,23,26 These new second line 
treatments will cause bias when comparing older regimens like doxorubicin 50mg/m2 
combined with ifosfamide 5g/m2 to newer regimens like doxorubicin 75mg/m2 combined 
with ifosfamide 10g/m2. The improved supportive care over the years will increase this 
bias somewhat further.
In this study, treatment regimen had only a significant effect on PFS, with doxorubicin 
75mg/m2 combined with ifosfamide 10g/m2 having the best PFS. No significant effect 
7
Binnenwerk_Productie.indd   151 2/10/2021   8:04:49 PM
152
Chapter 7
on OS was found, but a trend towards an increase in OS was found for patients with 
doxorubicin/ifosfamide combination therapy, which is more or less comparable with 
our study on this regimen, showing only a very little improvement in OS compared with 
doxorubicin 75mg/m2 monotherapy.3 The increase in PFS without an increase in OS in this 
study could be the effect of sequentially using these agents compared to using them 
concurrently. For other tumours like colorectal cancer it has been shown that sequential 
treatment is comparable to concurrent treatment.27 Second, as the study design selects 
for responding patients, the difference in OS between this study and the EORTC 62012 
study could be caused by the increased response rate with doxorubicin/ifosfamide.
Importantly, this study shows no effect of histology on the outcome of patients, 
although the number of separately studied subtypes was small. This is in contrast 
to earlier studies, showing a better survival in for example synovial sarcoma.28 These 
differences could be caused by the low number of included patients in this study, or 
by the exclusion of patients with progression during treatment, thereby selecting for 
responding patients.
Conclusions
This is the first study reporting the progression-free survival and OS of patients 
completing 6 cycles of doxorubicin containing treatment without progressive disease 
before completion of treatment. These data are important for future study design and 
daily patient care as one of the ways forwards to improve survival in advanced STS could 
be maintenance treatment for the minority of patients whose disease is sensitive to 
chemotherapy. Future trials on maintenance treatment after first-line doxorubicin should 
only include patients receiving at least 6 (or more) cycles of doxorubicin or, when also 
including patients with less than 6 cycles of doxorubicin, should stratify for the number 
of cycles doxorubicin given.
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1 34 6 5 6 10 59 10 12 26 3 4 4 179
2 94 7 9 20 33 107 18 22 62 6 10 28 416
3 30 0 1 15 20 56 15 13 36 5 4 13 208
4 32 2 3 7 23 63 18 12 28 4 6 15 213
5 17 1 0 14 17 40 13 5 21 2 0 5 135
6 225 22 23 8 25 70 31 16 81 6 14 34 555
7 1 0 0 10 12 48 5 21 26 13 2 1 139
8 0 0 0 7 29 46 1 6 14 0 1 0 104
9 0 0 0 2 4 23 0 0 5 0 0 0 34
10 0 0 0 3 13 14 0 0 8 0 0 0 38
11 0 0 0 1 0 5 0 0 2 0 0 0 8
12 0 0 0 0 4 1 0 0 0 0 0 0 5
13 0 0 0 1 1 1 0 0 0 0 0 0 3
14 0 0 0 0 0 3 0 0 0 0 0 0 3
15 0 0 0 0 2 1 0 0 0 0 0 0 3
16 0 0 0 0 0 1 0 0 0 0 0 0 1
17 0 0 0 0 1 0 0 0 0 0 0 0 1
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Supplementary table 3a distribution of histological subtype and grade in patients 
treated with more than 6 cycles
More than 6 cycles
Pts who 
progress before 
or at the end of 
treatment
(N=66)
Pts who did not 
progress before 





N (%) N (%) N (%)
Histological cell type
MFH  5 (7.6)  39 (14.3)  44 (13.0)
Fibrosarcoma  5 (7.6)  13 (4.8)  18 (5.3)
Liposarcoma  6 (9.1)  25 (9.2)  31 (9.1)
Leiomyosarcoma  25 (37.9)  79 (28.9)  104 (30.7)
Rhabdomyosarcoma  2 (3.0)  4 (1.5)  6 (1.8)
Angiosarcoma  2 (3.0)  10 (3.7)  12 (3.5)
Synovial sarcoma  6 (9.1)  29 (10.6)  35 (10.3)
Neurogenic sarcoma  5 (7.6)  19 (7.0)  24 (7.1)
Miscellaneous  6 (9.1)  27 (9.9)  33 (9.7)
Unclassified  4 (6.1)  14 (5.1)  18 (5.3)
Missing  0 (0.0)  14 (5.1)  14 (4.1)
Histopathological grade
I  8 (12.1)  24 (8.8)  32 (9.4)
II  15 (22.7)  59 (21.6)  74 (21.8)
III  18 (27.3)  93 (34.1)  111 (32.7)
Missing  25 (37.9)  97 (35.5)  122 (36.0)
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Supplementary table 3b distribution of histological subtype and grade in patients 








did not progress 





N (%) N (%) N (%)
Histological cell type
MFH  5 (6.3)  35 (7.4)  40 (7.2)
Fibrosarcoma  4 (5.0)  8 (1.7)  12 (2.2)
Liposarcoma  4 (5.0)  65 (13.7)  69 (12.4)
Leiomyosarcoma  23 (28.8)  128 (26.9)  151 (27.2)
Rhabdomyosarcoma  0 (0.0)  10 (2.1)  10 (1.8)
Angiosarcoma  3 (3.8)  22 (4.6)  25 (4.5)
Synovial sarcoma  10 (12.5)  71 (14.9)  81 (14.6)
Neurogenic sarcoma  10 (12.5)  13 (2.7)  23 (4.1)
Miscellaneous  13 (16.3)  92 (19.4)  105 (18.9)
Unclassified  5 (6.3)  21 (4.4)  26 (4.7)
Missing  3 (3.8)  10 (2.1)  13 (2.3)
Histopathological grade
I  6 (7.5)  52 (10.9)  58 (10.5)
II  16 (20.0)  162 (34.1)  178 (32.1)
III  30 (37.5)  169 (35.6)  199 (35.9)
Missing  28 (35.0)  92 (19.4)  120 (21.6)
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Supplementary table 3c distribution of histological subtype and grade in patients 
treated with less than 6 cycles and stopped for other reasons then progression
Less than 6 cycles
Pts who 
progress before 
or at the end of 
treatment
(N=567)
Pts who did not 
progress before 





N (%) N (%) N (%)
Histological cell type
MFH  58 (10.2)  79 (13.5)  137 (11.9)
Fibrosarcoma  11 (1.9)  22 (3.8)  33 (2.9)
Liposarcoma  47 (8.3)  47 (8.0)  94 (8.2)
Leiomyosarcoma  192 (33.9)  180 (30.8)  372 (32.3)
Rhabdomyosarcoma  16 (2.8)  16 (2.7)  32 (2.8)
Angiosarcoma  23 (4.1)  14 (2.4)  37 (3.2)
Synovial sarcoma  32 (5.6)  59 (10.1)  91 (7.9)
Neurogenic sarcoma  18 (3.2)  29 (5.0)  47 (4.1)
Miscellaneous  93 (16.4)  80 (13.7)  173 (15.0)
Unclassified  49 (8.6)  30 (5.1)  79 (6.9)
Missing  28 (4.9)  28 (4.8)  56 (4.9)
Histopathological grade
I  38 (6.7)  30 (5.1)  68 (5.9)
II  140 (24.7)  162 (27.7)  302 (26.2)
III  191 (33.7)  204 (34.9)  395 (34.3)
Missing  198 (34.9)  188 (32.2)  386 (33.5)
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Supplementary table 3d distribution of histological subtype and grade in patients 
treated with exactly 6 cycles according to treatment protocol


















N (%) N (%) N (%) N (%) N (%)
Histological cell type
MFH  9 (4.0)  12 (15.0)  7 (11.1)  7 (6.4)  35 (7.4)
Fibrosarcoma  2 (0.9)  1 (1.3)  3 (4.8)  2 (1.8)  8 (1.7)
Liposarcoma  36 (16.1)  7 (8.8)  6 (9.5)  16 (14.7)  65 (13.7)
Leiomyosarcoma  66 (29.6)  25 (31.3)  13 (20.6)  24 (22.0)  128 (26.9)
Rhabdomyosarcoma  6 (2.7)  1 (1.3)  2 (3.2)  1 (0.9)  10 (2.1)
Angiosarcoma  12 (5.4)  2 (2.5)  2 (3.2)  6 (5.5)  22 (4.6)
Synovial sarcoma  37 (16.6)  8 (10.0)  7 (11.1)  19 (17.4)  71 (14.9)
Neurogenic sarcoma  4 (1.8)  4 (5.0)  5 (7.9)  0 (0.0)  13 (2.7)
Miscellaneous  40 (17.9)  11 (13.8)  8 (12.7)  33 (30.3)  92 (19.4)
Unclassified  10 (4.5)  4 (5.0)  7 (11.1)  0 (0.0)  21 (4.4)
Missing  1 (0.4)  5 (6.3)  3 (4.8)  1 (0.9)  10 (2.1)
Histopathological grade
I  26 (11.7)  12 (15.0)  8 (12.7)  6 (5.5)  52 (10.9)
II  78 (35.0)  12 (15.0)  19 (30.2)  53 (48.6)  162 (34.1)
III  80 (35.9)  26 (32.5)  14 (22.2)  49 (45.0)  169 (35.6)
Missing  39 (17.5)  30 (37.5)  22 (34.9)  1 (0.9)  92 (19.4)
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Supplementary table 4 Progression free survival of patients treated with >6 cycles
Treatment Patients (N) Observed Events (O) Median (95% CI) (Months)
PFS from Randomisation
DOX 75 336 308 8.48 (7.92, 9.10)
DOX 50-IFO 5 215 188 10.61 (9.82, 11.70)
DOX 75-IFO 5 88 81 9.31 (8.25, 11.60)
DOX 75-IFO 10 109 98 9.66 (8.77, 11.37)
Total 748 675 9.40 (8.94, 9.89)
PFS from End of treatment
DOX 75 336 308 3.42 (3.12, 4.07)
DOX 50-IFO 5 215 188 4.70 (3.68, 5.68)
DOX 75-IFO 5 88 81 4.93 (3.61, 6.97)
DOX 75-IFO 10 109 98 4.99 (4.37, 6.67)
Total 748 675 4.27 (3.84, 4.73)
Supplementary table 5 Progression free survival from End of treatment by histology for 
patients treated with >6 cycles
Histology Patients (N) Observed Events (O) Median (95% CI) (Months)
DOX 75
Leiomyosarcoma  103  97 3.42 (2.92, 4.44)
Synovial sarcoma  44  41 3.42 (2.07, 4.34)
Other  183  166 3.42 (2.76, 4.44)
DOX 50-IFO 5
Leiomyosarcoma  58  52 3.25 (2.10, 4.53)
Synovial sarcoma  26  25 3.81 (2.14, 5.62)
Other  120  101 6.93 (5.03, 8.44)
DOX 75-IFO 5
Leiomyosarcoma  22  21 3.99 (2.60, 7.36)
Synovial sarcoma  11  10 3.19 (0.92, 11.93)
Other  50  45 6.34 (3.15, 10.09)
DOX 75-IFO 10
Leiomyosarcoma  24  22 4.90 (2.92, 8.51)
Synovial sarcoma  19  19 4.24 (2.96, 8.28)
Other  65  56 5.13 (4.37, 7.43)
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Supplementary table 6 Overall survival of patients treated with >6 cycles
Treatment Patients (N) Observed Events (O) Median (95% CI) (Months)
OS from Randomisation
DOX 75  336  237 18.73 (16.99, 21.88)
DOX 50-IFO 5  215  162 18.92 (16.66, 21.49)
DOX 75-IFO 5  88  77 19.19 (15.01, 23.75)
DOX 75-IFO 10  109  83 23.59 (19.32, 28.19)
Total  748  559 19.48 (18.20, 21.29)
OS from End of treatment
DOX 75  336  237 13.96 (11.99, 16.76)
DOX 50-IFO 5  215  162 12.81 (10.94, 16.10)
DOX 75-IFO 5  88  77 15.05 (10.58, 18.89)
DOX 75-IFO 10  109  83 18.89 (14.95, 23.79)
Total  748  559 14.52 (12.78, 16.10)
Supplementary table 7 Overall survival from End of treatment by histology for patients 












Leiomyosarcoma  103  70 16.59 (11.17, 22.11) 1.00
Synovial sarcoma  44  36 14.23 (9.30, 18.43) 1.18 (0.79, 1.76)
Other  183  127 12.94 (11.27, 16.76) 1.08 (0.80, 1.44)
DOX 50-IFO 5
Leiomyosarcoma  58  49 10.68 (8.08, 13.08) 1.00
Synovial sarcoma  26  22 12.29 (7.56, 16.10) 1.10 (0.66, 1.83)
Other  119  80 18.63 (13.96, 22.34) 0.56 (0.39, 0.80)
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Leiomyosarcoma  22  21 15.97 (9.20, 22.37) 1.00
Synovial sarcoma  11  10 14.78 (4.73, 26.71) 1.27 (0.60, 2.71)
Other  50  42 11.53 (7.75, 20.47) 0.93 (0.55, 1.58)
DOX 75-IFO 10
Leiomyosarcoma  24  20 17.35 (9.99, 26.71) 1.00
Synovial sarcoma  19  17 18.89 (8.15, 25.10) 1.37 (0.71, 2.63)
Other  65  46 18.04 (11.37, 27.17) 0.85 (0.50, 1.44)














DOX 75  223  209 7.59 (7.23, 8.38) 1.00 0.021 (df=3)
DOX 50-IFO 5  80  74 8.85 (7.33, 10.81) 0.84 (0.65, 1.10)
DOX 75-IFO 5  63  59 9.10 (7.36, 11.40) 0.74 (0.55, 0.99)
DOX 75-IFO 10  109  98 9.66 (8.77, 11.37) 0.71 (0.56, 0.90)
Total  475  440 8.67 (8.18, 9.13)
PFS from End of treatment
DOX 75  223  209 3.38 (2.73, 4.07) 1.00 0.036 (df=3)
DOX 50-IFO 5  80  74 4.47 (3.06, 5.88) 0.86 (0.66, 1.12)
DOX 75-IFO 5  63  59 4.73 (3.12, 6.97) 0.75 (0.56, 1.00)
DOX 75-IFO 10  109  98 4.99 (4.37, 6.67) 0.73 (0.57, 0.92)
Total  475  440 4.24 (3.71, 4.80)
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Leiomyosarcoma 66 64 3.19 (2.60, 4.73)
Synovial sarcoma 37 35 2.89 (1.94, 4.07)
Other 119 110 3.71 (2.27, 5.09)
DOX 50-IFO 5
Leiomyosarcoma 25 23 3.29 (2.04, 5.88)
Synovial sarcoma 8 8 4.09 (0.03, 14.23)
Other  42  38 7.43 (3.48, 9.63)
DOX 75-IFO 5
Leiomyosarcoma 13 12 3.68 (2.37, 6.51)
Synovial sarcoma 7 6 3.19 (0.92, 14.78)
Other 40 38 5.80 (3.09, 10.09)
DOX 75-IFO 10
Leiomyosarcoma 24 22 4.90 (2.92, 8.51)
Synovial sarcoma 19 19 4.24 (2.96, 8.28)
Other 65 56 5.13 (4.37, 7.43)














DOX 75  223  148 18.96 (17.08, 22.34) 1.00 0.340 (df=3)
DOX 50-IFO 5  80  63 20.11 (15.67, 24.61) 1.08 (0.81, 1.46)
DOX 75-IFO 5  63  56 19.19 (15.01, 24.87) 1.15 (0.84, 1.56)
DOX 75-IFO 10  109  83 23.59 (19.32, 28.19) 0.86 (0.66, 1.12)
Total  475  350 20.14 (18.30, 22.34)
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OS from End of treatment
DOX 75  223  148 14.59 (12.55, 17.81) 1.00 0.356 (df=3)
DOX 50-IFO 5  80  63 14.52 (11.53, 20.30) 1.09 (0.81, 1.47)
DOX 75-IFO 5  63  56 15.05 (10.58, 20.47) 1.15 (0.85, 1.57)
DOX 75-IFO 10  109  83 18.89 (14.95, 23.79) 0.87 (0.66, 1.14)
Total  475  350 15.74 (14.00, 17.81)
Supplementary table 11 Overall survival from End of treatment by histology for patients 










Leiomyosarcoma  66  38 17.31 (12.55, 28.88)
Synovial sarcoma  37  30 14.23 (9.30, 18.43)
Other  119  80 14.00 (11.63, 18.27)
DOX 50-IFO 5
Leiomyosarcoma  25  22 13.08 (8.64, 23.59)
Synovial sarcoma  8  7 12.52 (7.56, 16.95)
Other  42  29 20.76 (13.70, 30.62)
DOX 75-IFO 5
Leiomyosarcoma  13  12 15.05 (11.33, 27.10)
Synovial sarcoma  7  6 13.37 (2.50, 26.71)
Other  40  35 15.31 (7.06, 21.85)
DOX 75-IFO 10
Leiomyosarcoma  24  20 17.35 (9.99, 26.71)
Liposarcoma  19  17 18.89 (8.15, 25.10)
Other  65  46 18.04 (11.37, 27.17)
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Supplementary table 12 Progression free survival of patients treated with less than 6 










DOX 75  233  222 2.76 (2.27, 3.09)
DOX 50-IFO 5  169  155 3.88 (3.32, 4.90)
DOX 75-IFO 5  111  107 6.93 (5.85, 8.11)
DOX 75-IFO 10  71  65 5.09 (3.84, 7.29)
Total  584  549 3.81 (3.45, 4.30)
Supplementary table 13 PFS from End of treatment by histology for patients treated with 










Leiomyosarcoma  53  52 3.12 (1.71, 3.88)
Synovial sarcoma  23  21 2.79 (1.68, 14.92)
Other  147  140 2.56 (2.23, 2.96)
DOX 50-IFO 5
Leiomyosarcoma  58  55 3.48 (2.79, 4.90)
Synovial sarcoma  23  23 4.57 (3.09, 9.07)
Other  78  70 3.75 (2.76, 5.19)
DOX 75-IFO 5
Leiomyosarcoma  43  43 7.13 (3.84, 8.51)
Synovial sarcoma  7  7 8.57 (6.14, 12.75)
Other  54  50 6.21 (5.16, 9.07)
DOX 75-IFO 10
Leiomyosarcoma  26  26 5.06 (2.66, 7.23)
Synovial sarcoma  6  6 9.53 (2.79, 37.49)
Other  38  32 4.63 (3.22, 8.18)
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Supplementary table 14 Overall survival of patients treated with less than 6 cycles AND 










DOX 75  233  194 8.15 (7.29, 9.76)
DOX 50-IFO 5  169  136 10.02 (8.21, 12.06)
DOX 75-IFO 5  111  103 12.12 (9.92, 13.93)
DOX 75-IFO 10  71  55 11.70 (9.95, 14.78)
Total  584  488 10.02 (9.07, 10.81)
Supplementary table 15 Overall survival from End of treatment by histology for patients 










Leiomyosarcoma  53  47 5.85 (3.38, 9.43)
Synovial sarcoma  23  13 17.05 (10.55, 32.10)
Other  147  125 5.26 (4.04, 6.80)
DOX 50-IFO 5
Leiomyosarcoma  58  50 6.31 (4.47, 8.77)
Synovial sarcoma  23  19 9.00 (4.73, 21.65)
Other  78  61 6.60 (4.76, 10.28)
DOX 75-IFO 5
Leiomyosarcoma  43  41 8.31 (5.98, 11.70)
Synovial sarcoma  7  7 11.89 (7.92, 19.12)
Other  54  48 9.99 (5.03, 13.90)
DOX 75-IFO 10
Leiomyosarcoma  26  24 9.48 (7.56, 12.98)
Liposarcoma  6  4 15.28 (6.31, N)
Other  38  26 8.61 (5.68, 17.02)
7
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Supplementary figure 1 Definition of end of treatment
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A remarkable response to 
pazopanib, despite recurrent liver 
toxicity, in a patient with a high 
grade endometrial stromal sarcoma, 
a case report
BMC Cancer. 2018 Jan 22;18(1):92.
A.J. Verschoor, F.A.R.M. Warmerdam, T. Bosse, J.V.M.G. Bovée, H. Gelderblom





Pazopanib is an oral tyrosine kinase inhibitor registered for metastatic renal cell 
carcinoma and soft tissue sarcoma. Liver toxicity is a common side effect for this class 
of agents. The current opinion is that in case of severe liver toxicity pazopanib should 
be interrupted and restarted at a lower dose after returning to Common Terminology 
Criteria for Adverse Events (CTCAE) grade 1. After recurrence of liver toxicity at the 
lower dose it is advised to permanently stop pazopanib. We describe a patient with an 
YWHAE-FAM22 translocated endometrial stromal sarcoma with a remarkable response 
to pazopanib despite recurrent liver toxicity.
Case
A 40-year-old woman was diagnosed with metastatic YWHAE-FAM22 translocated 
endometrial stromal sarcoma. She was treated successively with doxorubicin, megestrol 
acetate and anastrozole, before pazopanib was initiated. Several dose interruptions and 
reductions were necessary due to liver toxicity, but nevertheless she had a good partial 
response. Seven months after the start, pazopanib was permanently stopped because 
of a bilateral pneumothorax. Nine months later it was reinitiated because of progression 
and was continued for another 8 months until final disease progression.
Conclusion
In contrast to the current summary of product characteristics of pazopanib, the drug 
was successfully continued despite recurrent liver toxicity, and no further liver function 
deterioration was found. This case suggests that further dose reductions are good 
practice when liver toxicity limits treatment in responding patients.
Secondly, this patient with rare YWHAE-FAM22 translocated endometrial stromal 
sarcoma showed a remarkable response to VEGFR/KIT inhibitor pazopanib. Recently, it 
was reported that this specific subtype of endometrial stromal sarcoma overexpresses 
CD117, but has no KIT mutations.
This case illustrates that (a) pazopanib can be continued in patients with recurrent liver 
toxicity after dose reductions under strict surveillance and that (b) pazopanib shows 
good efficacy in YWHAE-FAM22 translocated endometrial stromal sarcoma.
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Background
The oral anti-angiogenic tyrosine kinase inhibitor (TKI) pazopanib is a multi-target TKI.1 
Its main activity is against vascular endothelial growth factor receptors (VEGFR) 1, 2 and 
3, platelet derived growth factor receptors (PDGFR) and KIT.1 The phase III PALETTE study 
showed an increase in the progression free survival (PFS) from 1.6 months with placebo 
to 4.6 months with pazopanib (Votrient®, GlaxoSmithKline) in patients with metastatic 
soft tissue sarcoma.2,3 Pazopanib is also effective in renal-cell carcinoma (RCC), with 
an increase in PFS from 4.2 months with placebo to 9.2 months with pazopanib.4 Overall 
survival (OS) was also significantly increased with pazopanib despite cross-over from 
placebo treatment to pazopanib treatment.5
Liver toxicity is a well-known side effect of pazopanib, with an incidence in the PALETTE 
study of a grade > 2 elevated alanine aminotransferase (ALAT) of 10% (placebo 3%) and 
aspartate aminotransferase (ASAT) of 8% (placebo 2%).2 An increase in total bilirubin 
was not seen in this study. In the RCC study, a National Cancer Institute (NCI) Common 
Terminology Criteria for Adverse Events (CTCAE) grade >3 increase in ALAT was found in 
12% (placebo 1%), ASAT 7% (<1%) and total bilirubin 3% (1%).4 Two patients in this RCC study 
were assessed as having died due to abnormal hepatic function. The current opinion 
is that physicians should be careful prescribing pazopanib in patients with abnormal 
ASAT, ALAT and total bilirubin levels and that treatment should be discontinued at 
least temporarily when grade 3 or more elevations occur during treatment. In case of 
recurrence of liver function abnormalities after restarting treatment pazopanib should 
be stopped permanently.6
Endometrial stromal neoplasms of the uterus are divided into four categories based 
on the 2014 WHO classification, i.e. endometrial stromal nodule, low-grade endometrial 
stromal sarcoma (ESS), high grade ESS and undifferentiated uterine sarcoma.7,8 ESS 
is very rare, representing 0.2% of all genital tract malignancies and the patients are 
generally younger than in other uterine malignancies. Low grade ESS is usually CD10 
positive and Cyclin D1 negative.9 Fifty to sixty percent of the ESS harbour translocations 
involving JAZF1. Recently, it was found that high grade ESS (negative for CD10, positive 
for Cyclin D1) are characterised by a t(10;17)(q22;p13) translocation resulting in a 
YWHAE-FAM22 (also known as YWHAE-NUTM2A/B) gene fusion.10,11 It is suggested that 
these tumours have a poor response to therapy compared to the lower grade ESS, 
which has a 5 year disease specific survival rate for FIGO stage III-IV of 50.3%.12 Current 
treatment for metastatic or locally advanced disease consists of hormonal therapy and 
chemotherapy, i.e. doxorubicin or ifosfamide monotherapy or gemcitabine/docetaxel 
combination therapy.9 Pazopanib is also registered for this soft tissue sarcoma subtype, 
but specific studies are not available and will not be run because of the rarity of this 
histologic subtype.
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This case report describes a patient successfully treated with pazopanib for an ESS 
developing abnormal liver chemistry, which continued treatment with adapted dosing 
of pazopanib under careful surveillance of liver function. She had a remarkable response 
on pazopanib.
Case
A 40-year-old female presented with a 4 months history of recurrent right sided lower 
thoracic pain during sports. Medical history consisted of a hysterectomy for symptomatic 
uterine myomatosis four years previously, after giving birth to her second child. This was 
a non-radical non-oncological resection. The original pathology report revealed a 15 
cm low grade ESS. Now, four years after the hysterectomy, a CT scan showed a large 
mediastinal mass with expansion in the upper abdomen and compression of the left 
atrium and multiple lesions in both lungs. A bronchoscopic biopsy showed cells similar 
to the earlier diagnosed ESS. Treatment with six courses of doxorubicin resulted in a 
very good partial response. Maintenance therapy with megestrol acetate 160 mg was 
started hoping to prolong the time to progression. Two years later, an increase in size and 
number of the lung metastases was observed, so megestrol acetate was stopped and 
anastrozole 1 mg started. Further disease progression was noticed 4 months later (figure 
1A). Pazopanib 800 mg orally once daily was started in the named patient program 
in collaboration with the Leiden University Medical Centre, one of the Dutch sarcoma 
reference centres. At the same time, pathology review was performed, confirming the 
diagnosis of low grade ESS, but also noticing a CyclinD1 positive and CD10 negative 
higher grade component suggesting a YWHAE-FAM22 translocated ESS. (Figure 2 A-D) 
Fluorescent in situ hybridisation confirmed the diagnosis. The tumour showed high 
expression of KIT in the high-grade component of the tumour.
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Figure 1 CT scans
Evaluation CT scans before start of pazopanib (A) and 12 weeks after start of pazopanib (so 6 
weeks on pazopanib and 6 weeks off because of liver toxicity) (B) showing a shrinking pulmonary 
metastasis measured by largest diameter at both times.
8




A: Normal HE slides of the lower grade component of ESS, showing spindled cells in a storiform 
pattern. B: HE slides of the high-grade component of ESS, showing round cells and open nuclei. C: 
Cyclin D1 expression of the lower grade component is weak and more heterogeneous. D: Diffuse 
and strong Cyclin D1 expression in the high-grade areas.
Six weeks after start of pazopanib 800 mg once daily an increase in ALAT to >10 times the 
upper limit of normal (ULN) was observed. (Figure 3) Hepatitis serology, liver ultrasound 
and liver biopsy were not performed because of the clear relationship of the increased 
liver enzymes with the start of pazopanib. She had no history of liver disease, no liver 
metastases and no liver function abnormalities before start of pazopanib. During the 
previous treatment with doxorubicin, y-glutamyl transferase increased to 20x ULN and 
ALAT to 6x ULN, no other liver function abnormalities occurred. The CT scan showed a 
decrease in the sum of the largest diameters of the target lesions of 23%. Pazopanib 
was put on hold immediately until the liver enzymes returned to normal. (Figure 3)
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Figure 3 Course of pazopanib dose and laboratory parameters in time
ULN: upper limit of normal
After six weeks without pazopanib the CT scan showed a further decrease of the target 
lesions of 38% compared to baseline (19% compared to the previous CT scan) indicating 
a partial response. (Figure 1B) At the time the liver toxicity had almost recovered, a 
re-challenge with pazopanib 200 mg once daily was performed, but after one-week 
liver function abnormalities recurred and pazopanib was stopped again. After liver 
function recoverage, pazopanib 200 mg once every other day was initiated, but again 
after 2 weeks liver enzymes increased to >3x ULN. Another week later pazopanib 200mg 
every third day was given for 2 weeks, until a CT scan showed progression (six months 
after the start of pazopanib). She was still in very good clinical condition and besides 
the remarkable inclination of liver enzymes at the beginning of treatment and lesser 
rises thereafter she had had little other toxicity with pazopanib. She consented to 
another challenge with pazopanib 200 mg every day under further strict surveillance 
of liver enzymes. The liver enzymes remained < 3 times ULN, but 3 weeks later she was 
admitted with a bilateral pneumothorax and pazopanib was stopped. On the right 
side a pleurodesis was performed and on the left side it was drained. Anastrozole and 
leuprorelin were prescribed, hoping to slow down progression. Two months later, a CT 
scan again showed progressive disease, and ifosfamide chemotherapy (5 gram/m2 in 
a 24-hour continuous infusion every 3 weeks) was initiated. CT scans after 3 and 6 cycles 
showed stable disease. During ifosfamide treatment only a slight increase in y-glutamyl 
transferase was noticed (increase to <2x ULN). Two months after the last ifosfamide 
administration, radiological progression was observed again and pazopanib 400 mg 
daily was prescribed again under strict weekly surveillance of the liver enzymes. This 
dose was chosen because patient had a pleural effusion due to the progression and 
8
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thereby a lot of complaints. To be sure of a therapeutic dose of pazopanib we started 
with 400mg daily. Two weeks after reinitiating pazopanib the pneumothorax on the left 
side recurred and persisted. Pazopanib was held for two weeks, but was then reinitiated 
after discussion of the risks with the patient. CT scans 6 weeks and 3.5 months after the 
restart of pazopanib showed stable disease. Pazopanib was stopped permanently 6 
months after the restart because of progressive disease, and she died 2 weeks later. 
In the second period of pazopanib treatment, no liver toxicity occurred. No differences 
between co-medication were found between the first period of pazopanib treatment 
and the second. A summary of the patients’ history is given in figure 4.
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The DNA of the patient was analyzed for single nucleotide polymorphisms (SNPs) 
in enzymes known to be involved in the absorption, distribution, metabolism and 
elimination of pazopanib.13 The genes analyzed were CYP3A4, CYP1A2, CYP2C8, ABCB1 
and SLCO1B1. The main metabolizing enzyme for pazopanib, CYP3A4 did not have SNPs 
associated with a decreased metabolic function. Two SNP variants in CYP1A2 (rs762551 
and rs2470890) and one in SLCO1B1 (rs4149057) were detected, but no evidence exists 
that these polymorphisms cause elevated levels of pazopanib. So, this analysis did not 
result in the elucidation of a cause for the liver toxicity in this patient.
Discussion and Conclusion
This case report has 2 new learning messages: we present a patient with an ESS with a 
remarkable response on pazopanib and we describe clinical management of pazopanib 
induced recurrent liver toxicity.
Liver function test abnormalities, mainly elevations in ASAT and ALAT, are a common side 
effect of pazopanib and more in general of TKIs.14 The exact pathophysiologic mechanism 
is unknown. A distinctive class effect seems to be unlikely, because pharmacologically 
different TKIs are known to be hepatotoxic and the substances are also very different 
chemical compounds. In a case series of two patients with liver toxicity of pazopanib liver 
histology showed mild active cholestatic hepatitis with inflammation that predominantly 
involved portal tracts.15 Recently, it was reported that treatment with pazopanib in 
combination with prednisolone in case of liver function abnormalities prevented 
recurrence of liver function abnormalities in two patients.16 UDP-glucuronosyltransferase 
isoform 1A1 has been related to bilirubin elevations during pazopanib treatment. These 
are probably patients with latent Gilbert syndrome becoming evident due to the 
inhibitory effect of pazopanib.14 More recently, an association between HLA-B*57:01 and 
pazopanib induced liver toxicity was found.17 Whether other germline genetic causes of 
pazopanib induced liver toxicity exist is unclear. The summary of product characteristics 
(SmPC) of pazopanib contains guidelines on handling liver toxicity.6 If the elevation of 
ASAT and ALAT between 3 and 8x ULN it is safe to continue pazopanib with strict control 
of ASAT and ALAT until grade 1 toxicity. If ASAT and/or ALAT is more than 8x ULN then 
pazopanib should be stopped until recovery till grade I or less and if reinitiated restart 
with pazopanib once daily 400mg. It should be stopped permanently if ASAT and/or 
ALAT rise again to >3x ULN. Pazopanib should also be stopped if ASAT and/or ALAT are 
elevated >3x ULN concurrently with a bilirubin elevated >2x ULN. In our case, despite 
these recommendations, pazopanib was reintroduced at further reduced dose and no 
progressive liver insufficiency developed. Ultimately this strategy seemed to be effective 
until a dose reduction to 200mg once every second day. Another possible solution for 
toxicity management would be therapeutic drug monitoring, which is possible for 
pazopanib with a dried blood spot assay.18 However, because the intrapatient variability 
of pazopanib levels is high, a recent study could not show an effect of therapeutic drug 
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monitoring on the interpatient variation.19 A SNP analysis of genes for enzymes known to 
be involved in the metabolism of pazopanib did not provide an explanation for elevated 
pazopanib levels or liver toxicity in our patient. In case of further dose reductions after 
reduction to once daily 400mg, we suggest that patients should be monitored closely 
with once weekly liver function testing.
The second message of this case report regards the pazopanib response related 
to the tumour type. When feasible ESS is treated with radical surgery. Treatment of 
metastatic or locally progressive ESS consists of endocrine therapy as first line and 
when progressive on endocrine therapy chemotherapy. No specific data on the use 
of pazopanib in ESS is available, but this case report shows that pazopanib induced a 
partial response and prolonged PFS of 9 months which is more than the median PFS in 
the PALETTE study. Although in general ESS does not overexpress KIT, it was recently shown 
that ESS harbouring the YWHAE-FAM22 fusion gene frequently overexpress KIT (without 
a mutation in the KIT oncogene) in the high grade component of the tumour, as was 
the case in our patient.11,20 This could explain the good response, in this rare histologic 
subtype, to pazopanib, which is an inhibitor of VEGFRs, PDGFRs and KIT. Based on these 
findings there may also be a potential role for imatinib, which was already reported in 
two cases.21,22 Most probably the evidence for treatments in ESS will be not better than 
small case series due to the rarity of this disease.
The 3rd teaching point of this case report regarding the occurrence and clinical 
development of a pneumothorax during pazopanib treatment in (responding) patients 
with pleurally located metastatic lesions was addressed in a previous case series. 23
In conclusion this case illustrates two important new points:
- First, reversible severe liver toxicity with pazopanib treatment is a known rare 
side effect of pazopanib and low dose personalized rechallenge in responding patients 
is a therapeutic option in experienced hands. This low dose personalized rechallenge is 
in conflict with the current SmPC of pazopanib and patients should be closely monitored 
for liver function abnormalities with for example weekly testing of the liver functions.
- Second, pazopanib was found to result in a good response in this patient with 
a YWHAE-FAM22A/B translocated ESS which may be related to the KIT overexpression in 
these tumours.
8
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Recently, the phase III PALETTE study introduced pazopanib (Votrient®) as treatment for 
adult patients with locally advanced or metastatic non-liposarcoma soft tissue sarcoma 
after prior treatment with doxorubicin and/or ifosfamide. Pneumothorax was reported as 
adverse event in 8 of 246 treated patients (3.3%) in that study. This case series presents 
the incidence and clinic of this complication in the Leiden University Medical Centre.
Cases
Forty-three patients were treated with pazopanib of which six patients (14.0%) developed 
a pneumothorax. These six patients were treated for malignant peripheral nerve sheath 
tumour, angiosarcoma, synovial sarcoma, fibromyxomatoid sarcoma, pleomorphic 
sarcoma and endometrial stromal sarcoma. All six patients had subpleural pulmonary 
or pleural metastases at the start of pazopanib and the pneumothorax developed 
during or shortly after treatment with pazopanib and was difficult to treat.
Discussion
The incidence reported by us is higher than the incidence in the PALETTE study. Trials 
with pazopanib in renal cell carcinoma, urothelial carcinoma and cervix carcinoma 
did not report pneumothorax as an adverse event, suggesting pneumothorax as a 
specific adverse event in soft tissue sarcoma patients treated with pazopanib. This 
may be related to the fact that there is often pleural metastatic involvement and cystic 
degeneration due to pazopanib treatment may add to the risk.
Conclusion
The risk of an, often difficult to treat, pneumothorax during pazopanib therapy should be 
discussed with the patient before initiation of treatment for a pulmonary metastasized 
sarcoma and physicians should be alert to the occurrence of such an event.
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Background
Soft tissue sarcomas (STS) are rare mesenchymal tumours originating from visceral and 
connective tissue. This group of tumours accounts for approximately one percent of all 
malignancies and consists of more than 50 histological subtypes.1 The only curative 
treatment is surgical resection with large margins with or without adjuvant radiotherapy.1 
Treatment for locally advanced and metastatic disease is usually palliative and was 
until recently mostly confined to anthracycline or ifosfamide based chemotherapy, 
apart from specific chemotherapy regimens used for specific subgroups.1 Reported 
response rates vary between 16-27% and median survival is reported to be 12 months.2 
Trabectedin was introduced recently for STS, mainly for patients with (myxoid) lipo- and 
leiomyosarcomas.3,4
More recently, the phase III PALETTE study5 introduced pazopanib (Votrient®) as treatment 
for adult patients with non-lipomatous advanced STS who have received prior 
chemotherapy for metastatic disease or who have progressed within 12 months after 
(neo)adjuvant therapy. This was based on a progression free survival of 4.6 months for 
pazopanib versus 1.6 months in the placebo arm. Pazopanib is an oral anti-angiogenic 
multi-targeted tyrosine kinase inhibitor with activity against vascular endothelial growth 
factor receptors (VEGFR) 1, 2 and 3, platelet derived growth factor receptors and KIT. In 
the PALETTE study, treatment with pazopanib was complicated by the occurrence of a 
pneumothorax in 8 of the 246 patients. This case series reports on the incidence and 
clinic of this complication in all consecutive patients treated at the Leiden University 
Medical Centre.
Cases
In our institution, 43 STS patients were treated with pazopanib, of which 39 had pulmonary 
metastases and 36 of these patients had pleural or subpleural pulmonary metastases. 
Treatment was complicated by a pneumothorax in six (14.0%) patients.
The first patient is a 24-year old male, with a malignant peripheral nerve sheath tumour 
of the left brachial plexus, diagnosed three years before. Initial treatment consisted of 
local resection and irradiation, repeated one year later because of local recurrence. 
Pulmonary metastases, some localised pleural, were found seven months later for which 
six cycles of 3-weekly doxorubicin 75 mg/m2 was initiated. Progressive disease was 
diagnosed six months after the first doxorubicin cycle and treatment with pazopanib 
was started. A CT scan at the start of pazopanib showed a necrotizing metastasis in 
the left lung (Figure 1A, B). A month later a left-sided pneumothorax occurred after a 
skiing trip at 3000 meters height, persisting after drainage and later also a right sided 
pneumothorax occurred. The CT scan detecting the pneumothorax on the left side, also 
showed cystic degeneration of metastases in the right lower lobe (Figure 1 C, D). The 
9
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persistent bilateral pneumothorax was complicated by a pyothorax on the left side. He 
died six months after the start of pazopanib, which was continued until his death.
Figure 1 CT scans of patient 1. A and B: CT scan of the thorax at start of pazopanib, 
showing a pleural metastasis of the left lung with central hypodensities suggesting 
necrosis (A, arrow) and showing a pulmonary metastasis in the right lung (B, arrow). 
C and B: CT scan, when presenting with a left-sided pneumothorax (D), showing pro-
gressive hypodensity of the pleural metastasis on the left side (C, arrow) and central 
cavitation in the metastasis in the right lung (D, arrow).
Patient 2 is a 79-year old male, who was diagnosed two years before with an 
angiosarcoma of the scalp. Primary treatment was combined paclitaxel and 
radiotherapy. However, one year later a local recurrence was diagnosed and a CT 
scan showed pulmonary metastases, of which some were pleural, for which 3-weekly 
doxorubicin 75 mg/m2 was started. The local recurrence was progressive after six 
months and pazopanib was initiated, which was stopped three months thereafter 
because of progressive disease. Some of the pulmonary metastases already showing 
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cavitation at start of pazopanib (Figure 2A) were increasing in number, size and 
cavitation during treatment (Figure 2B, C). One week after the start of pazopanib a 
right sided pneumothorax occurred (Figure 2D), which was treated with drainage, but 
without pleurodesis, however it recurred one week later and again drained. A month 
thereafter a left-sided pneumothorax was diagnosed, which was left untreated. He died 
one week later due to disease progression, four months after the start of pazopanib.
Figure 2 CT scans and X-thorax of patient 2. A: CT scan at start of pazopanib show-
ing metastases in both lungs with a large necrotizing metastasis on the left side. The 
pleural metastasis indicated by the arrow is also visible in B, which is a CT scan after 
3 months of pazopanib treatment, now showing cavitations. C is also an image from 
the CT scan after 3 months of pazopanib treatment showing a metastasis (arrow) 
with cavitation next to the pleura. D: The X-thorax shows the right sided pneumotho-
rax. The visceral pleural line is indicated by the arrow.
The third patient is a 34-year old male, three years before diagnosed with a synovial 
sarcoma of the left femur with synchronous lung metastases, some with a pleural 
9
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localisation, and malignant pleural effusion. Treatment consisted of resection of the 
primary tumour and doxorubicin/ifosfamide chemotherapy followed by pulmonary 
metastasectomy and isolated melphalan lung perfusion. Treatment with trabectedin 
was started, but stopped after nine cycles because of progressive disease and 
pazopanib was started. He was treated for a remarkable 15 months when progression 
occurred and a hydropneumothorax was diagnosed on a routine follow-up CT scan 
(Figure 3A, B), treated with drainage and talc pleurodesis. Pazopanib was stopped. 
The CT scan did not show necrotizing metastases. Two weeks later the pleural effusion 
recurred and persisted until he died 2 months later.
Figure 3 CT scans of patient 3. Routine follow-up CT scan showing the pneumothorax 
on the right side. A shows one of the pulmonary metastasis, B shows a pleural metas-
tasis.
The fourth patient is a 53-year old female, who had resection of a low-grade 
fibromyxomatoid sarcoma of the left lower extremity 13 years before. Nine years later, 
pulmonary, liver and lymph node metastases were diagnosed, treated with 2 cycles of 
liposomal doxorubicin, which was stopped because of toxicity. Some of the pulmonary 
metastases were localised adjacent to the pleura. Treatment was continued with low 
dose doxorubicin weekly for 3 months, which was repeated one year later because of 
progressive disease. Three months after the last doxorubicin treatment progressive 
disease was diagnosed and pazopanib was prescribed. After seven months treatment 
with pazopanib she developed a left-sided pneumothorax (Figure 4), successfully 
treated with drainage. No cavitation of the metastases was found. At the moment, 
treated for 31 months with pazopanib, she has stable disease.
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Figure 4 CT scan of patient 4. The CT scan shows the massive pulmonary metastases 
and a left-sided pneumothorax.
Patient five is a 72-year old female, who presented with a high grade undifferentiated 
pleomorphic sarcoma of the right lower extremity with pulmonary metastases, of 
which some are localised next to the pleura, one year before. She was treated with 
local resection, radiotherapy and 3-weekly doxorubicin 75 mg/m2. Five months after the 
start of doxorubicin progressive disease was diagnosed and pazopanib was prescribed 
(Figure 5A). After two months of treatment she developed a left-sided pneumothorax, 
treated with drainage and pleural rubbing (Figure 5B). Part of the pulmonary metastases 
showed cavitation. During admission a right-sided pneumothorax occurred and was 
drained successfully. However, she died one week later due to progressive disease.
9
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Figure 5 CT scans of patient 5. A: CT scan before the start of pazopanib showing mul-
tiple metastases in the right lung, one is indicated by the arrow. B: Routine follow-up 
CT scan during pazopanib treatment showing the left-sided pneumothorax and the 
earlier mentioned metastasis in the right lung is now showing cavitation.
The sixth patient is a 40-year old female diagnosed with a low grade endometrial 
stromal sarcoma, six years before, after a uterus extirpation for uterine myomatosis. 
When she presented four years later with thoracic pain, CT scan of the thorax showed a 
large mediastinal mass and pulmonary metastases, also localised next to the pleural 
space. Treatment with doxorubicin was started and resulted in partial regression of the 
tumour masses. Eighteen months later pazopanib was started under the supervision 
of the reference centre because of progression of the pulmonary metastases. Due to 
liver toxicity the pazopanib dose was tapered to a minimum dose of 200 mg with short 
pauses in treatment, however treatment was successful (Figure 6A, B). Treatment was 
permanently stopped after 33 months because of a bilateral pneumothorax and disease 
progression (Figure 6C). She was successfully treated with drainage.
Figure 6 CT scan of patient 6. A: CT scan at start of pazopanib showing a metasta-
sis in the right lower lobe with a diameter of 49.6 mm. B: CT scan after 12 weeks of 
pazopanib (6 weeks of treatment and 6 weeks on hold due to liver toxicity), showing a 
decrease in diameter of the metastasis to 33.1 mm. C: CT scan showing the bilateral 
pneumothorax.
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Discussion
The incidence of pneumothorax of 14.0% in our institution was higher than the previous 
reported incidence (3.3%) in the PALETTE trial.5 Literature does not provide the incidence 
of secondary spontaneous pneumothorax in STS patients, but it is probably uncommon. 
Other trials with pazopanib in for example urothelial cancer, renal cell cancer, pancreatic 
neuroendocrine tumours and cervical cancer did not report pneumothorax as an 
adverse event.6-11 Trials with sunitinib, another VEGFR inhibitor, in renal cell carcinoma 
also do not report pneumothorax as an adverse event.12,13 Only, two cases are published 
in literature of patients with a spontaneous pneumothorax during sunitinib treatment for 
renal cell carcinoma.14,15 This suggests that this is a specific adverse event in metastatic 
STS treated with pazopanib, however, it could still be due to underreporting in other 
studies or due to the natural course of this disease that predominantly metastasizes 
to the lungs.
One of the proposed mechanisms is necrosis of a metastasis due to therapy, resulting 
in a pleural defect. Another possible explanation would be a check valve mechanism 
due to compression of bronchioles by a lung metastasis causing hyperinflation of a lung 
segment and rupture of lung parenchyma.16 In our patients all cases of pneumothorax 
were related to pleural or subpleural lung metastases, and were observed in both 
progressive and responding patients. Smoking is a risk factor for primary spontaneous 
pneumothorax, but only one of our six patients had a smoking history. We do not think 
smoking history is relevant for the occurrence of a pneumothorax in these patients. 
As with other cancer related pneumothoraxes they were difficult to treat. One of the 
explanations for the difficult treatment in these patients could be the use of pazopanib, 
which inhibits angiogenesis and thereby tissue regeneration.
A larger series is needed in a case control setting to gain more understanding of this 
phenomenon.
Conclusion
The risk of a difficult to treat pneumothorax during pazopanib therapy should be 
discussed with the patient before initiation of treatment for a pulmonary metastasized 
sarcoma and physicians should be alert to the occurrence of such an event.
Consent
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pazopanib compassionate use program for use of their medical data for scientific 
purposes. A copy of the written informed consent is available for review by the Editor-
in-Chief of this journal.
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Giant cell tumours of bone (GCT-B) are rare, locally aggressive tumours characterized 
by an abundance of giant cells. Incidence studies for GCT-B are rare. This is the first 
study using a fully automated 100% covering pathology database, the nationwide 
Dutch Pathology Registry (17 million inhabitants), PALGA, to calculate incidence rates 
for GCT-B.
Patients and methods
From PALGA, all pathology excerpts were retrieved for patients diagnosed with GCT-B, 
giant cell tumours of tenosynovium and giant cell tumours of soft tissue between 
January 1, 2009 and December 31, 2013. The incidence of GCT-B was calculated.
Results
In total, 8156 excerpts of 5922 patients were retrieved; these included 138 first GCT-B 
diagnosis. For GCT-B the incidence was 1.7 per million inhabitants per year with a male 
to female ratio of 1:1.38 and a median age of 35 years (9-77). Most common localization 
was the femur (35%), followed by the tibia (18%). No differences in localization according 
to age and sex were found. Incidence rate of local recurrence was 0.40 per million 
inhabitants per year.
Interpretation
This is the first nationwide study reporting the incidence of GCT-B, based on a nationwide 
pathology database with 100% coverage of pathology departments. Current incidence 
calculations are based only on doctor-driven registries. We confirmed that GCT-B is 
a rare disease with an incidence that is slightly higher than previously published. The 
relatively young median age of patients and the high incidence of recurrence stresses 
the importance to develop more effective treatments for this disease.
Binnenwerk_Productie.indd   204 2/10/2021   8:04:56 PM
205
Incidence of GCT-B in the Netherlands
Introduction
Giant Cell Tumour of Bone (GCT-B) is a locally aggressive neoplasm composed of sheets 
of mononuclear cells admixed with uniformly distributed large osteoclast-like giant 
cells, primarily affecting the metaphysis of long bones.1 These cells express receptor of 
nuclear factor kappa-B ligand (RANKL).2,3 GCT-B are rare; however, the incidence is not 
exactly known and is for example not stated in the World Health Organization (WHO) 
classification of Tumours of Soft Tissue and Bone.1 The incidence was recently estimated 
at between 1.03 and 1.33 per million per year based on cancer registries in Australia, 
Japan and Sweden (Table 1).4,5 Median age of onset ranges between 20 and 40 years 
with an equal distribution between the sexes or a slight female predominance.1,5
Patients with GCT-B typically present with pain, swelling and often decreased 
joint movement. In 5-30% of patients a pathologic fracture is noted.1,6 Although this 
tumour rarely metastasizes, it is known to be locally aggressive, which may result in 
joint destruction and, uncommonly, neurological deficit in axial tumours. 1 Treatment 
options are curettage, curettage with an adjuvant treatment or resection with joint 
replacement.7 In GCT-B the local recurrence rate is 6-42%.6,8 Recently, denosumab, a 
human IgG2 monoclonal antibody against RANKL, was registered for use in GCT-B and 
showed tumour response in 2 phase II studies.9,10
Table 1 Review of all available incidence data on GCT-B














Doctor-driven 1.03-1.33 20-40 (na) na
Amelio, 
2016*








1.66 35 (9-77) 42%
na: not available. The study by Liede does not report an exact median age, but only a median age 
group.
*These studies probably also included patients with a giant cell tumour of the small bones of hands 
or feet and patients with central giant cell granulomas of the jaw.
According to our knowledge, current literature in GCT-B contains incidence calculations 
based solely on cancer registry studies. These studies are doctor-driven with a risk of 
underreporting (Table 1).4,5 In this study we use the non-profit nationwide network and 
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registry of histo- and cytopathology in the Netherlands, PALGA. This fully automated 
nationwide database contains all pathology reports in the Netherlands (17 million 
inhabitants).11 In an effort not to miss GCT-B cases, our search included the following 
giant cell containing tumours: GCT-B, tenosynovial giant cell tumours and giant cell 
tumours of soft tissue.
We calculated the incidence, demographics and localizations of GCT-B in a nationwide 
pathology database study between January 1, 2009 and December 31, 2013.
Methods
Patients
PALGA covers all pathology reports of all pathology laboratories in the Netherlands 
since 1993.11 Patient registration in PALGA is based on social service number and thereby 
multiple reports of one patient will be grouped and not lead to double registration of one 
patient. Excerpts matching our search criteria were retrieved from PALGA: encoded either 
as giant cell tumour of bone (PALGA code m9250*) or giant cell tumour of tenosynovium 
(m9252*) or pigmented villonodular synovitis (m9252*) or giant cell tumour of soft tissue 
(m9251*) and terms separately used as free text between January 1, 2009 and December 
31, 2013.11 In our search, giant cell tumours of soft tissue and tenosynovium were included, 
to be as comprehensive as possible. Additionally, for all these patients historical excerpts 
were retrieved matching our search criteria. When date of first diagnosis met our 5-year 
timeframe, the patient was included for incidence calculations. Patients with a giant 
cell tumour of the small bones of the hands or feet were excluded, since these are 
considered a separate entity according to the current WHO classification of tumours of 
soft tissue and bone.12 Patients with a GCT-B affecting the mandible were also excluded, 
because these are probably central giant cell granulomas of the jaw.13
Based on the combination of the historical and current excerpts we could calculate the 
incidence of first local recurrences during the 5-year study period. It is essential to note 
that this is not the same as the incidence of recurrences for the patients diagnosed 
during these 5 years of study. To calculate the latter, a longer interval between the study 
period and the moment of reporting would be necessary.
Excerpts contained an encrypted patient identification number (allowing to identify 
multiple excerpts of one patient), data on age and sex, date of arrival of the histological 
tissue, and the conclusion of the pathology report. AJV extracted the data and uncertain 
pathology conclusions in the reports were discussed with HG and JVMGB.
Disaggregated incidence rate calculations for localized and diffuse-type are necessary 
in giant cell tumours of tenosynovium. The PALGA database lacks information on tumour-
type (i.e., whether a giant cell tumour of tenosynovium is a localized type or a diffuse 
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type as this is a combined diagnosis of radiological and pathological examinations), 
therefore additional chart review in giant cell tumours of tenosynovium was performed 
and published elsewhere.14
Data collection
Anonymized data were collected on age, sex, year of diagnosis, localization, GCT type, 
date of local recurrence.
Statistics
For statistical analysis, the Statistical Package for Social Sciences (SPSS) version 
23.0.0 (IBM Corp, Armonk, NY, USA) was used. Incidence of GCT-Bs was calculated 
per million inhabitants per year and standardized for 5 year age groups and sex for 
the Dutch population in 2012, as published by the Central Bureau of Statistics (CBS).15 
Incidence standardized to the WHO standard population for 5-year age groups was 
also calculated.16
We estimated first recurrences, defined as biopsied lesions or surgically treated 
recurrences, as the registry only contained reports for histological specimens. Both 
95% confidence intervals (CI) for incidence rates (Mid-P exact) and frequencies (Wilson 
score) were calculated using www.openepi.com.
Ethics, source of funding and potential conflicts of interest
As pathology excerpts were fully anonymized, no ethics approval was necessary for this 
study. This work was supported by Daiichi-Sankyo with an unconditional financial grant. 
There are no potential conflicts of interest.
Results
Search results
From PALGA, 8156 excerpts of 5922 patients were retrieved matching the search criteria 
(Figure 1). Of these 5922 patients, 5756 patients were excluded. 151 new cases of GCT-B 
were identified; however, 13 of these new cases were actually not GCT-B, but either giant 
cell tumours of the small bones of hands or feet or central giant cell granulomas of the 
jaw. 15 patients were only diagnosed with a first recurrence during the study period and 
had a primary tumour before the study period.
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Binnenwerk_Productie.indd   207 2/10/2021   8:04:56 PM
208
Chapter 10
Figure 1 Diagram showing in- and exclusion of all patients with GCT in the Netherlands 
between 2009 and 2013
This resulted in 138 cases with a crude incidence ranging from 1.3 to 2.1 per million 
inhabitants per year (mean: 1.7; standard deviation (SD) 0.3; CI 1.4-2.0), age and sex 
corrected incidence ranged between 1.3 and 2.1 per million inhabitants per year (mean: 
1.7; SD 0.3; CI 1.4-1.9), and the WHO standardized incidence was 1.4 to 2.3 per million 
inhabitants per year (mean: 1.7; SD 0.3; CI 1.4-2.0. Table 2 and Figure 2). 42% of patients 
were male (CI 34 - 50). The median age of patients was 35 years (9-77). 6% were below 18 
years of age. The age distribution of GCT-B seems to be bimodal with a peak incidence 
between 20 and 39 and between 50 and 59 years (Figure 3). Most affected localization 
was the femur (35%), followed by the tibia (18%) (Table 3).
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Table 2 Overview of incidence rates
Crude incidence







GCT-B total 1.7 (1.4-1.9) 35 (9-77) 42 (34-50)
Long bones 1.3 (1.1 – 1.6) 35 (9-77) 41 (33-51)
Axial 0.35 (0.21 – 0.45) 38 (17-73) 46 (29-65)
Figure 2 Crude incidence rates of GCT-B in the Netherlands with 95% confidence 
interval.
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Figure 3 Age distribution of GCT-B in the Netherlands.
During these 5 years, 33 patients were diagnosed with a first recurrence. Consequently, 
crude incidence of pathology confirmed first recurrences was 0.40 per million inhabitants 
per year (CI 0.28-0.55). Median age of patients with a first recurrence was 32 years (10-
63). Median time between first diagnosis and first recurrence was 23 months (range 2 
– 142). 30% of the recurrences occurred within 1 year, 24% in the second year and 30% in 
the third year after diagnosis. Most common localization of recurrence were the femur 
and tibia (both 30%; Table 4).
Incidence rates for the long bones and the axial skeleton were 1.3 (CI 1.1 – 1.6) and 0.31 (CI 
0.21 – 0.45) per million inhabitants per year, respectively (1 patient could not be allocated 
to one of the groups). WHO standardized incidence rates were 1.40 and 0.31 per million 
per year. Incidence of recurrence were 0.32 (CI 0.21 – 0.47) and 0.07 (CI 0.03 – 0.15) per 
million per year. The median age of patients for the 2 groups was 35 (9-77) and 38 (17-
73) years. Percentage of males was 41% (CI 33-51) and 46% (CI 29-65) respectively.
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Table 3 Frequencies of localizations of GCT-B
Localisation Absolute frequency Percentage (CI)
Femur 48 35 (27–43)
Tibia 25 18 (12–25)
Radius 14 10 (6 – 16)
Fibula 13 9 (6 – 15)
Spine 13 9 (6 – 15)
Ulna 5 4 (2 – 8)
Pelvis 5 4 (2 – 8)
Humerus 2 1 (0 – 5)
Mastoid 2 1 (0 – 5)
Patella 2 1 (0 – 5)
Scapula 2 1 (0 – 5)
Other* 3 2 (1 – 6)
Unknown 4 3 (1 – 7)
Total 138 100
*Other: 4th rib, maxilla and petrous bone
Table 4 Localization of recurrences
Localisation Frequency Percentage (95% CI)
Femur 10 30 (17–47)
Tibia 10 30 (17–47)
Spine 4 12 (5–27)
Radius 3 9 (3–24)
Humerus 2 6 (2–20)
Fibula 1 3 (1–15)
Ulna 1 3 (1–15)
Scapula 1 3 (1–15)
Pelvis 1 3 (1–15)
Total 33 100
10
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The localization of the tumours did not differ according to sex. Only 1 of the patients 
below 18 years of age had an axial localization of his GCT-B. However, this difference 
could be attributed to the low incidence of axial GCT-B.
During the 5-year study period, only 1 malignant GCT-B was reported.
Discussion
This is the first study on GCT-B incidence, based on a fully automated pathology 
database covering 100% of pathology reports in the Netherlands. Our calculated GCT-B 
incidence shows a higher number, compared with previously reported incidence rates 
(Table 1).4,5 In addition, the study by Amelio et al. does not seem to exclude giant cell 
tumours of the small bones of the hands or feet and central giant cell granulomas of 
the jaw, suggesting that the actual incidence of giant cell tumours of bone in this study 
is actually lower.5 However, this is not exactly stated in the paper, but derived from the 
graphs showing localizations. For the study by Liede et al (2014), no data on localization 
were reported. The higher incidence may be explained by the use of the 100% covering 
Dutch nationwide pathology database PALGA. Incidence of GCT-B seems to decrease 
slightly during the 5 years of study; this could be attributed to a normal variation in the 
low absolute count of GCT-B per year. As expected, most GCT-Bs were localized in the 
lower, weight-bearing extremities, as described in previous studies.4,5 Both slight female 
preponderance and age distribution are comparable to these earlier reports.4,5 Age 
distribution seems to be bimodal (between 20 and 39 years and 50 and 59 years of 
age), which is comparable to data described by Liede, et al (2014). However, this variation 
could also be due to the small number.
GCT-Bs generally affect young patients (median age 35 years) and 6% are younger than 
18 years. This is lower compared to the 14% in the Swedish study and the approximately 
8% in Japan (manually calculated, based on published data).4,5 Reporting bias could be 
the cause of the higher percentage of patients < 18 years with a GCT-B in the Swedish 
and Japanese registries, because these are doctor-driven registries.
Although we do not calculate an exact incidence rate of first local recurrences for the 
patients diagnosed between 2009 and 2013 in this study, we calculated an incidence of 
all first recurrences during this time period of 0.40 per million inhabitants per year. This 
results in a rate of recurrence of approximately 24% (although the denominator is not 
exactly known), which is lower compared to the Swedish study (recurrence rate 41%).4,5 
2 retrospective cohort studies reported rates of recurrence between 6 and 42%.6,8 The 
relatively higher recurrence rate in the Swedish study could be attributed to an effect of 
reporting bias (patients with a recurrence will have a higher chance of being registered). 
The differences in recurrence could be caused by different treatment strategies, which 
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cannot be studied in these studies due to a lack of data in our study and the other 
studies.6
Compared with the other studies, the reported incidence of malignant GCT-B (1 patient 
in 5 years, 1 of 138 patients) during these years was much lower than in the study by 
Liede et al. (27/337). We have no explanation for this difference.
In the future, additional nationwide studies are needed to calculate a more accurate 
worldwide incidence, because at the moment only incidence rates for countries in 
North and West Europe are available. Furthermore, the incidence calculations should 
include information on the incidence of GCT-B subdivided into long bones and the axial 
skeleton.
Concluding, this study is the first to report incidence of GCT-B based on a 100% coverage 
nationwide pathology database. These incidence numbers are of value for research 
and healthcare planning.
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The effectiveness of second-line palliative chemotherapy in patients with recurrent/
metastatic osteosarcoma is not well defined. Several small studies (6-19 patients) have 
reported on ifosfamide as second-line treatment. In this study we report our single 
centre experience, with second-line ifosfamide monotherapy in patients treated for 
recurrent/metastatic osteosarcoma.
Methods
Of all osteosarcoma patients treated with ifosfamide from 1978 until 2017 a chart review 
was conducted. Until 1997 a 5 gram/m2 regimen was used and from 1997 onwards 9 
gram/m2 regimen was used. Overall survival (OS) from start of ifosfamide was the 
primary end point. Progression free survival (PFS) from start of treatment was also 
studied. To assess difference in survival between groups the log rank test was applied. 
To investigate the effect of ifosfamide dose and WHO performance status (PS) a Cox 
proportional hazard regression model was estimated.
Results
Sixty-two patients were selected with recurrent/metastatic osteosarcoma treated with 
second-line ifosfamide monotherapy (26 dose of 5 gram/m2 and 36 9 gram/m2). OS was 
significantly better in univariate analysis for 9 gram/m2 compared to 5 gram/m2 (10.9 
(95% confidence interval (95%CI) 9.3–12.6) vs. 6.7 months (95%CI 5.9-7.6) respectively) 
and for PS (median OS PS 0: 13.0 months (95%CI 2.3-23.8), PS 1 8.2 months (95%CI 5.4-11.1) 
PS>2 6.2 months (95%CI 2.2-10.3) and unknown 5.4 months (95%CI 2.2-8.5). In multivariate 
analysis only PS showed a significant difference. No difference in PFS was found between 
5 and 9 gram/m2 ifosfamide treatment or PS.
Conclusion
This study suggests that ifosfamide is an effective second-line treatment for patients 
with recurrent/metastatic osteosarcoma.
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Introduction
Osteosarcoma is the most common primary bone malignancy, but remains a rare 
tumour affecting predominantly adolescents and patients of advanced age. Primary 
treatment of high-grade osteosarcoma in case of local disease or local disease with 
pulmonary metastases is perioperative chemotherapy combined with surgery. The 
3-year event free survival is approximately 60-70%.1-4 Current first line treatment in 
most of the Western world is combination chemotherapy consisting of methotrexate, 
doxorubicin and cisplatin. The EURAMOS study tried to improve cure rate in patients with 
a poor pathological response to the first cycles of chemotherapy by the addition of 
ifosfamide and etoposide to the perioperative regimen of methotrexate, doxorubicin and 
cisplatin, but this study failed to reach its primary endpoint.5 At present, more than 40% 
of all osteosarcoma patients continue to develop local recurrent or distant metastatic 
disease after primary treatment. These patients may still be cured when recurrence or 
metastases are limited and amenable to surgery.6,7
When cure is no longer possible, different palliative chemotherapeutic regimens 
are available, e.g. ifosfamide, etoposide, ifosfamide/etoposide and gemcitabine/
docetaxel.8-14 These treatment regimens were studied in small, single arm, studies and 
case series. No randomized phase II or III trials are available. Reported outcomes of 
these treatments are poor with response rates of 17% for gemcitabine/docetaxel, one 
out of eight patients for etoposide, and a higher response rate of 48-59% for ifosfamide/
etoposide, but as first line treatment.8-11 Progression free survival (PFS) for gemcitabine/
docetaxel was 3.5 months.11 Ifosfamide as second line treatment was studied in several 
small studies (between 6 and 19 patients per study) studying varying ifosfamide doses, 
ranging from 5 gram/m2 in one day to a total of 14 gram/m2 continuously over 7 days.12-
15 None of these studies reported the overall survival (OS) and/or PFS. Overall response 
rates varied between 24% and 44%.
A retrospective analysis of 7 Children’s Oncology Group studies, all with inactive drugs 
(according to the study criteria), by Lagmay et al. showed an event free survival (which 
is usually called PFS) of 12% at 4 months, which can be used as reference for new single 
arm studies.16 In a recently published small randomised phase II study, including 43 
patients, regorafenib was shown to have an 8 weeks PFS of 65% versus 0% for the placebo 
group.17
This study reports the Leiden University Medical Center experience with ifosfamide 
monotherapy as palliative treatment in patients with osteosarcoma. It also studies (to 
the authors knowledge for the first time in literature) whether the currently used dose 
of 9 gram/m2 over 3 days continuously is better than the previously used 5 gram/m2 as 
bolus infusion.
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From our hospital cancer registry all patients treated palliatively with ifosfamide 
monotherapy for an osteosarcoma were selected. Sixty-two patients were identified, 
of which 2 were excluded (1 was actually a salivary gland tumour and 1 was a uterine 
leiomyosarcoma treated as osteosarcoma). Three additional patients had the outdated 
diagnosis malignant fibrous histiocytoma (MFH). All three patients with so-called 
malignant fibrous histiocytoma of bone had pathology review before study entry by 
an expert bone tumour pathologist (JVMGB). For two patients osteoid deposition by 
tumour cells was focally observed and the diagnosis was changed to high grade 
osteosarcoma, and these two patients were included. The third patient was diagnosed 
with undifferentiated pleomorphic sarcoma after revision and was excluded. Patients 
were grouped based on their actual primary ifosfamide dose being <6 grams/m2 
(hereafter called intended dose 5 gram/m2) or >6 grams/m2 (called intended dose 9 
gram/m2). In our reference centre ifosfamide 9 gram/m2 was introduced in 1997. Before 
1997, 5 gram/m2 was used. The cut-off of 6 gram/m2 was chosen because this cut-off 
takes into account a little overdosing in the 5 gram/m2 dosed patients and a small dose 
reduction in patients with an intended dose of 9 gram/m2.
For all of these patients a chart review was conducted. Data was collected on age 
and sex, date of primary diagnosis, primary localization, histological subtype, primary 
treatment, primary intend of treatment (palliative or curative), metastases at diagnosis, 
localization of metastases at diagnosis, date of recurrence, date of start ifosfamide, 
planned dose of ifosfamide, actual primary dose of ifosfamide given, number of cycles 
of ifosfamide, given dose of ifosfamide, dates of response evaluation, outcomes of 
response evaluations and treatment after progression on ifosfamide.
Endpoints
The primary endpoint was OS, calculated as the time between start of ifosfamide and 
death. Secondary endpoints were PFS, calculated as time between start of ifosfamide 
and first documented progression and overall response rate, i.e. complete remission, 
partial remission, stable disease and progressive disease according to RECIST 1.1 or in 
case of only clinical evaluation clinical benefit. Covariates studied were histological 
subtype, WHO performance status (PS) at start of ifosfamide treatment and time 
between primary diagnosis and start of ifosfamide treatment. Toxicity was graded 
according to the NCI CTCAE version 4.0.
Statistics
Statistical analysis was performed with IBM Statistical Package for Social Sciences (SPSS) 
Statistics 24. Categorical data were summarized by frequencies and percentages, 
continuous variables were summarized by median and overall range. These were 
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presented according to the two different groups. The characteristics were compared 
with χ2-test for categorical variables and a Mann-Whitney U test for the continuous 
variables. A χ2-test was used to compare response rates between the two treatment 
groups. Kaplan Meier’s methodology was used to estimate OS and PFS. Univariate and 
multivariate Cox proportional hazard regression model was estimated to investigate 
the effect of prognostic factors on OS and PFS.
To compare with existing literature, 8 weeks and 3 months PFS and 9- and 12-months 
OS were estimated by using Kaplan Meier’s methodology.




In total, 62 patients treated with palliative ifosfamide treatment for osteosarcoma were 
identified from our hospital cancer registry. Thirty-six patients had a primary intended 
dose of 9 gram/m2 ifosfamide and the other 26 had an intended dose of 5 gram/m2. 
Table 1 shows the characteristics of the included patients. Patients with an intended 
dose of 9 gram/m2 were older (30.0 (17-70) years vs. 22.5 (15-56) years), received 
more radiotherapy before start of ifosfamide and received more cycles of ifosfamide 
treatment (median 3 vs 4 cycles). As expected, mean cycle dose and cumulative dose 
of ifosfamide was higher in patients with an intended dose of 9 gram/m2. Only, 1 patient 
(9 gram/m2) was pretreated with a regimen containing ifosfamide. (Supplementary 
table 2) More patients were treated with chemotherapy or other treatment options after 
the end of ifosfamide in the dose 9 gram/m2 group (21 vs 12 patients). (Supplementary 
table 4 and 5)
11
Binnenwerk_Productie.indd   221 2/10/2021   8:04:57 PM
222
Chapter 11
Table 1: baseline characteristics
Ifosfamide
Intended dose of 5 
gram/m2
N=26




Age (in years, median, range) 22.5 (15-56) 30.0 (17-70) 0.031
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Table 1: Continued.
Ifosfamide
Intended dose of 5 
gram/m2
N=26















Previous surgery 23 (89%) 29 (81%) 0.404
Previous radiotherapy 1 (4%) 10 (28%) 0.018
Number of cycles Median 
(range)
3 (1-16) 4 (1-13) 0.059




















a Treated as high grade. b Mean dose/cycle and cumulative dose were not statistically compared 
because these were the subject of our study. c See also supplementary table 1.
Overall survival
Median OS was 9.1 months (95%CI 7.8 – 10.4) after start of ifosfamide (this is also the 
median follow-up of the patients because all patients died).(Figure 1A) The OS was 
significantly different between the intended dose of 5 gram/m2 and 9 gram/m2 (P=0.046). 
For the intended dose of 5 gram/m2 the median OS was 6.7 months (95%CI 5.9-7.6) versus 
10.9 months (95%CI 9.3 – 12.6) for the intended dose of 9 gram/m2.(Figure 1B) The OS was 
also significantly different between PS 0, 1 and >2 (P=0.012) with a median OS for PS 0 
of 13.0 months (95%CI 2.3-23.8), PS 1 8.2 months (95%CI 5.4-11.1) PS >2 6.2 months (95%CI 
2.2-10.3) and PS unknown 5.4 months (95%CI 2.2-8.5).(Figure 1C). In multivariate analysis 
only PS was statistically significant associated to OS. (Table 2) The 9- and 12-month OS 
were estimated to compare with other studies. (Table 3)
11
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Figure 1: Overall survival, A all patients, B split based on dose, C split based on WHO 
performance score
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The overall median PFS was 2.6 months (95%CI 2.2-3.0) after start of ifosfamide.(Figure 
2A) The PFS showed a trend towards a better PFS for patients treated with an intended 
dose of 9 gram/m2.(P=0.098) (Figure 2B) For the intended dose of 5 gram/m2 the median 
PFS was 2.1 months (95%CI 1.3-2.9) versus 3.8 months (95%CI 2.2-5.4) for the intended 
dose of 9 gram/m2.(Figure 2B) The PFS did not differ between the WHO performance 
states.(Figure 2C) The results of multivariate analysis resembled the univariate analysis. 
The 8 weeks and 3 months PFS were estimated to compare with other studies. (Table 
3)
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Figure 2: Progression free survival, A all patients, B split based on dose, C split based 
on WHO performance score
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Table 3 Overall survival and progression free survival percentages at specific time points
Intended dose 5 
gram/m2
Intended dose 9 
gram/m2
Overall survival 9 months 35% (95%CI 17 – 52) 69% (95%CI 52 – 82)
Overall survival 12 months 19% (95%CI 7 – 36) 44% (95%CI 28 – 60)
Progression free survival 8 weeks 54% (95%CI 33 – 71) 78% (95%CI 60 - 88)
Progression free survival 4 months 12% (95%CI 3 - 27) 44% (95%CI 28 – 60)
Overall response rate
Best overall responses are reported in table 4. Significant more patients had at least 
stable disease (78% vs 42%) when treated with ifosfamide 9 gram/m2(P=0.005). Overall 
response rate did not differ significantly (36% vs 25%, p=0.27).












6 (23%) 5 (19%) 15 (58%) 0 (0%) 26 (100%)
9 gram/
m2
13 (36%) 15 (42%) 7 (19%) 1 (3%) 36 (100%)
Total 19 (31%) 20 (32%) 22 (35%) 1 (2%) 62 (100%)
Toxicity
As this is a retrospective study, toxicity was based on the reported toxicity in both the 
medical and nursing charts. This data is available in the supplementary data, table 5.
Discussion
This study is the largest study reporting the outcomes of ifosfamide monotherapy in 
the palliative treatment of osteosarcoma patients. Until now, only small studies with 6 
to 19 patients reported outcome for patients treated with ifosfamide monotherapy. It 
shows that PS is an important prognostic factor for overall survival of osteosarcoma, 
but it was unfortunately not possible to detect a significant difference between 9 gram/
m2 and 5 gram/m2.
11
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To our knowledge, this is the first study to report both OS and PFS of patients treated with 
second line or later line ifosfamide chemotherapy for locally advanced or metastatic 
osteosarcoma. The overall response rate in this study (intended dose 5 gram/m2 23% 
and 9 gram/m2 36%) is comparable to earlier reports on ifosfamide monotherapy in 
these patients.12-15,18 Additionally, in an ASCO 2015 abstract, results of ifosfamide 15 gram/
m2 continuously over 5 days were reported.18 The overall response percentage was 22%, 
OS at 1 year was 60% and PFS at 6 months was 53%. Compared to these data, our study 
reports probably a lower 1 year OS and 6 months PFS in a patient population with worse 
PS and older age, but their results were not yet published.18 In the French REGOBONE 
study, a placebo group was included with an 8 weeks PFS of 0% and in the regorafenib 
arm 65%.17 In our study, ifosfamide showed an 8 week PFS of 54% (95%CI 33 – 71) for 5 
gram/m2 and 78% (95%CI 60 - 88) for 9 gram/m2, suggesting a higher PFS for ifosfamide 
9 gram/m2 compared to regorafenib. The 4 month PFS of ifosfamide 9 gram/m2 also 
compares favourably to the 4 months PFS defined in the retrospective study of the COG 
(44% (95%CI 28 – 60) vs. 12% (95% CI 6 – 19).16 Also, an increase in clinical benefit rate is 
shown, when comparing 5 gram/m2 to 9 gram/m2.
One of the important results of this study is the prognostic impact of PS. This was already 
shown for some other tumours, e.g. soft tissue sarcoma.19
This study is limited by its retrospective character, the long study period and no routine 
monitoring interval of CT scan. All patients underwent CT scan at least each 2-3 cycles. 
We did an effort to report the toxicity of ifosfamide therapy, but this is probably an 
underestimation of the real toxicity and is probably also biased. The toxicity of ifosfamide 
monotherapy is well known. The long study period and the different time periods the 
study groups were treated in (5 gram/m2 until 1997 and 9 gram/m2 from 1997 until now) 
hamper the study because supportive care has improved during the years and this 
could cause a difference in OS. Also, the improvements in imaging could result in an 
earlier diagnosis of recurrent disease and thereby a suggested improvement in OS. 
Although in univariate analysis overall survival was better for 9 gram/m2 and there was 
a trend towards a better PFS for patients treated with 9 gram/m2, no significant impact 
of the dose on OS was found in multivariate analysis. This study is still underpowered 
because of the still small number of patients included, but also other causes are present. 
At baseline, there were differences in the number of pretreated patients between both 
groups (higher number of patients with 2 lines of chemotherapy in the 5 gram/m2 
group). This could have an impact on the results in several ways: selecting for patients 
with a more indolent disease and a more chemosensitive tumour or creating more 
chemoresistant tumours. It is not possible to determine what the most dominant effect 
is. Also, PS was slightly imbalanced at baseline, favouring the 9 gram/m2 group, which 
could improve the OS in this patient group. Due to the still small patient group it is not 
possible to distinguish the effect of PS and ifosfamide dose. Although being the largest 
series, the small number of patients did not allow us to detect differences in for example 
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histologic subtypes of osteosarcoma. Lastly, we could not compare the outcomes of 
ifosfamide treatment to an untreated patient cohort of the Leiden University Medical 
Center. Although an untreated patient group exists, most of these patients had a reason 
why they were not treated and the comparison would result in a biased study. However, 
we did compare the data with the placebo arm of the REGOBONE study and with the 
retrospective study of the COG, showing that ifosfamide is an effective treatment (as 
reported above).16,17
This is the largest study until now, reporting data on OS and PFS of ifosfamide monotherapy 
as palliative treatment of osteosarcoma. This study suggests that ifosfamide is an 
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Supplementary table 1: Osteosarcoma subtype
Ifosfamide
Intended dose 5 gram/m2
N=26


















Supplementary table 2: Pretreatment
Intended dose 






Doxorubicin/cisplatin 20 (77%) 27 (75%)




MTX/vincristin/doxorubicin 1 (4%) 0
Doxorubicin 0 2 (6%)






No treatment 21 34
* Patient received only one cycle of this treatment
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MTX < 1 gram/m2 7 2
















Supplementary table 4: Number of post ifosfamide treatment
Intended dose  5 gram/m2  
N=26







Binnenwerk_Productie.indd   233 2/10/2021   8:04:58 PM
234
Chapter 11
Supplementary table 5: Toxicity (NCI CTCAE grade 3-5)
Intended dose 5 gram/m2 
N=26
Intended dose 9 gram/m2 
N=36  
No reported grade 3-5 
toxicity
18 (69%) 13 (36%)
Febrile neutropenia 1 (4%) 7 (19%)










Acute kidney injury 2 (6%)
Dehydration 1 (3%)
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This thesis discusses several retrospective studies in mesenchymal tumours. As 
mesenchymal tumours are rare, the use of all available data is essential for a rapid 
progress of scientific research without the need of large patient groups. Although 
retrospective studies have their limitations, these studies use the available patient data 
as much as possible. The results of the retrospective studies in this thesis are essential 
for the design of future studies and daily patient care.
Soft tissue tumours
Desmoid-type fibromatosis
The first two studies consider several aspects of desmoid-type fibromatosis, a disease 
with a highly variable natural behaviour varying from spontaneous regression to rapidly 
progressive disease with debilitating effects. Until several years ago primary treatment 
consisted of surgery, but now a wait and see policy or other, non-surgical, treatment 
options such as systemic treatment or radiotherapy are preferred first line therapies.1 
In chapter 2, we studied the frequencies and results of current non-surgical first-line 
treatment options of desmoid-type fibromatosis in the Netherlands. The frequency of 
non-surgical treatment has clearly increased between 1993 and 2013 (0.6% of patients 
in the period 1993-1998 up to 12.8% in 2009-2013). Still, surgery is the most common 
treatment modality for desmoid-type fibromatosis. As this disease is rare, the study 
included only 37 patients with active surveillance, 35 with radiotherapy and 19 with 
systemic therapy in first line. Of the patients with a wait and see policy, 16.2% had a 
partial remission or better and 56.8% stable disease as best response, suggesting 
that a wait and see policy is safe. Radiotherapy also showed good results with a best 
response of partial remission or better of 42.8% and stable disease in 45.7%. However, 
the results of our study should be interpreted with care because patients were, at least 
partially, selected for a wait and see policy after referral from another hospital to a 
tertiary sarcoma referral hospital and so there was already knowledge of the natural 
behaviour of the disease. On the other hand, it shows that there is, as earlier mentioned, 
a wide variety in natural behaviour as some patients also had progressive disease when 
a wait and see policy was applied. This study is not able to provide a suggestion on 
which treatment would be best for which patient. Previous studies have shown predictive 
factors for natural behaviour, such as age, tumour localization and CTNNB1 mutation. 
In the future, studies on desmoid-type fibromatosis should preferably be randomised 
controlled trials to account for this variable natural behaviour and these studies should 
also incorporate known predictive factors.2-7
Chapter 3 focusses on a potential side effect of one of the treatment modalities in 
desmoid-type fibromatosis. Radiotherapy is an established treatment option for 
desmoid-type fibromatosis, but, as this tumour is frequently a chronic disease, there 
are concerns about its long-term toxicity especially in young adults. In a study by Keus 
et al. radiotherapy has shown a local control rate of 80% with an average dose of 56 Gy.8 
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In this study we report 6 unique cases of radiation induced sarcoma from 4 different 
referral hospitals and investigate whether these sarcomas occurring after radiotherapy 
originate from the desmoid-type fibromatosis or from the surrounding tissue. The first 
observation in this study is that radiotherapy induced sarcomas are very rare. Second, 
it was shown that sarcomas occurring after radiation of desmoid-type fibromatosis 
can develop as a new primary sarcoma (not harbouring a CTNNB1 mutation) or as 
a malignant transformation of the desmoid-type fibromatosis (retaining the CTNNB1 
mutation). Different CTNNB1 mutations were found in our series and so, no association 
between CTNNB1 mutation and a higher risk of a radiotherapy induced sarcoma was 
found. However, our series only contained six cases. Thus, radiotherapy induced sarcoma 
in desmoid-type fibromatosis is extremely rare and may arise either de novo or from 
malignant transformation of desmoid-type fibromatosis cells.
Gastro-intestinal stromal cell tumour
Chapters 4 and 5 study gastro-intestinal stromal cell tumours (GIST), a rare tumour 
which has now a relatively favourable prognosis due to the introduction of imatinib 
in 2002 and thereafter sunitinib and regorafenib.9-15 New drugs are currently studied, 
such as ripretinib and avapritinib (BLU-285), and are showing promising results.16,17 The 
discovery of KIT and later DOG-1 as immunohistochemical markers for GIST enabled 
pathologists to distinguish GIST from leiomyosarcomas.18,19 As a consequence GIST 
could be studied as a separate entity, thereby allowing the introduction of imatinib 
and improving the prognosis of these patients. Due to the introduction of imatinib 
the importance of correctly diagnosing GIST has further increased. In 2005, a Dutch 
nationwide population based study on the incidence of GIST was published studying 
the impact of the introduction of imatinib on the incidence of GIST, probably due to 
increased recognition by pathologists, showing a reported incidence of 12.7 patients 
per million inhabitants in the Netherlands, which was 2.1 in 1995.20 As incidence numbers 
are important for both health care planning and study design, chapter 4 studied the 
development of the incidence of diagnosed GIST between 2003 and 2012, again showing 
an increase; from 12.2 to 17.7 patients per million inhabitants per year. This is in line 
with other studies in amongst others the United States, Taiwan and Shanghai.21-23 The 
reason for this increase cannot be derived from this study. Improvements in diagnostic 
procedures and increased awareness are probably at least partially the cause for this 
increase. A real increase in the incidence is also possible, but causal or risk factors for 
GIST are not known. The incidence in The Netherlands is on the higher end as compared 
to other reported incidences, which is probably due to the use of PALGA, the Dutch 
nationwide pathology registry, which fully automatically archives all Dutch pathology 
reports and so also registers small and incidental GISTs.21-24
In this study, the adherence to the ESMO guideline was also evaluated, which gives 
amongst others recommendations on mutational analysis and pathology review.25 
Only a minority of patients had pathology revision in a reference centre with mutation 
12
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analysis. For the high-risk patients, 67% had a mutational status and 67% had a 
pathology revision in a reference centre. Of all high-risk patients, revision in a reference 
centre and mutation analysis was performed in 92.3% of patients while only 16.7% of 
high-risk patients in one of the other centres had mutation analysis done. In conclusion, 
this second nationwide GIST incidence study in the Netherlands showed an increase 
in incidence during the years and a low adherence to the guidelines. The low rate of 
mutation analysis in the non-reference centres stresses the importance of pathology 
revision in a reference centre and of adherence to international guidelines.
As already mentioned, the introduction of imatinib had a great impact on the overall 
survival (OS) of patients with metastatic GIST. Side effects are often limited, but drug-
induced agranulocytosis (neutrophil count <0.5*103/ml) is a rare, but serious adverse 
event. It can result in potentially life-threatening infections. Imatinib is used both in 
chronic myeloid leukaemia (CML) and in GIST. In CML patients treated with imatinib, 
grade 3-4 neutropenia (neutrophil count 0.5-1.0 and <0.5) is common, occurring in 
approximately 35-45% of patients treated with 400 mg/day.26 However, this is expected 
as imatinib administration results in the suppression of the malignant cells by inhibition 
of the BCR-ABL fusion gene. However, imatinib induced myelosuppression is also seen 
in GIST patients with an assumed normal bone marrow function. Although the KIT 
proto-oncogene (the target of imatinib) is present in several cell types, in vitro studies 
show that the effect of imatinib is also independent of c-kit.27-29 Chapter 5 reports our 
experience with imatinib induced agranulocytosis. Four patients were identified in three 
Dutch GIST reference centres. All four patients showed rapid and full recovery after the 
discontinuation of imatinib. One patient could restart with a reduced dose without further 
events, one patient could continue with imatinib concomitantly with prednisolone, one 
patient had a recurrence after first rechallenge, but could continue with a reduced 
dose in a second rechallenge. Patient 4 was treated neo-adjuvant and had surgery 
after recovery of the neutropenia. Two patients were also treated with granulocyte 
colony stimulating factor, maybe resulting in a more rapid recovery of granulocyte 
count. Unfortunately, no imatinib drug levels were monitored in our study and we do not 
know what caused the imatinib-induced agranulocytosis in these patients. Our study 
suggests a possible management algorithm for imatinib induced agranulocytosis, with 
the suggestion of stopping imatinib until recovery. After full recovery, restart imatinib at 
the same dose. In case of recurrence after the rechallenge, consider restarting imatinib 
at a reduced dose and/or together with low dose corticosteroids (e.g. prednisolone 10 
mg/day) and/or granulocyte-colony stimulating factor (G-CSF). If corticosteroids are 
started, the dose should be tapered slowly under strict monitoring of the hemogram. 
This study provides some guidance for treating imatinib-induced agranulocytosis.
Soft tissue sarcomas
Chapter 6, 7, 8 and 9 in this thesis are studies in soft tissue sarcoma. Chapter 6 and 7 are 
two retrospective European Organisation for Research and Treatment of Cancer (EORTC) 
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database studies. Chapter 6 describes the differences in survival between patients 
with locally advanced disease, patients with distant metastatic disease only or patients 
with both locally advanced disease and distant metastases. Chapter 7 was a result of 
the development of a maintenance study with trabectedin after doxorubicin first line 
treatment and reports the survival after completing doxorubicin monotherapy as first 
line palliative treatment in soft tissue sarcomas. This study provides data on OS and 
progression-free survival (PFS) in patients completing at least 6 cycles of doxorubicin 
treatment.
As soft tissue sarcomas are rare, and the specific subtypes even rarer, stratification for 
prognostic factors is often difficult to apply in phase III studies. However, in chapter 6 it 
is shown that an important difference in OS, PFS and overall response rate (ORR) exists 
between patients with only locally advanced disease versus patients with only distant 
metastatic disease versus patients with both locally advanced and distant metastatic 
disease (OS 15.4, 12.9 and 10.6 months, respectively and PFS 5.8, 4.3 and 3.2 months, 
respectively). The improved survival in patients with locally advanced disease only 
could be due to additional radiotherapy or surgery after chemotherapeutical treatment, 
but no data was available to test this. Prognostic factors, such as time since initial 
diagnosis, localization of primary tumour, histologic subtype and performance status 
had a different impact between the different disease stage groups. Major limitation of 
this study is the long time period this study stretches.
A second EORTC database study was done as prework for a study with trabectedin as 
maintenance therapy after first line doxorubicin treatment in patients with soft tissue 
sarcoma. Chapter 7 describes the results of this study. The knowledge of data on the 
number of patients completing 6 cycles (the current standard maximum number 
of doxorubicin 75 mg/m2 cycles) of doxorubicin without progression and data on OS 
and PFS after completing 6 cycles of doxorubicin is essential when designing studies 
of maintenance treatment after doxorubicin. As continuation for a longer time with 
doxorubicin is not possible due to its cardiotoxic effects, other ways to improve survival 
are explored. Survival of patients with metastatic soft tissue sarcoma remains poor with 
a median OS ranging between 13 and 18 months.30-33 Olaratumab, a monoclonal antibody 
against platelet -derived growth factor alpha (PDGFRα), was thought to improve the 
survival of patients in a phase II study, but this could not be confirmed in the phase III 
study.34,35 Another way of improving survival would be to start maintenance treatment 
after doxorubicin treatment. This is a well-established concept in e.g. colorectal cancer, 
non-small cell lung cancer and ovarian cancer.36-38 Progression after first line treatment 
can result in deterioration of condition and thereby making it difficult to administer 
second line treatment. Maintenance treatment tries to improve the PFS, but at the cost 
of continuing adverse events. Our study shows that approximately 36.6% of all patients 
treated with first-line doxorubicin qualify for maintenance treatment, so a major patient 
group will not be considered for this treatment modality. The PFS of 8.7 months and the 
12
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OS of 20.1 months after randomisation is much longer than the commonly reported 
PFS and OS, but this is due to the selection of responding patients. However, this is 
an important factor to account for when designing phase II studies on maintenance 
treatment. One of the major limitations is, again, the long-time interval of inclusion of 
patients and thereby with time the addition of new treatment options as pazopanib, 
eribulin and trabectedin.
The data of these two database studies is essential for designing future studies. The 
study in chapter 6 stresses the importance of stratifying for disease stage or including 
only patients with distant metastatic disease. Not accounting for the difference in 
disease stage and/or the different prognostic factors could cause serious imbalances 
and thereby causing a reduction in value of the study results. The database study 
of chapter 7 reports important data for the design of maintenance studies after 
doxorubicin monotherapy and without these data designing phase II studies would be 
a wild guess.
Chapters 8 and 9 report adverse events of pazopanib treatment, a new drug in soft 
tissue sarcoma treatment. The phase III study with pazopanib versus placebo (PALETTE) 
showed a significant improvement in PFS of 4.6 months over 1.6 months with placebo.39 
OS was not improved by pazopanib in this study. One of the major adverse events 
causing treatment discontinuation is hepatic toxicity (grade > 2 elevated alanine 
aminotransferase (ALAT) was 10% (placebo 3%) and aspartate aminotransferase 
(ASAT) was 8% (placebo 2%) in the PALETTE study). Chapter 8 describes a patient with 
an endometrial stromal sarcoma and liver function test abnormalities. The mechanism 
for this hepatic toxicity is until now unknown. No liver biopsy was done in the patient 
described so the cause is also unknown in our patient. For this patient the dose of 
pazopanib was decreased to 200 mg every second day in several steps. Treatment was 
still effective with a time on treatment of 9 months. Currently the summary of product 
characteristics of pazopanib contains guidelines on handling liver toxicity that suggest 
to stop pazopanib in case of ASAT or ALAT elevations >8x upper limit of normal and restart 
it after near-normalisation of liver function abnormalities with a dose of 400 mg. In case 
of reoccurrence pazopanib should be stopped permanently. The results in our patient 
suggest that pazopanib can be continued safely in a lower dose under strict follow up of 
liver functions. Recently also a strategy with the addition of prednisolone was reported 
in literature to be effective.40 The second message of this case report is the long PFS of 
a patient with an endometrial stromal cell sarcoma treated with pazopanib.
The second chapter (chapter 9) focusses on the development of a spontaneous 
pneumothorax as another side effect of pazopanib, that is reported for six patients 
treated with pazopanib for a metastatic soft tissue sarcoma. In total, we found a 
pneumothorax in 14% of soft tissue sarcoma patients treated with pazopanib in our 
centre, which was considerably higher than in the PALETTE study (3.3%).39 Other trials with 
Binnenwerk_Productie.indd   242 2/10/2021   8:04:59 PM
243
Discussion and future perspectives
pazopanib in other cancers did not report pneumothorax as an adverse event, which 
suggests that it is a specific adverse event in metastatic soft tissue sarcoma.41-46 All 
cases developing a pneumothorax had pleural or subpleural metastases and showed 
some necrosis. The treatment of pazopanib associated pneumothorax was difficult, 
probably due to the fact that pazopanib inhibits VEGFR (Vascular Endothelial Growth 
Factor Receptor).
The reported cases in chapter 8 and 9 are important as on one hand these report new 
treatment strategies for common side effects and thereby enabling continuation of 
pazopanib in case of toxicity, and on the other hand report new observations concerning 
side effects not earlier noted.
Bone tumours
The last part of this thesis focuses on two rare bone tumours, i.e. giant cell tumours of 
bone (GCT-B) and osteosarcoma.
Giant cell tumour of bone
GCT-B is an intermediate, locally aggressive tumour causing a lot of morbidity. Recently, 
denosumab, a monoclonal antibody against RANKL (receptor of nuclear factor kappa-B 
ligand), was introduced as a medical treatment for GCT-B. The incidence of GCT-B 
was not exactly known. Approximately 5% of all bone tumours are GCT-B and the 
incidence is estimated between 1.03-1.33 per million per year in doctor-driven cancer 
registries.47-49 Chapter 10 reports the results of a study on the incidence of GCT-B in the 
Netherlands based on the Dutch nationwide pathology registry, PALGA. The incidence is 
approximately 1.7 patients per million inhabitants in the Netherlands. The median age of 
patients was 35 years (range 9-77) and the tumours were most commonly localized in 
the femur (35%) and tibia (18%). The incidence of local recurrence was 0.40 patients per 
million inhabitants per year. The incidence we report is higher than previously reported 
in literature, probably due to the use of PALGA, which covers all Dutch pathology reports 
and is archiving these automatically.48,49 Previous studies were based on doctor-driven 
registries. The recurrence rate was probably lower than in previous studies, which could 
be due to reporting bias. A recurrent tumour will be reported more frequently than an 
innocent primary tumour in a doctor-driven registry.
In summary, this study is the first to report incidence of GCT-B based on a 100% covering 
nationwide pathology database. Without these numbers it is difficult to plan health care 
and future research.
Osteosarcoma
The last tumour studied in this thesis is osteosarcoma. This is the most common 
malignant bone tumour, but is still very rare. First line treatment is well-defined, 
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consisting of doxorubicin and cisplatin with or without high dose methotrexate. 
Currently, approximately 40% of all osteosarcoma patients develop local recurrence 
or distant metastatic disease after first line treatment. Second-line treatment is not 
well-established. Chemotherapeutic regimens as ifosfamide, etoposide, ifosfamide/
etoposide and gemcitabine/docetaxel are used.50-56 Ifosfamide as second line 
treatment was studied in several small studies (between 6 and 19 patients per study) 
studying varying ifosfamide doses, ranging from 5 g/m2 in one day to a total of 14 g/
m2 continuously over 7 days.54-57 None of these studies reported the OS and/or PFS. 
Chapter 11 reports the results of ifosfamide monotherapy as palliative treatment in 
osteosarcoma patients. Sixty-two patients treated with ifosfamide monotherapy were 
identified in the Leiden University Medical Center of which 26 were treated with an 
intended dose of 5 g/m2 and 36 with an intended dose of 9 g/m2. This study shows an 
improvement in OS for patients treated with 9 g/m2 compared to 5 g/m2 in univariate 
analysis (10.9 months (95%CI 9.3 – 12.6) versus 6.7 months (95%CI 5.9-7.6) resp.), but not 
in multi-variate analysis. PFS was not significantly different, but showed a trend towards 
a better PFS for the intended dose of 9 g/m2 compared to 5 g/m2 (3.8 months (95%CI 
2.2-5.4) versus 2.1 months (95%CI 1.3-2.9) (P=0.098)). To our knowledge, this is the first 
study to report both OS and PFS of patients treated with second or later line ifosfamide 
chemotherapy for locally advanced or metastatic osteosarcoma. The placebo arm of 
the French REGOBONE study could be used as a surrogate arm for comparison.58 The 
placebo group had an 8 weeks PFS of 0% and in the regorafenib arm 65%. In our study, 
ifosfamide showed an 8 week PFS of 54% (95%CI 33 – 71) for 5 gram/m2 and 78% (95%CI 
60 - 88) for 9 gram/m2, suggesting a higher PFS for ifosfamide 9 gram/m2 compared to 
regorafenib. The 4 month PFS of ifosfamide 9 gram/m2 also compares favourably to the 
4 months PFS defined in the retrospective study of the COG (44% (95%CI 28 – 60) vs. 12% 
(95% CI 6 – 19).59 One of the other important results of this study is the prognostic impact 
of WHO performance status, i.e. a better performance status is associated with a better 
survival. Unfortunately, this study has still some major limitations. Patients in the lower 
dosed group were treated until 1997 and the patients with higher dosed ifosfamide were 
treated from 1997 onwards. In this time period new treatment options became available 
and diagnostics have improved, leading to earlier diagnosis of recurrence and so to 
a longer OS. This study is the largest until now reporting survival data for ifosfamide 
monotherapy as palliative treatment in osteosarcoma. The results of the study can 
be used as benchmark for future studies, when comparing new treatment options in 
phase II studies.
Future perspectives
Half of the studies in this thesis provide evidence for the improvement of future clinical 
trials. To improve care for patients with mesenchymal tumours it is essential to use the 
data already available as much as possible. Based on the results of the two incidence 
studies (chapters 4 and 10) future studies in gastro-intestinal stromal cell tumours and 
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giant cell tumours of bone can be developed without the risk of too low accrual due to an 
overestimation of the incidence. Also, health care authorities and providers have insight 
in the incidence of these tumours, which helps to predict health care consumption 
caused by these diseases.
The two EORTC database studies (chapters 6 and 7) provide evidence for future soft 
tissue sarcoma trials. It is important that future studies stratify or at least in some way 
account for differences in prognosis between different disease stages and for prognostic 
factors. These studies should also try to prospectively confirm the differences in survival 
found. The study proves that, although splitting sarcoma patients in different subgroups 
based on different disease stage or histologic subtype results in smaller subgroups, 
splitting in subgroups improves the validity of study results. The low incidence of these 
tumours remains a difficulty for further studies in soft tissue sarcoma and international 
cooperation is of utmost importance to include enough patients in studies. A way 
forward could be the implementation of registries of soft tissue sarcoma patients and 
thereby making the accrual of patients with specific subtypes easier. The integration 
of biobanking in these registrations will help to rapidly screen patients for studies.
These research infrastructures will help to improve the survival of soft tissue sarcoma 
patients, which is currently poor. As earlier mentioned, new studies will be necessary to 
study new drugs, but also other strategies should be explored, such as combining drugs, 
maintenance treatment with relatively low toxic drugs and the combination of treatment 
modalities. The data provided on survival after doxorubicin-based first line treatment 
helps the design of maintenance studies after first line doxorubicin-based treatment.
The study on ifosfamide as palliative treatment for osteosarcoma patients (chapter 11) 
provides evidence for the effectivity of ifosfamide monotherapy as second line palliative 
treatment in osteosarcoma. It sets a reference standard for the design of new phase II 
studies. Also, these future studies should concentrate on new drugs, new combinations 
of drugs and new strategies e.g. maintenance treatment. Due to the low incidence it is 
again of high importance that for these studies international collaboration is sought.
The results of non-surgical strategies as first-line in desmoid-type fibromatosis 
(chapter 2) show that the natural behaviour of this tumour is highly variable when a 
wait and see policy is applied. This stresses the importance of randomized trials in this 
tumour, because this will account for the variation in natural behaviour of this tumour. 
Second, non-surgical management of desmoid-type fibromatosis should be further 
developed and be compared to surgery to determine which is the best treatment for 
which patient.
The last studies (chapters 3, 5, 8 and 9), studying side effects, show that case reports 
and case series have great value in detecting good responding rare tumours, finding 
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new serious adverse event and regimens for the treatment of adverse events. Although 
these do not provide the highest level of evidence, these do provide hypotheses and 
suggestions for further research. It should be encouraged to publish case reports of 
interesting findings to generate new hypothesis.
In general, one of the major problems in mesenchymal tumour care is the availability 
of drugs and the regulatory process of these drugs. Currently registration of most drugs 
is based on large randomised phase III trials, including high numbers of patients. This is 
not possible for very rare subtypes of mesenchymal tumours. On one hand, to achieve 
large studies, international collaboration should be encouraged and made as easy as 
possible by health care authorities, but on the other hand new study designs should 
be developed in collaboration with health care authorities, needing lower numbers of 
patients, but designed in such way that health care authorities accept it as registration 
studies. As already mentioned, large patient registries/biobanks should be developed. 
These registries/biobanks allow for rapid patient identification for studies, screening for 
specific treatment targets and thereby allowing for faster accrual in studies.
In order to improve the medical care for these rare group of mesenchymal tumour 
patients and guarantee the possibility to offer studies to every patient, each patient 
should be treated in a network with expertise in mesenchymal tumour/sarcoma 
care. Each case should be discussed at essential moments in the care process in 
an expert team. Based on disease stage, type of treatment and patient wishes, the 
hospital of treatment should be chosen. If necessary, it should be centralised, but if 
possible, it should be as close to the patient as possible. This could imply for some 
very rare mesenchymal tumours, that only one expert centre exists in The Netherlands, 
to which all patients are referred at least at diagnosis and thereafter are treated at a 
subsite. Even international multidisciplinary team meetings should be considered for 
daily patient care. However, with all changes in the organisation of care for patients 
with mesenchymal tumours, at every moment the patient’s preferences should be 
considered.
Binnenwerk_Productie.indd   246 2/10/2021   8:04:59 PM
247
Discussion and future perspectives
References
1. Kasper B, Baumgarten C, Garcia J, et al. An update on the management of sporadic 
desmoid-type fibromatosis: a European Consensus Initiative between Sarcoma PAtients 
EuroNet (SPAEN) and European Organization for Research and Treatment of Cancer 
(EORTC)/Soft Tissue and Bone Sarcoma Group (STBSG). Annals of oncology : official journal 
of the European Society for Medical Oncology / ESMO 2017;28:2399-408.
2. Hayry P, Reitamo JJ, Totterman S, Hopfner-Hallikainen D, Sivula A. The desmoid tumor. II. 
Analysis of factors possibly contributing to the etiology and growth behavior. American 
journal of clinical pathology 1982;77:674-80.
3. Crago AM, Denton B, Salas S, et al. A prognostic nomogram for prediction of recurrence 
in desmoid fibromatosis. Ann Surg 2013;258:347-53.
4. Dômont J, Salas S, Lacroix L, et al. High frequency of beta-catenin heterozygous mutations 
in extra-abdominal fibromatosis: a potential molecular tool for disease management. 
British journal of cancer 2010;102:1032-6.
5. Colombo C, Miceli R, Lazar AJ, et al. CTNNB1 45F mutation is a molecular prognosticator of 
increased postoperative primary desmoid tumor recurrence: an independent, multicenter 
validation study. Cancer 2013;119:3696-702.
6. Lazar AJ, Tuvin D, Hajibashi S, et al. Specific mutations in the beta-catenin gene (CTNNB1) 
correlate with local recurrence in sporadic desmoid tumors. The American journal of 
pathology 2008;173:1518-27.
7. van Broekhoven DL, Verhoef C, Grunhagen DJ, et al. Prognostic value of CTNNB1 gene 
mutation in primary sporadic aggressive fibromatosis. Annals of surgical oncology 
2015;22:1464-70.
8. Keus RB, Nout RA, Blay JY, et al. Results of a phase II pilot study of moderate dose 
radiotherapy for inoperable desmoid-type fibromatosis--an EORTC STBSG and ROG study 
(EORTC 62991-22998). Annals of oncology : official journal of the European Society for 
Medical Oncology / ESMO 2013;24:2672-6.
9. The ESMO/European Sarcoma Network Working Group. Gastrointestinal stromal tumours: 
ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of 
Oncology 2014;25:iii21-iii6.
10. Verweij J, van Oosterom A, Blay JY, et al. Imatinib mesylate (STI-571 Glivec®, Gleevec™) 
is an active agent for gastrointestinal stromal tumours, but does not yield responses in 
other soft-tissue sarcomas that are unselected for a molecular target: Results from an 
EORTC Soft Tissue and Bone Sarcoma Group phase II study. European journal of cancer 
2003;39:2006-11.
11. Demetri GD, von Mehren M, Blanke CD, et al. Efficacy and safety of imatinib mesylate 
in advanced gastrointestinal stromal tumors. The New England journal of medicine 
2002;347:472-80.
12. Verweij J, Casali PG, Zalcberg J, et al. Progression-free survival in gastrointestinal stromal 
tumours with high-dose imatinib: randomised trial. The Lancet 2004;364:1127-34.
13. Demetri GD, van Oosterom AT, Garrett CR, et al. Efficacy and safety of sunitinib in patients 
with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised 
controlled trial. Lancet 2006;368:1329-38.
12
Binnenwerk_Productie.indd   247 2/10/2021   8:04:59 PM
248
Chapter 12
14. George S, Blay JY, Casali PG, et al. Clinical evaluation of continuous daily dosing of sunitinib 
malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. 
European journal of cancer 2009;45:1959-68.
15. Demetri GD, Reichardt P, Kang YK, et al. Efficacy and safety of regorafenib for advanced 
gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an 
international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 
2013;381:295-302.
16. Smith BD, Kaufman MD, Lu WP, et al. Ripretinib (DCC-2618) Is a Switch Control Kinase 
Inhibitor of a Broad Spectrum of Oncogenic and Drug-Resistant KIT and PDGFRA Variants. 
Cancer Cell 2019;35:738-51.e9.
17. Evans EK, Gardino AK, Kim JL, et al. A precision therapy against cancers driven by KIT/
PDGFRA mutations. Sci Transl Med 2017;9.
18. Hirota S, Isozaki K, Moriyama Y, et al. Gain-of-Function Mutations of c-kit in Human 
Gastrointestinal Stromal Tumors. Science 1998;279:577-80.
19. West RB, Corless CL, Chen X, et al. The novel marker, DOG1, is expressed ubiquitously 
in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. The 
American journal of pathology 2004;165:107-13.
20. Goettsch WG, Bos SD, Breekveldt-Postma N, Casparie M, Herings RM, Hogendoorn PC. 
Incidence of gastrointestinal stromal tumours is underestimated: results of a nation-wide 
study. European journal of cancer 2005;41:2868-72.
21. Ma GL, Murphy JD, Martinez ME, Sicklick JK. Epidemiology of gastrointestinal stromal tumors 
in the era of histology codes: results of a population-based study. Cancer Epidemiol 
Biomarkers Prev 2015;24:298-302.
22. Chiang NJ, Chen LT, Tsai CR, Chang JS. The epidemiology of gastrointestinal stromal tumors 
in Taiwan, 1998-2008: a nation-wide cancer registry-based study. BMC cancer 2014;14:102.
23. Lv M, Wu C, Zheng Y, Zhao N. Incidence and survival analysis of gastrointestinal stromal 
tumors in shanghai: a population-based study from 2001 to 2010. Gastroenterology 
research and practice 2014;2014:834136.
24. Casparie M, Tiebosch AT, Burger G, et al. Pathology databanking and biobanking in The 
Netherlands, a central role for PALGA, the nationwide histopathology and cytopathology 
data network and archive. Cellular oncology : the official journal of the International 
Society for Cellular Oncology 2007;29:19-24.
25. Casali PG, Blay J-Y, Experts ObotECECPo. Gastrointestinal stromal tumours: ESMO 
Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 
2010;21:v98-v102.
26. Kantarjian H, Sawyers C, Hochhaus A, et al. Hematologic and cytogenetic responses to 
imatinib mesylate in chronic myelogenous leukemia. The New England journal of medicine 
2002;346:645-52.
27. Escribano L, Ocqueteau M, Almeida J, Orfao A, San Miguel JF. Expression of the c-kit (CD117) 
molecule in normal and malignant hematopoiesis. Leuk Lymphoma 1998;30:459-66.
28. Bartolovic K, Balabanov S, Hartmann U, et al. Inhibitory effect of imatinib on normal 
progenitor cells in vitro. Blood 2004;103:523-9.
Binnenwerk_Productie.indd   248 2/10/2021   8:04:59 PM
249
Discussion and future perspectives
29. Su RJ, Zhang XB, Li K, et al. Platelet-derived growth factor promotes ex vivo expansion of 
CD34+ cells from human cord blood and enhances long-term culture-initiating cells, 
non-obese diabetic/severe combined immunodeficient repopulating cells and formation 
of adherent cells. Br J Haematol 2002;117:735-46.
30. Judson I, Verweij J, Gelderblom H, et al. Results of a randomised phase III trial (EORTC 62012) 
of single agent doxorubicin versus doxorubicin plus ifosfamide as first line chemotherapy 
for patients with advanced, soft tissue sarcoma: a survival study by the EORTC Soft Tissue 
and Bone Sarcoma Group. Connective Tissue Oncology Society. Prague2012.
31. Seddon B, Strauss SJ, Whelan J, et al. Gemcitabine and docetaxel versus doxorubicin as 
first-line treatment in previously untreated advanced unresectable or metastatic soft-
tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial. The lancet oncology 
2017;18:1397-410.
32. Tap WD, Papai Z, Van Tine BA, et al. Doxorubicin plus evofosfamide versus doxorubicin 
alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/
SARC021): an international, multicentre, open-label, randomised phase 3 trial. The lancet 
oncology 2017;18:1089-103.
33. Ryan CW, Merimsky O, Agulnik M, et al. PICASSO III: A Phase III, Placebo-Controlled Study of 
Doxorubicin With or Without Palifosfamide in Patients With Metastatic Soft Tissue Sarcoma. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
2016;34:3898-905.
34. Tap WD, Jones RL, Van Tine BA, et al. Olaratumab and doxorubicin versus doxorubicin alone 
for treatment of soft-tissue sarcoma: an open-label phase 1b and randomised phase 2 
trial. Lancet 2016;388:488-97.
35. Tap WD, Wagner AJ, Papai Z, et al. ANNOUNCE: A randomized, placebo (PBO)-controlled, 
double-blind, phase (Ph) III trial of doxorubicin (dox) + olaratumab versus dox + PBO in 
patients (pts) with advanced soft tissue sarcomas (STS). Journal of Clinical Oncology 
2019;37:LBA3-LBA.
36. Simkens LH, van Tinteren H, May A, et al. Maintenance treatment with capecitabine and 
bevacizumab in metastatic colorectal cancer (CAIRO3): a phase 3 randomised controlled 
trial of the Dutch Colorectal Cancer Group. Lancet 2015;385:1843-52.
37. Paz-Ares L, de Marinis F, Dediu M, et al. Maintenance therapy with pemetrexed plus best 
supportive care versus placebo plus best supportive care after induction therapy with 
pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer 
(PARAMOUNT): a double-blind, phase 3, randomised controlled trial. The lancet oncology 
2012;13:247-55.
38. Oza AM, Cook AD, Pfisterer J, et al. Standard chemotherapy with or without bevacizumab 
for women with newly diagnosed ovarian cancer (ICON7): overall survival results of a 
phase 3 randomised trial. The lancet oncology 2015;16:928-36.
39. van der Graaf WT, Blay JY, Chawla SP, et al. Pazopanib for metastatic soft-tissue sarcoma 
(PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet 
2012;379:1879-86.
40. Vlenterie M, van Erp NP, van der Graaf WTA. Promising management of pazopanib-induced 
liver toxicity. Acta Oncologica 2015;54:1064-6.
41. Friedlander M, Hancock KC, Rischin D, et al. A Phase II, open-label study evaluating 
pazopanib in patients with recurrent ovarian cancer. Gynecologic oncology 2010;119:32-7.
12
Binnenwerk_Productie.indd   249 2/10/2021   8:04:59 PM
250
Chapter 12
42. Necchi A, Mariani L, Zaffaroni N, et al. Pazopanib in advanced and platinum-resistant 
urothelial cancer: an open-label, single group, phase 2 trial. The lancet oncology 
2012;13:810-6.
43. Sternberg CN, Hawkins RE, Wagstaff J, et al. A randomised, double-blind phase III study of 
pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall 
survival results and safety update. European journal of cancer 2013;49:1287-96.
44. Rautiola J, Utriainen T, Peltola K, Joensuu H, Bono P. Pazopanib after sunitinib failure in 
patients with metastatic renal cell carcinoma. Acta Oncologica 2014;53:113-8.
45. Pili R, Qin R, Flynn PJ, et al. A Phase II Safety and Efficacy Study of the Vascular Endothelial 
Growth Factor Receptor Tyrosine Kinase Inhibitor Pazopanib in Patients With Metastatic 
Urothelial Cancer. Clinical Genitourinary Cancer 2013;11:477-83.
46. Ahn HK, Choi JY, Kim KM, et al. Phase II study of pazopanib monotherapy in metastatic 
gastroenteropancreatic neuroendocrine tumours. British journal of cancer 2013;109:1414-9.
47. Athanasou NA, Bansal M, Forsyth R, Reid RP, Sapi Z. Giant cell tumour of bone. In: Fletcher 
CD, Bridge JA, Hogendoorn PC, Mertens F, eds. WHO Classification of Tumours of Soft Tissue 
and Bone. 4th ed. Lyon: IARC; 2013:321-4.
48. Liede A, Bach BA, Stryker S, et al. Regional variation and challenges in estimating the 
incidence of giant cell tumor of bone. The Journal of bone and joint surgery American 
volume 2014;96:1999-2007.
49. Amelio JM, Rockberg J, Hernandez RK, et al. Population-based study of giant cell tumor of 
bone in Sweden (1983-2011). Cancer epidemiology 2016;42:82-9.
50. Gentet JC, Brunat-Mentigny M, Demaille MC, et al. Ifosfamide and etoposide in childhood 
osteosarcoma. A phase II study of the French Society of Paediatric Oncology. European 
journal of cancer 1997;33:232-7.
51. Goorin AM, Harris MB, Bernstein M, et al. Phase II/III trial of etoposide and high-dose 
ifosfamide in newly diagnosed metastatic osteosarcoma: a pediatric oncology group trial. 
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 
2002;20:426-33.
52. Kebudi R, Gorgun O, Ayan I. Oral etoposide for recurrent/progressive sarcomas of 
childhood. Pediatric blood & cancer 2004;42:320-4.
53. Palmerini E, Jones RL, Marchesi E, et al. Gemcitabine and docetaxel in relapsed and 
unresectable high-grade osteosarcoma and spindle cell sarcoma of bone. BMC cancer 
2016;16:280.
54. Patel SR, Vadhan-Raj S, Papadopolous N, et al. High-dose ifosfamide in bone and soft 
tissue sarcomas: results of phase II and pilot studies--dose-response and schedule 
dependence. Journal of clinical oncology : official journal of the American Society of 
Clinical Oncology 1997;15:2378-84.
55. Antman KH, Ryan L, Elias A, Sherman D, Grier HE. Response to ifosfamide and mesna: 124 
previously treated patients with metastatic or unresectable sarcoma. Journal of clinical 
oncology : official journal of the American Society of Clinical Oncology 1989;7:126-31.
56. Marti C, Kroner T, Remagen W, Berchtold W, Cserhati M, Varini M. High-dose ifosfamide in 
advanced osteosarcoma. Cancer treatment reports 1985;69:115-7.
Binnenwerk_Productie.indd   250 2/10/2021   8:04:59 PM
251
Discussion and future perspectives
57. Lee SH, Chang MH, Baek KK, et al. High-dose ifosfamide as second- or third-line 
chemotherapy in refractory bone and soft tissue sarcoma patients. Oncology 2011;80:257-
61.
58. Duffaud F, Mir O, Boudou-Rouquette P, et al. Efficacy and safety of regorafenib in adult 
patients with metastatic osteosarcoma: a non-comparative, randomised, double-blind, 
placebo-controlled, phase 2 study. The lancet oncology 2019;20:120-33.
59. Lagmay JP, Krailo MD, Dang H, et al. Outcome of Patients With Recurrent Osteosarcoma 
Enrolled in Seven Phase II Trials Through Children’s Cancer Group, Pediatric Oncology 
Group, and Children’s Oncology Group: Learning From the Past to Move Forward. 
2016;34:3031-8.
12
Binnenwerk_Productie.indd   251 2/10/2021   8:04:59 PM










This thesis consists of several retrospective studies in mesenchymal tumours. As 
mesenchymal tumours are rare, the use of all available data is essential for a rapid 
progress of scientific research without the need of large patient groups. Although 
retrospective studies have their limitations, these studies use the available patient data 
as much as possible. The results of the retrospective studies in this thesis will improve 
the design of future studies and daily patient care. 
Soft tissue tumours
Desmoid-type fibromatosis
Chapter 2 studies the non-surgical treatment of desmoid-type fibromatosis, a disease 
with a highly variable natural behaviour. Based on pathology reports from PALGA, the 
Dutch nationwide pathology registry, this study shows that the incidence of non-surgical 
treatment has increased between 1993 to 2013 from 0.6% to 12.8%, but that surgery is 
still the primary treatment in most patients. The study shows a favourable outcome in 
patients with active surveillance or treated with radiotherapy or with systemic therapy. 
Because of the rarity of the non-surgical treatments and the variable natural behaviour 
of this disease, these results should be interpreted with care, but provide a base for 
further studying non-surgical treatments.  
Chapter 3 focusses on a potential side effect of radiotherapy as one of the established 
treatment modalities in desmoid-type fibromatosis. Radiotherapy has shown an 80% 
control rate with an average dose of 56 Gy. This study reports six unique cases of 
radiation induced sarcoma from four different referral hospitals which indicates that 
these radiation induced sarcomas arising in desmoid–type fibromatosis are extremely 
rare. It was investigated whether these sarcomas occurring after radiotherapy originate 
from the desmoid-type fibromatosis or from the surrounding tissue. The results show 
that sarcomas occurring after radiation of desmoid-type fibromatosis can develop as 
a new primary sarcoma (not harbouring a CTNNB1 mutation, which was present in the 
desmoid-type fibromatosis) or as a malignant transformation of the desmoid-type 
fibromatosis (retaining the CTNNB1 mutation). We did not find an association between 
the type of CTNNB1 mutations and a higher risk of a radiotherapy induced sarcoma. 
Gastro-intestinal stromal cell tumour
In chapters 4 and 5 gastro-intestinal stromal cell tumours (GIST) are studied. GISTs 
are the most frequent mesenchymal tumours of the gastrointestinal tract. This rare 
tumour has a relatively favourable prognosis due to treatment with tyrosine kinase 
inhibitors, such as imatinib, sunitinib and regorafenib. The discovery of CD117 (KIT) 
and later DOG-1 as immunohistochemical markers for GIST enabled pathologists to 
distinguish GIST more easily as a separate entity and so it could also be studied as 
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separate entity for drug trials. The introduction of imatinib made it even more important 
to diagnose GIST correctly. A Dutch nationwide population based study on the incidence 
of GIST was published in 2005 and showed a reported incidence of 12.7 patients per 
million inhabitants. As incidence numbers are important for both health care planning 
and study design, chapter 4 studied the development of the incidence of diagnosed 
GIST between 2003 and 2012, showing an increase from 12.2 to 17.7 patients per million 
inhabitants per year. Improvements in diagnostic procedures and increased awareness 
are probably at least partially the cause for this increase. A real increase in the incidence 
is also possible, but causal or risk factors for GIST are not known. This study also evaluates 
the adherence to the current ESMO (European Society for Medical Oncology) guidelines 
and shows that only a minority of patients had pathology revision in a reference centre 
and/or mutation analysis. Both increased for tumours with a higher risk of metastases. 
Due to the importance of a correct diagnosis of GIST for a good prognosis, it is important 
to adhere to these guidelines. 
Chapter 5 reports our experience with imatinib-induced agranulocytosis in patients 
with metastatic GIST. In general imatinib has limited side effects and is well tolerated. 
Although neutropenia is rare, imatinib is the most effective drug in GIST and it is 
important to continue treatment if possible for the best overall outcome.  In three Dutch 
GIST reference centres, four patients were identified. All four patients showed rapid and 
full recovery after the discontinuation of imatinib. Several treatment options for the 
prevention of a recurrence of this side effect are discussed such as dose reduction, 
cotreatment with prednisolone and granulocyte colony stimulating factor. The study 
suggests a possible management algorithm for imatinib induced agranulocytosis.
Soft tissue sarcomas 
The next four chapters (chapters 6, 7, 8 and 9) discuss studies in soft tissue sarcoma. Soft 
tissue sarcomas are a group of rare tumours originating from connective tissue, such 
as muscles, adipose tissue, nerves and so on. Chapter 6 and 7 are two retrospective 
European Organisation for Research and Treatment of Cancer (EORTC) database 
studies. Chapter 6 describes the differences in survival between patients with locally 
advanced disease, patients with distant metastatic disease only and patients with both 
locally advanced disease and distant metastases. Chapter 7 reports the survival after 
completing doxorubicin monotherapy as first line palliative treatment in soft tissue 
sarcomas and provides data on overall survival and progression-free survival in patients 
completing at least 6 cycles of doxorubicin treatment.
Because of the rarity of soft tissue sarcomas these tumours are often studied as one 
group, despite differences in prognosis for different histologic subtype and other 
prognostic factors. Chapter 6 shows an important difference in overall survival, 
progression free survival and overall response rate between patients with only locally 
advanced disease versus patients with only distant metastatic disease versus patients 
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with both locally advanced and distant metastatic disease. Prognostic factors, such 
as time since initial diagnosis, localization of primary tumour, histologic subtype and 
performance status, had a different impact between the different disease stage groups. 
Prospective validation of these results is necessary. 
To improve prognosis of patients with soft tissue sarcoma new treatment strategies 
are studied, such as maintenance treatment after first line doxorubicin. Chapter 7 
describes the overall survival and progression free survival of patients completing 6 
cycles of doxorubicin without progression. This data is essential when designing these 
maintenance studies. The study shows that only approximately 36.6% of all patients 
treated with first-line doxorubicin qualify for maintenance treatment. The progression 
free survival of 8.7 months and the overall survival of 20.1 months after randomisation is 
much longer than the commonly reported progression free survival and overall survival, 
but this is due to the selection of responding patients. However, this increased survival 
for these patients should be accounted for in maintenance trials.
One of the new drugs in the treatment of soft tissue sarcoma is pazopanib, a tyrosine 
kinase inhibitor, that has shown a 3 months increase of progression free survival 
compared to placebo.  Chapters 8 and 9 report adverse events of pazopanib: hepatic 
toxicity and pneumothorax. Hepatic toxicity is one of the major adverse events causing 
treatment discontinuation. Chapter 8 describes a patient with an endometrial stromal 
sarcoma and liver function test abnormalities. In this patient the dose was reduced 
in several steps to 200 mg every second day (usual dose 800 mg/day). In this dose, 
treatment was still effective with a time on treatment of 9 months. This report suggests 
that dose reduction lower than the recommended minimal dose of 400 mg per day 
can be safe and effective in patients with hepatic toxicity. This study also reports a 
remarkable long progression free survival in a patient with endometrial stromal cell 
sarcoma treated with pazopanib. 
Pneumothorax as side effect of pazopanib is studied in chapter 9. It reports the 
development of a spontaneous pneumothorax in six patients treated with pazopanib 
for a soft tissue sarcoma. The incidence of spontaneous pneumothorax as side effect in 
patients treated for soft tissue sarcoma was estimated to be 14% in our centre. Literature 
suggests this side effect to be sarcoma specific as it is not reported in other cancers. 
In all patients reported in this study pleural or subpleural metastases were present and 
some of these showed necrosis, which could be the cause of the occurrence of the 
pneumothorax. The treatment of the pneumothorax was difficult, probably because 
pazopanib inhibits VEGFR 1, 2 and 3 (Vascular Endothelial Growth Factor Receptor).
The results of chapter 8 and 9 are important as these chapters report new side effects 
or new treatments for side effects of a relatively new drug.  




The last part of the thesis focuses on two rare bone tumours: giant cell tumours of bone 
(GCT-B) and osteosarcoma. 
Giant cell tumour of bone
GCT-B is an intermediate, locally aggressive tumour causing a lot of morbidity. 
Denosumab, a monoclonal antibody against RANKL (receptor of nuclear factor kappa-B 
ligand), was recently introduced as treatment for GCT-B. Until now, the incidence of 
GCT-B is not exactly known. Chapter 10 reports the results of a study on the incidence 
of GCT-B in the Netherlands based on the Dutch nationwide pathology registry, PALGA. 
The incidence is approximately 1.7 patients per million inhabitants in the Netherlands. 
The median age of patients was 35 years (range 9-77) and the tumours were most 
commonly localized in the femur (35%) and tibia (18%). The incidence of local recurrence 
was 0.40 patients per million inhabitants per year. The incidence we report is higher 
than previously reported in literature, probably due to the use of PALGA, which covers 
all Dutch pathology reports and is archiving these automatically. The data of this study 
help to plan care for these patients and to plan future research.
Osteosarcoma
Although osteosarcoma is the most common malignant bone tumour, it is still very rare. 
First line treatment with doxorubicin and cisplatin with or without methotrexate is well 
defined, but second line treatment is not well-established. Several regimens are used. 
In the Leiden University Medical Center ifosfamide is currently used as a second line 
treatment, but literature lacks data on overall and progression free survival. Chapter 11 
reports the results of ifosfamide monotherapy in the Leiden University Medical Center. 
Sixty-two patients treated with ifosfamide monotherapy were identified in the Leiden 
University Medical Center treated with an intended dose of 5 g/m2 or 9 g/m2. This study 
shows an improvement in overall survival for patients treated with 9 g/m2 compared 
to 5 g/m2 in univariate analysis (10.9 versus 6.7 months resp.), but not in multi-variate 
analysis. Progression free survival was not significantly different, but showed a trend 
towards a better PFS for the intended dose of 9 g/m2 compared to 5 g/m2 (3.8 vs 2.1 
months resp.). One of the other important results of this study is the prognostic impact 
of WHO performance status, i.e. a better performance status is associated with a better 
survival. This study can be used as benchmark for future studies, when comparing new 
treatment options in phase II studies. 
Discussion and future perspectives
Chapter 12 summarizes the evidence generated in the retrospective studies reported 
in this thesis and discusses the results of the separate studies against the background 
of the other studies of this thesis and the current literature. It also describes future 
perspectives for sarcoma research and daily patient care.




Dit proefschrift omvat verschillende studies in mesenchymale tumoren. Omdat 
mesenchymale tumoren zeldzaam zijn, is het essentieel om alle beschikbare data 
te gebruiken voor een snelle vooruitgang in het wetenschappelijk onderzoek zonder 
dat grote patiëntengroepen noodzakelijk zijn. De resultaten van deze retrospectieve 
studies dragen bij aan het verbeteren van het ontwerp van toekomstige studies en aan 
verbeteringen in de dagelijkse patiëntenzorg.
Weke delen tumoren
Desmoïd-type fibromatose
Hoofdstuk 2 bestudeert de niet-chirurgische behandeling van desmoïd-type 
fibromatose, een ziekte met een sterk variabel natuurlijk beloop. Met behulp van 
pathologie verslagen uit PALGA, de Nederlandse landelijke pathologie registratie 
database, toont deze studie aan dat het gebruik van niet-chirurgische behandeling 
toegenomen is van 0,6% van de patiënten in 1993 naar 12,8% in 2013. Chirurgie blijft tot 
op heden de primaire behandeling in de meeste patiënten. De studie laat verder zien 
dat patiënten die actief vervolgd worden zonder dat ze een behandeling ondergaan, of 
na behandeling met radiotherapie of systemische behandelingen, een goede prognose 
hebben. Ondanks dat de resultaten met enig voorbehoud geïnterpreteerd moeten 
worden, vanwege de zeldzaamheid van niet-chirurgische behandelingen en door het 
variabele natuurlijke gedrag van deze ziekte, geven de resultaten een basis om verder 
onderzoek te doen naar niet-chirurgische strategieën.
Hoofdstuk 3 richt zich op een potentiële bijwerking van radiotherapie als één van de 
behandelingsmogelijkheden voor desmoïd-type fibromatose. Bestraling heeft een kans 
op ziektecontrole van ongeveer 80% bij een gemiddelde stralingsdosis van 56 Gy. Het 
onderzoek beschrijft zes unieke casus van stralingsgeïnduceerde sarcomen uit vier 
verschillende tertiaire verwijzingsziekenhuizen voor sarcomen. Dit geeft aan dat deze 
stralingsgeïnduceerde tumoren uiterst zeldzaam zijn. De studie onderzoekt of deze 
stralingsgeïnduceerde sarcomen zijn ontstaan als nieuwe primaire tumoren of dat 
deze sarcomen zijn ontstaan uit de bestraalde desmoïd-type fibromatosen. Het blijkt 
dat sarcomen die ontstaan na bestraling van desmoïd-type fibromatose zowel kunnen 
ontstaan als nieuwe primaire tumoren (sarcomen die geen CTNNB1 mutatie bevatten, 
welke wel aanwezig is in de desmoïd-type fibromatose) of als maligne transformatie 
vanuit de desmoïd-type fibromatose (met behoud van de CTNNB1 mutatie). Een 
associatie tussen de specifieke CTNNB1 mutatie in de desmoïd-type fibromatose en 
een hoger risico van een stralingsgeïnduceerd sarcoom wordt niet gevonden.  




In hoofdstuk 4 en 5 worden gastro-intestinale stromaceltumoren (GIST) bestudeerd, 
de meest frequent voorkomende mesenchymale tumor in het maagdarmkanaal. 
Deze zeldzame tumor heeft een relatief goede prognose door de behandeling met 
tyrosine kinase remmers, te weten imatinib, sunitinib en regorafenib. De ontdekking 
van KIT en vervolgens DOG-1 als immunohistochemische markers voor GIST maakte 
het voor pathologen makkelijker om GIST als aparte entiteit te onderscheiden van 
andere sarcomen en zodoende kan het nu als aparte entiteit bestudeerd worden in 
geneesmiddelonderzoek. De introductie van imatinib maakte het nog belangrijker om de 
diagnose GIST correct te stellen, vanwege de sterk verbeterde prognose door imatinib. 
In 2005 werd een studie gepubliceerd naar het voorkomen, de incidentie, van GIST 
die gebaseerd was op de gehele Nederlandse bevolking. De studie rapporteerde een 
incidentie van 12,7 patiënten per miljoen inwoners per jaar. Omdat deze incidentiecijfers 
van belang zijn voor zowel gezondheidszorgplanning als ontwerp van toekomstige 
studies, wordt in hoofdstuk 4 de verdere ontwikkeling van de gerapporteerde incidentie 
van GIST tussen 2003 en 2012 bestudeerd. De incidentie is in deze periode toegenomen 
van 12,2 naar 17,7 patiënten per miljoen inwoners per jaar. Waarschijnlijk is dit het gevolg 
van verbeteringen in diagnostische procedures en een toegenomen bewustzijn en 
daardoor betere herkenning van de ziekte. Alhoewel een daadwerkelijke toename in 
de incidentie ook een rol zou kunnen spelen, zijn hiervoor tot op heden geen oorzaken 
aan te wijzen. In dit onderzoek wordt tevens het gebruik van de huidige ESMO (European 
Society for Medical Oncology) richtlijn in de Nederlandse praktijk geëvalueerd, waarbij 
blijkt dat slechts voor een minderheid van de patiënten een revisie van de pathologie in 
een referentiecentrum verricht wordt en hetzelfde geldt voor het bepalen van de in GIST 
aanwezige mutatie. Dit wordt wel vaker gedaan indien sprake is van een GIST met een 
hoog risico op metastasen (uitzaaiingen). Gezien het belang van een correcte diagnose 
voor een goede prognose is het belangrijk om deze richtlijn te hanteren.
Hoofdstuk 5 beschrijft onze ervaring met imatinib geïnduceerde agranulocytose in 
patiënten met gemetastaseerd GIST. Over het algemeen heeft imatinib slechts milde 
bijwerkingen en wordt het goed verdragen. Neutropenie is een zeldzame bijwerking van 
imatinib. Het is echter voor de prognose van GIST patiënten van belang om imatinib, 
indien mogelijk, veilig te continueren, omdat dit het meest effectieve geneesmiddel is. 
In drie Nederlandse GIST verwijscentra werden vier patiënten gevonden met een door 
imatinib geïnduceerde neutropenie. Deze vier patiënten lieten een volledig herstel zien 
na het staken van de imatinib. In de studie worden een aantal mogelijke behandelopties 
besproken ter preventie van een recidief van de neutropenie, zoals dosisreductie, 
gelijktijdige behandeling met prednison en/of granulocyt kolonie stimulerende factoren. 
We introduceren een mogelijk behandelingsschema voor patiënten met een imatinib 
geïnduceerde agranulocytose. 




De hoofdstukken 6, 7, 8 en 9 presenteren de uitkomsten van studies in wekedelen 
sarcomen. Wekedelen sarcomen zijn tumoren uitgaande van het steun en bindweefsel, 
zoals spieren, vetweefsel en zenuwen. Hoofdstukken 6 en 7 beschrijven de resultaten 
van twee retrospectieve studies op basis van gegevens uit de database van de 
EORTC (European Organisation for Research and Treatment of Cancer). Hoofdstuk 6 
rapporteert de verschillen in overleving tussen patiënten met lokaal gevorderde ziekte, 
patiënten met op afstand gemetastaseerde ziekte en patiënten die zowel lokale ziekte 
als afstandsmetastasen hebben. Hoofdstuk 7 beschrijft vervolgens de overleving van 
patiënten na behandeling met doxorubicine monotherapie als eerstelijns behandeling 
voor patiënten met wekedelen sarcoom en geeft resultaten van de algehele overleving 
en progressievrije overleving in patiënten die tenminste 6 kuren doxorubicine 
volmaken. 
Door de zeldzaamheid van wekedelen sarcomen worden ze vaak als één grote groep 
bestudeerd, ondanks verschillen in prognose op basis van histologisch subtype en 
andere prognostische factoren. Hoofdstuk 6 laat belangrijke verschillen in algehele 
overleving, progressievrije overleving en response percentages zien tussen patiënten 
met lokaal gevorderde ziekte, patiënten met enkel afstandsmetastasen en patiënten 
met zowel lokale ziekte als afstandsmetastasen. Prognostische factoren, zoals tijd sinds 
primaire diagnose, lokalisatie van de primaire tumor, histologisch subtype en conditie 
(WHO performance status) hebben een verschillend effect in deze drie subgroepen. 
Deze resultaten moeten gevalideerd worden in een prospectieve studie.
Ten einde de prognose van patiënten met wekedelen sarcomen te verbeteren worden 
nieuwe behandelstrategieën bestudeerd, zoals onderhoudsbehandeling na eerstelijns 
behandeling met doxorubicine. Hoofdstuk 7 beschrijft de algehele overleving en 
progressievrije overleving voor patiënten na behandeling met 6 kuren doxorubicine 
zonder progressie onder behandeling. Deze resultaten zijn nodig voor het ontwerp 
van studies naar onderhoudsbehandelingen. De studie laat zien dat slechts ongeveer 
36,6% van alle patiënten die behandeld zijn met eerstelijns doxorubicine therapie in 
aanmerking komen voor een onderhoudsbehandeling. De progressievrije overleving 
van 8,7 maanden en de algehele overleving van 20,1 maanden na randomisatie zijn 
beduidend langer dan de overlevingscijfers die over het algemeen gerapporteerd 
worden, maar dit is het gevolg van de selectie op patiënten die goed reageerden 
op de therapie. Met deze verlenging van de algehele overleving en progressievrije 
overleving moet rekening gehouden worden bij het ontwerp van studies naar 
onderhoudsbehandelingen. 
Eén van de nieuwe geneesmiddelen in de behandeling van wekedelen sarcoom is 
pazopanib, een tyrosine kinase remmer, met een aangetoonde verbetering van de 
progressievrije overleving van 3 maanden vergeleken met placebo. De hoofdstukken 
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8 en 9 rapporteren bijwerkingen van pazopanib, te weten leverchemieafwijkingen en 
pneumothorax (een klaplong). Levertoxiciteit is één van de belangrijkste bijwerkingen 
die leiden tot het staken van behandeling. Hoofdstuk 8 beschrijft een patiënt met een 
sarcoom van de baarmoeder (endometriaal stromacel sarcoom) en leverfunctietest 
afwijkingen. In deze patiënt werd de dosis pazopanib geleidelijk aan afgebouwd naar 
200mg elke tweede dag (standaarddosis 800 mg/dag). Deze dosis liet nog steeds 
effectiviteit zien met een behandelingsduur van in totaal 9 maanden. Dit hoofdstuk 
suggereert dat een verdere dosisreductie, lager dan de geadviseerde minimumdosis 
van 400 mg, veilig en effectief kan zijn in patiënten met levertoxiciteit. Daarnaast 
rapporteert deze studie een opmerkelijk lange progressievrije overleving van een patiënt 
met een endometriaal stromacel sarcoom, die behandeld werd met pazopanib. 
Hoofdstuk 9 bestudeert de pneumothorax als bijwerking van behandeling met 
pazopanib. Het beschrijft het ontstaan van een spontane pneumothorax in zes 
patiënten, die behandeld werden met pazopanib voor een wekedelen sarcoom. Op 
basis van dit onderzoek wordt ingeschat dat deze bijwerking voorkomt bij ongeveer 
14% van de patiënten in ons centrum. De literatuur suggereert dat dit een sarcoom 
specifieke bijwerkingen is, aangezien het niet in andere tumortypen beschreven is. 
In alle beschreven patiënten waren pleurale of subpleurale metastasen aanwezig 
en sommigen hiervan toonden necrose. Necrose in deze pleurale of subpleurale 
metastasen kan een verklaring zijn voor het ontwikkelen van de pneumothorax. De 
behandeling van de pneumothorax was vaak gecompliceerd, waarschijnlijk doordat 
pazopanib VEGFR 1, 2 en 3 (Vasculair Endotheliaal GroeiFactor Receptor) remt.
De uitkomsten van de hoofdstukken 8 en 9 zijn belangrijk, omdat deze hoofdstukken 
nieuwe bijwerkingen beschrijven of nieuwe behandelingen voor bekende bijwerkingen 
geven.
Bottumoren 
Het laatste deel richt zich op twee zeldzame bottumoren: reusceltumor van het bot en 
osteosarcoom.
Reusceltumoren van het bot
De reusceltumor van het bot is een lokaal agressieve tumor, die zorgt voor veel 
morbiditeit, ziektelast. Denosumab, een monoklonaal antilichaam tegen RANKL (receptor 
voor nucleair factor Kappa-B ligand), is recent geïntroduceerd als behandeling voor 
deze ziekte. Tot op heden is de incidentie van deze reusceltumoren van het bot niet 
exact bekend. Hoofdstuk 10 beschrijft de resultaten van een studie naar de incidentie 
van reusceltumoren van het bot in Nederland, gebaseerd op data uit de Nederlandse 
landelijke pathologie database, PALGA. De incidentie wordt geschat op 1,7 patiënten per 
miljoen inwoners. De mediane leeftijd van patiënten was 35 jaar, spreiding 9-77 jaar, 
en de tumoren waren het vaakst gelokaliseerd in het femur (35%) en de tibia (18%). De 
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incidentie van een lokaal recidief was 0,40 per miljoen patiënten per jaar. De incidentie 
die wij rapporteren is hoger dan de eerder gerapporteerde incidentie in de literatuur, 
waarschijnlijk door het gebruik van PALGA, dat alle pathologie verslagen in Nederland 
bevat. De resultaten van deze studie helpen bij het plannen van toekomstig onderzoek 
en bij het plannen van dagelijkse patiëntenzorg voor deze patiëntengroep.
Osteosarcoom
Alhoewel het osteosarcoom de meest voorkomende kwaadaardige bottumor is, 
is het nog steeds erg zeldzaam. De primaire behandeling met chemotherapie met 
doxorubicine en cisplatina met of zonder methotrexaat is duidelijk vastgesteld, maar 
vervolgbehandelingen zijn dat niet. Verschillende combinaties worden voor deze 
situatie gebruikt in de wereld. In het Leids Universitair Medisch Centrum wordt ifosfamide 
momenteel als optie gebruikt in de tweedelijns behandeling van osteosarcomen, maar 
in de literatuur ontbreken gegevens over de algehele en progressievrije overleving van 
deze patiënten. Hoofdstuk 11 beschrijft de resultaten met ifosfamide monotherapie in het 
Leids Universitair Medisch Centrum. Tweeënzestig patiënten werden geïdentificeerd, die 
behandeld zijn met een geplande dosis van 5 gram/m2 of 9 gram/m2. De studie toont een 
toename in algehele overleving voor patiënten behandeld met 9 gram/m2 in vergelijking 
tot 5 gram/m2 in univariate analyse (10,9 versus 6,7 maanden respectievelijk), maar niet 
in multivariate analyse. De progressievrije overleving is niet significant verschillend, maar 
laat een trend naar een betere overleving zien in patiënten behandeld met 9 gram/m2 
vergeleken met 5 gram/m2 (3,8 versus 2,1 maanden resp.). Eén van de belangrijkste 
uitkomsten van deze studie is het prognostisch belang van WHO performance status, 
een betere conditie is geassocieerd met een betere overleving. De resultaten uit deze 
studie kunnen gebruikt worden als benchmark voor toekomstige studies, die nieuwe 
behandeling onderzoeken in fase II studies.  
Discussie en toekomstperspectief
Hoofdstuk 12 vat de uitkomsten van de diverse studies in dit proefschrift samen en zet 
deze in het perspectief van de overige studies in dit proefschrift en die van de literatuur. 
Het beschrijft ook het toekomstperspectief van het onderzoek naar sarcomen en van 
de dagelijkse patiëntenzorg.
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